Enzymatic peracid generation formulation

ABSTRACT

Disclosed herein are multi-component formulations for enzymatically producing aqueous solutions of peroxycarboxylic acids suitable for use in, e.g., disinfectant and/or bleaching applications. The multi-component peroxycarboxylic acid formulations comprise at least one carbohydrate esterase family 7 enzyme having perhydrolytic activity.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional PatentApplication Nos. 61/102,505; 61/102,512; 61/102,514; 61/102,520;61/102,531; and 61/102,539; each filed Oct. 3, 2008, each of whichincorporated by reference herein in their entireties.

FIELD OF THE INVENTION

This invention relates to the field of enzymatic peroxycarboxylic acidsynthesis and in situ enzyme catalysis. Specifically, a multi-componentformulation is provided for enzymatically producing an aqueous solutionof a peroxycarboxylic acid. At least one peroxycarboxylic acid isproduced at sufficient concentrations as to be efficacious for thedisinfection or sanitization of surfaces, medical instrumentsterilization, food processing equipment sterilization, and suitable foruse in laundry care applications such as bleaching, destaining,deodorizing, and sterilization.

BACKGROUND OF THE INVENTION

Peroxycarboxylic acid compositions have been reported to be effectiveantimicrobial agents. Methods to clean, disinfect, and/or sanitize hardsurfaces, meat products, living plant tissues, and medical devicesagainst undesirable microbial growth have been described (e.g., U.S.Pat. Nos. 6,545,047; 6,183,807; 6,518,307; 5,683,724; and U.S. PatentApplication Publication No. 2003/0026846). Peroxycarboxylic acids havealso been reported to be useful in preparing bleaching compositions forlaundry detergent applications (e.g., U.S. Pat. Nos. 3,974,082;5,296,161; and 5,364,554).

Peroxycarboxylic acids can be prepared by the chemical reaction of acarboxylic acid and hydrogen peroxide (see Organic Peroxides, DanielSwern, ed., Vol. 1, pp 313-516; Wiley Interscience, New York, 1971). Thereaction is usually catalyzed by a strong inorganic acid, such asconcentrated sulfuric acid. The reaction of hydrogen peroxide with acarboxylic acid is an equilibrium reaction, and the production ofperoxycarboxylic acid is favored by the use of an excess concentrationof peroxide and/or carboxylic acid, or by the removal of water.

Some peroxycarboxylic acid-based disinfectants or bleaching agents arecomprised of an equilibrium mixture of peroxycarboxylic acid, hydrogenperoxide, and the corresponding carboxylic acid. One disadvantage ofthese commercial peroxycarboxylic acid cleaning systems is that theperoxycarboxylic acid is oftentimes unstable in solution over time. Oneway to overcome the stability problem is to generate theperoxycarboxylic acid prior to use by combining multiple reactioncomponents that are individually stable for extended periods of time.Preferably, the individual reaction components are easy to store,relatively safe to handle, and capable of quickly producing anefficacious concentration of peroxycarboxylic acid upon mixing.

One way to overcome the disadvantages of chemical peroxycarboxylic acidproduction is to use an enzyme catalyst having perhydrolysis activity.U.S. patent application Ser. No. 11/638,635 and U.S. Patent ApplicationPublication Nos. 2008/0176783; 2008/0176299; and 2009/0005590 toDiCosimo et al. disclose enzymes structurally classified as members ofthe CE-7 family of carbohydrate esterases (i.e., cephalosporin Cdeacetylases [CAHs] and acetyl xylan esterases [AXES]) that arecharacterized by significant perhydrolysis activity for convertingcarboxylic acid esters (in the presence of a suitable source ofperoxygen, such as hydrogen peroxide) into peroxycarboxylic acids atconcentrations sufficient for use as a disinfectant and/or a bleachingagent. Some members of the CE-7 family of carbohydrate esterases havebeen demonstrated to have perhydrolytic activity sufficient to produce4000-5000 ppm peracetic acid from acetyl esters of alcohols, diols, andglycerols in 1 minute and up to 9000 ppm between 5 minutes and 30minutes once the reaction components were mixed (DiCosimo et al., U.S.2009/0005590).

The enzymatic peroxycarboxylic acid generation systems system describedby DiCosimo et al. in each of the cited patent application publicationsmay be based on a two-component system, where each component is storedin a separate compartment until use. Typically, the enzyme catalysthaving perhydrolysis activity is stored in one compartment with thecarboxylic acid ester substrate and the source of peroxygen (typicallyan aqueous solution use of hydrogen peroxide) is stored in a secondcompartment. The multiple reaction components of the two compartmentsare mixed to produce the desired aqueous solution of peroxycarboxylicacid.

However, multi-component enzymatic peracid generation systems may alsosuffer from certain problems. One problem may be the use of one or morecarboxylic acid ester substrates that are insoluble or partiallyinsoluble in water after mixing of the two components. The limitedsolubility of certain carboxylic acid ester substrates can result in atleast three conditions that interfere with the ability to efficaciouslyproduce and deliver a peroxycarboxylic acid product: first, theviscosity of the enzyme catalyst/substrate constituent can be too highto permit efficient mixing with a second constituent comprising a sourceof peroxygen, which decreases the rate of production of peroxycarboxylicacid; second, the viscosity of the enzyme catalyst/substrate constituentcan be too high to permit certain modes of delivery of a productcomprising a mixture of the enzyme catalyst/substrate constituent andthe source of peroxygen, such as spraying; third, the dissolution rateof the substrate in the enzyme/substrate component after mixing with asecond component comprising a source of peroxygen in aqueous solution istoo low to permit a satisfactory rate of production of peroxycarboxylicacid. The carboxylic acid ester solubility problems also become evidentin situations where use of a particular ratio of a component comprisingan aqueous source of peroxygen to a component comprising an enzymecatalyst/substrate constituent is desired. As such, commercial uses ofmulti-component systems that involve the storage of the enzyme catalysthaving perhydrolysis activity and substrate separately from a source ofperoxygen until a desired time of reaction have remained impracticablefor some applications.

The use of organic cosolvents to enhance mixing and/or alter theviscosity of the carboxylic acid ester in water may be problematic.Organic solvents can be deleterious to the activity of enzymes, eitherwhen enzymes are suspended directly in organic solvents, or whenmiscible organic/aqueous single phase solvents are employed. Twoliterature publications that review the effects of organic solvents onenzyme activity and structure are: (a) C. Laane et al., Biotechnol.Bioeng. 30:81-87 (1987) and (b) Cowan, D. A. and Plant, A., Biocatalysisin Organic Phase Systems., Ch. 7 in Biocatalysis at ExtremeTemperatures, Kelly, R. W. W. and Adams, M., eds., Amer. Chem. Soc.Symposium Series, Oxford University Press, New York, N.Y., pp 86-107(1992). Cowan and Plant note (on page 87) that there is little or novalue in using organic solvents having a log P≦2 to stabilizeintracellular enzymes in an organic phase system. Organic solventshaving a log P between two and four can be used on a case-by-case basisdependent on enzyme stability, and those having a log P>4 are generallyuseful in organic phase systems.

Cowan and Plant, supra, further note (on page 91) that the effect ofdirect exposure of an enzyme dissolved in a single-phase organic-aqueoussolvent depends on solvent concentration, solvent/enzyme surface groupinteractions, and solvent/enzyme hydration shell interactions. Because asolvent's log P value must be sufficiently low so that the solvent isfully miscible with the aqueous phase to produce a single-phase, asingle-phase organic-aqueous solvent containing a low log P organicsolvent usually has a negative effect on enzyme stability except in loworganic solvent concentration applications.

The storage stability of a CE-7 enzyme having perhydrolysis activity isa concern when stored in a carboxylic acid ester substrate or a mixtureof the carboxylic acid ester and one or more cosolvents having apartition coefficient (as measured by a log P value, i.e., the logarithmof the partition coefficient of a substance between octanol and water,where P equals [solute]_(octanol)/[solute]_(water)) of two or less.Several of the organic ester substrates described by DiCosimo et al. inU.S. 2009/0005590 have log P values of less than two. For example,triacetin is reported to have a log P of 0.25 (Y. M. Gunning, et al., J.Agric. Food Chem. 48:395-399 (2000)), similar to that of ethanol (log P−0.26) and isopropanol (log P 0.15) (Cowan and Plant); therefore thestorage of enzyme powder in triacetin would be expected to result inunacceptable loss of enzyme activity, as would the use of additionalcosolvents with log P<2 (e.g., cyclohexanone, log P=0.94) (Cowan andPlant); 1,2-propanediol, log P=−1.41 (Gunning, et al.); 1,3-propanediol,log P=−1.3 (S-J. Kuo, et al., J. Am. Oil Chem. Soc. 73:1427-1433 (1996);diethylene glycol butyl ether, log P=0.56 (N. Funasaki, et al., J. Phys.Chem. 88:5786-5790 (1984); triethyleneglycol, log P=−1.75 (L. Braeken,et al., Chem Phys Chem 6:1606-1612 (2005)).

Co-owned, co-filed, and copending U.S. patent application under attorneydocket number CL4205 US NA entitled “ENZYMATIC PERACID PRODUCTION USINGA COSOLVENT” describes the use of organic co-solvents having a log Pvalue of about 2 or less to control the viscosity of asubstrate-containing component and to enhance the solubility of thesubstrate in an aqueous reaction mixture without causing substantialloss of perhydrolytic activity of the enzyme catalyst.

Co-owned, co-filed, and copending U.S. patent applications underattorney docket numbers CL4386 US NA and CL4387 US NA, each having thetitle “STABILIZATION OF PERHYDROLASES”, describe various ways tostabilize enzymatic perhydrolysis activity of enzyme powders whenpresent in the carboxylic acid ester substrate component of amulti-component peroxycarboxylic acid generation system.

Co-owned, co-filed, and copending U.S. patent application under attorneydocket number CL4392 US NA (“IMPROVED PERHYDROLASES FOR ENZYMATICPERACID GENERATION”) describes variant CE-7 enzymes having improvedperhydrolytic activity.

The problem to be solved is to provide multi-component peroxycarboxylicacid generation formulations comprising a combination of ingredientscharacterized by enhanced storage stability of the CE-7 catalyst'sperhydrolytic activity and/or improved mixing and/or viscositycharacteristics of the carboxylic acid ester substrate-containingcomponent. In a further embodiment, the multi-component peroxycarboxylicacid generation formulation preferably comprises a variant CE-7 enzymehaving improved perhydrolytic activity

SUMMARY OF THE INVENTION

The stated problem has been solved by providing multi-componentformulations characterized by enhanced storage stability and/or improvedmixing characteristics.

In one embodiment, a multi-component formulation for producingperoxycarboxylic acid is provided comprising:

-   -   (a) a first component comprising:        -   (i) an enzyme powder comprising:            -   (1) at least one enzyme catalyst having perhydrolysis                activity, wherein said enzyme catalyst comprises an                enzyme having a carbohydrate esterase family 7 (CE-7)                signature motif that aligns with SEQ ID NO: 1 using                CLUSTALW, said signature motif comprising:                -   (A) an RGQ motif at amino acid positions aligning                    with 118-120 of SEQ ID NO:1;                -   (B) a GXSQG motif at amino acid positions aligning                    with 179-183 of SEQ ID NO:1; and                -   (C) an HE motif at amino acid positions aligning                    with 298-299 of SEQ ID NO:1;                -   said enzyme comprising at least 30% amino acid                    identity to SEQ ID NO: 1; and            -   (2) at least one excipient;        -   (ii) a carboxylic acid ester substrate selected from the            group consisting of            -   (1) one or more esters having the structure                [X]_(m)R₅                -   wherein                -   X is an ester group of the formula R₆C(O)O;                -   R₆ is a C1 to C7 linear, branched or cyclic                    hydrocarbyl moiety, optionally substituted with a                    hydroxyl group or C1 to C4 alkoxy group, wherein R₆                    optionally comprises one or more ether linkages                    where R₆ is C2 to C7;                -   R₅ is a C1 to C6 linear, branched, or cyclic                    hydrocarbyl moiety optionally substituted with a                    hydroxyl group, wherein each carbon atom in R₅                    individually comprises no more than one hydroxyl                    group or no more than one ester group, and                -   wherein R₅ optionally comprises one or more ether                    linkages;                -   m is 1 to the number of carbon atoms in R₅,                -   said one or more esters having solubility in water                    of at least 5 ppm at 25° C.;            -   (2) one or more glycerides having the structure

-   -   -   -   -   wherein R₁ is a C1 to C7 straight chain or branched                    chain alkyl optionally substituted with an hydroxyl                    or a C1 to C4 alkoxy group and R₃ and R₄ are                    individually H or R₁C(O);

            -   (3) one or more esters of the formula

-   -   -   -   -   wherein R₁ is a C1 to C7 straight chain or branched                    chain alkyl optionally substituted with an hydroxyl                    or a C1 to C4 alkoxy group and R₂ is a C1 to C10                    straight chain or branched chain alkyl, alkenyl,                    alkynyl, aryl, alkylaryl, alkylheteroaryl,                    heteroaryl, (CH₂CH₂O)_(n), or (CH₂CH(CH₃)—O)_(n)H                    and n is 1 to 10;

            -   (4) one or more acetylated monosaccharides, acetylated                disaccharides, or acetylated polysaccharides; and

            -   (5) any combination of (1) through (4);

            -   wherein the amount of the carboxylic acid ester                substrate in the first component is designed to provide                a final concentration of 0.5 wt % to 10 wt % in a                reaction formulation formed by combining the first and                second components;

        -   (iii) a buffer selected from the group consisting of            bicarbonate, citrate, acetate, phosphate, pyrophosphate,            methylphosphonate, succinate, malate, fumarate, tartrate,            and maleate;

        -   (iv) a cosolvent selected from the group consisting of            tripropylene glycol methyl ether, dipropylene glycol methyl            ether, propylene glycol methyl ether, diethylene glycol            butyl ether, dipropylene glycol, triethylene glycol,            1,2-propanediol, N-ethyl-2-pyrroldinone, isopropanol,            ethanol, ethyl lactate, 1,3-propanediol, and any combination            thereof; and

        -   (v) optionally at least one surfactant; and

    -   (b) a second component comprising water, hydrogen peroxide, and        a hydrogen peroxide stabilizer.

In another embodiment, a two-component formulation for producingperoxycarboxylic acid is provided comprising:

-   -   (a) a first component comprising:        -   (i) an enzyme powder; said enzyme powder comprising:            -   (1) at least one CE-7 enzyme having perhydrolysis                activity, wherein said at least one CE-7 enzyme                comprises an amino acid sequence selected from the group                consisting of SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 19                and SEQ ID NO: 20 or an amino acid sequence                substantially similar to SEQ ID NO: 6, SEQ ID NO: 7, SEQ                ID NO: 19 or SEQ ID NO: 20; and            -   (2) at least one excipient;        -   (ii) a carboxylic acid ester substrate selected from the            group consisting of monoacetin, diacetin, triacetin, and a            mixtures thereof; wherein the amount of the carboxylic acid            ester substrate in the first component is designed to            provide a final concentration of 0.5 wt % to 10 wt % in a            reaction formulation formed by combining the first and            second components;        -   (iii) a buffer selected from the group consisting of            bicarbonate, citrate, acetate, phosphate, pyrophosphate,            methylphosphonate, succinate, malate, fumarate, tartrate,            and maleate;        -   (iv) a cosolvent selected from the group consisting of            tripropylene glycol methyl ether, dipropylene glycol methyl            ether, propylene glycol methyl ether, diethylene glycol            butyl ether, dipropylene glycol, triethylene glycol,            1,2-propanediol, N-ethyl-2-pyrroldinone, isopropanol,            ethanol, ethyl lactate, 1,3-propanediol, and any combination            thereof; and        -   (v) optionally at least one surfactant; and    -   (b) a second component comprising water, hydrogen peroxide, and        a hydrogen peroxide stabilizer.

In another embodiment, a two-component formulation for producingperoxycarboxylic acid is provided comprising:

-   -   (a) a first component comprising a formulation of        -   (i) about 0.1 wt % to about 5 wt % of the first component            being an enzyme powder comprising:            -   (1) about 20 wt % to about 33 wt % of the enzyme powder                comprising at least one GE-7 enzyme and having                perhydrolysis activity, wherein said at least one CE-7                enzyme comprising an amino acid sequence selected from                the group consisting of SEQ ID NO: 6, SEQ ID NO: 7, SEQ                ID NO: 19 and SEQ ID NO: 20;            -   (2) about 67 wt % to about 80 wt % of the enzyme powder                comprising at least one oligosaccharide excipient having                a number average molecular weight of at least about 1250                and a weight average molecular weight of at least about                9000; wherein the at least one oligosaccharide excipient                is selected from the group consisting of maltodextrin,                xylan, mannan, fucoidan, galactomannan, chitosan,                raffinose, stachyose, pectin, insulin, levan, graminan,                amylopectin, and mixtures thereof;        -   (ii) a carboxylic acid ester substrate selected from the            group consisting of monoacetin, diacetin, triacetin, and a            mixtures thereof; wherein the amount of the carboxylic acid            ester substrate in the first component is designed to            provide a final concentration of 0.5 wt % to 10 wt % in a            reaction formulation formed by combining the two reaction            components;        -   (iii) about 0.1 wt % to about 10% wt of he first component            comprising a buffer selected from the group consisting of            sodium bicarbonate, potassium bicarbonate, a mixture of            sodium bicarbonate and potassium bicarbonate, sodium            phosphate, potassium phosphate, and a mixture of sodium            phosphate and potassium phosphate;        -   (iv) up to 80 wt % of the first component comprising a            cosolvent having a log P value of less than 2, said            cosolvent selected from the group consisting of tripropylene            glycol methyl ether, dipropylene glycol methyl ether,            propylene glycol methyl ether, diethylene glycol butyl            ether, dipropylene glycol, triethylene glycol,            1,2-propanediol, N-ethyl-2-pyrroldinone, isopropanol,            ethanol, ethyl lactate, 1,3-propanediol, and any combination            thereof; and        -   (v) at least one surfactant in a range from about 0.1 wt %            to about 5 wt % based on the weight of total protein present            in the enzyme powder; and    -   (b) a second component comprising        -   (i) at least 70 wt % water;        -   (ii) hydrogen peroxide in an amount that provides a final            concentration of the hydrogen peroxide in the reaction            formulation in range from 0.33 wt % to about 30 wt %; and        -   (iii) about 0.01 wt % to about 1% of a hydrogen peroxide            stabilizer;            wherein combining said first and said second reaction            components produces an aqueous formulation of peracetic            acid.

In one aspect, the enzyme powder is formed by spray drying.

In another aspect, the excipient ranges from about 95 wt % to about 25wt % of the enzyme powder, preferably a spray dried enzyme powder. In apreferred aspect, the excipient is an oligosaccharide excipient. In afurther preferred aspect, the oligosaccharide excipient comprises anumber average molecular weight of at least about 1250 and a weightaverage molecular weight of at least about 9000. In a further aspect,the excipient is maltodextrin.

In a preferred aspect, the buffer is selected from the group consistingof sodium bicarbonate, potassium bicarbonate, mixtures of sodiumbicarbonate and potassium bicarbonate, sodium phosphate, potassiumphosphate, and mixtures of sodium phosphate and potassium phosphate.

In another aspect of the invention, a method of bleaching, deodorizing,destaining or disinfecting a surface, an article of clothing or atextile is provided, said method comprising

-   -   (a) providing a formulation listed above;    -   (b) combining the first component with the second component        whereby a reaction formulation comprising peroxycarboxylic acid        is produced; and    -   (c) applying the reaction formulation to the surface, the        article of clothing or the textile for bleaching, stain removal,        odor reduction, sanitization, disinfection, or a combination        thereof.

BRIEF DESCRIPTION OF THE FIGURES

FIGS. 1 a and 1 b depict an exemplary system for producingperoxycarboxylic acid in accordance with the present invention using atwo compartment spray bottle. Referring to FIG. 1 a, the generic spraybottle system comprises a first chamber [1] containing a first component[2] and a second chamber [3] containing a second component [4]. Transfertubing [5] is used to transport the first and second components to aflow control elements [6] and [7], preferably having a single adjustmentcontrol knob [8] that allows the two components to be mixed at a desiredv/v or w/w ratio. FIG. 1 a depicts a pump [9] that pumps and mixes bothliquid components prior to exiting the spray nozzle [10]. FIG. 1 b issimilar to FIG. 1 a except that the pump [9] and nozzle [10] areconfigured to delay mixing of the first and second components at thespray nozzle or on the target surface.

FIGS. 2 a and 2 b depict an exemplary system for producingperoxycarboxylic acid using multi-compartment packets. The barriermaterials form the exterior barrier of the multi-compartment system [11]and/or the internal compartment barrier [12] separating the firstcomponent [2] and the second component [4] are designed to be easilydegradable/breakable (mechanically, chemically, and/or thermally) togenerate the aqueous peroxycarboxylic acid mixture. Referring to FIG. 2a, the delivery system comprises a dissolvable package comprising abreakable exterior barrier [11] and an internal compartment having aninternal compartment barrier [12] comprising a first component [2] thatis surrounded by a second component [4]. The internal compartmentbarrier [12] is designed to be breakable and/or degradable to mix thetwo components to produce the desired peroxycarboxylic acid. FIG. 2 billustrates a dissolvable packet having the two compartments separatedin parallel. As depicted in FIG. 2 b, the 2 compartment packet comprisesa dissolvable and/or breakable exterior barrier [11] and a first andsecond compartments [1] and [3] containing components [2], [4]respectively. The first and second compartments separated using abarrier [13].

FIGS. 3 a and 3 b depict an exemplary system for producingperoxycarboxylic acid according to the present invention using amulti-compartment, flexible squeeze packet/bottle. Referring to FIG. 3a, a manually deformable container [16] comprises a non-rigid wall [14].Within container [16] is a manually disruptable/breakable internalcompartment [15] containing a first component, wherein compartment [15]is surrounded by a second component [4]. Disruption of the internalcompartment [15] permits mixing and generation of the activate material.As shown in FIG. 3 a, the manually deformable container (e.g., a plasticsqueeze bottle) further comprises a directional spout with a removablestopper [17]. FIG. 3 b depicts a non-rigid container [16] comprising afirst compartment [1] comprising a first component [2] and a secondcompartment [3] comprising a second component [4] wherein the twocompartments are separated in a parallel configuration. The manuallydeformable bottle in FIG. 3 b is also depicted to have a directionalspout [18] and a removable stopper [17], wherein the two components aremixed outside of the bottle.

BRIEF DESCRIPTION OF THE BIOLOGICAL SEQUENCES

The following sequences comply with 37 C.F.R. §§1.821-1.825(“Requirements for Patent Applications Containing Nucleotide Sequencesand/or Amino Acid Sequence Disclosures—the Sequence Rules”) and areconsistent with World Intellectual Property Organization (WIPO) StandardST. 25 (1998) and the sequence listing requirements of the EuropeanPatent Convention (EPC) and the Patent Cooperation Treaty (PCT) Rules5.2 and 49.5(a-bis), and Section 208 and Annex C of the AdministrativeInstructions. The symbols and format used for nucleotide and amino acidsequence data comply with the rules set forth in 37 C.F.R. §1.822.

SEQ ID NO:1 is the deduced amino acid sequence of a cephalosporin Cdeacetylase from Bacillus subtilis ATCC® 31954™.

SEQ ID NO:2 is the deduced amino acid sequence of a cephalosporin Cdeacetylase from B. subtilis ATCC® 6633™.

SEQ ID NO:3 is the deduced amino acid sequence of a cephalosporin Cdeacetylase from B. licheniformis ATCC® 14580™.

SEQ ID NO:4 is the deduced amino acid sequence of an acetyl xylanesterase from B. pumilus PS213.

SEQ ID NO:5 is the deduced amino acid sequence of an acetyl xylanesterase from Clostridium thermocellum ATCC®27405™.

SEQ ID NO:6 is the deduced amino acid sequence of an acetyl xylanesterase from Thermotoga neapolitana.

SEQ ID NO:7 is the deduced amino acid sequence of an acetyl xylanesterase from Thermotoga maritima MSB8.

SEQ ID NO:8 is the deduced amino acid sequence of an acetyl xylanesterase from Thermoanaerobacterium sp. JW/SL YS485.

SEQ ID NO:9 is the deduced amino acid sequence of a cephalosporin Cdeacetylase from Bacillus sp. NRRL B-14911. It should be noted that thenucleic acid sequence encoding the cephalosporin C deacetylase fromBacillus: sp. NRRL B-14911 as reported in GENBANK® Accession numberZP_(—)01168674 appears to encode a 15 amino acid N-terminal additionthat is likely incorrect based on sequence alignments with othercephalosporin C deacetylases and a comparison of the reported length(340 amino acids) versus the observed length of other CAH enzymes(typically 318-325 amino acids in length; see co-owed, co-filed, andcopending U.S. patent application under attorney docket number CL4205 USNA entitled “ENZYMATIC PERACID PRODUCTION USING A COSOLVENT”; hereinincorporated by reference). As such, the deduced amino acid sequencereported herein for the cephalosporin C deacetylase sequence fromBacillus sp. NRRL B-14911 does not include the N-terminal 15 amino acidsas reported under GENBANK® Accession number ZP_(—)01168674.

SEQ ID NO:10 is the deduced amino acid sequence of a cephalosporin Cdeacetylase from Bacillus halodurans C-125.

SEQ ID NO:11 is the deduced amino acid sequence of a cephalosporin Cdeacetylase from Bacillus clausii KSM-K16.

SEQ ID NO:12 is the deduced amino acid sequence of a Bacillus subtilisATCC® 29233™ cephalosporin C deacetylase (CAH).

SEQ ID NO:13 is the deduced amino acid sequence of aThermoanearobacterium saccharolyticum cephalosporin C deacetylase.

SEQ ID NO:14 is the deduced amino acid sequence of a Thermotogalettingae acetyl xylan esterase.

SEQ ID NO:15 is the deduced amino acid sequence of a Thermotogapetrophila acetyl xylan esterase.

SEQ ID NO:16 is the deduced amino acid sequence of a first acetyl xylanesterase from Thermotoga sp. RQ2 described herein as “RQ2(a)”.

SEQ ID NO:17 is the deduced amino acid sequence of a second acetyl xylanesterase from Thermotoga sp. RQ2 described herein as “RQ2(b)”.

SEQ ID NO:18 is the amino acid sequence of the region encompassing aminoacids residues 118 through 299 of SEQ ID NO:1.

SEQ ID NO:19 is the deduced amino acid sequence of a Thermotoganeapolitana acetyl xylan esterase variant from co-owned, co-filed, andcopending U.S. patent application Ser. No. 12/572,094 entitled “IMPROVEDPERHYDROLASES FOR ENZYMATIC PERACID GENERATION” (incorporated herein byreference in its entirety), where the Xaa residue at position 277 isAla, Val, Ser, or Thr.

SEQ ID NO:20 is the deduced amino acid sequence of a Thermotoga maritimaMSB8 acetyl xylan esterase variant from co-owned, co-filed, andcopending U.S. patent application Ser. No. 12/572,094, where the Xaaresidue at position 277 is Ala, Val, Ser, or Thr.

SEQ ID NO:21 is the deduced amino acid sequence of a Thermotogalettingae acetyl xylan esterase variant from co-owned, co-filed, andcopending U.S. patent application Ser. No. 12/572,094, where the Xaaresidue at position 277 is Ala, Val, Ser, or Thr.

SEQ ID NO:22 is the deduced amino acid sequence of a Thermotogapetrophila acetyl xylan esterase variant from co-owned, co-filed, andcopending U.S. patent application Ser. No. 12/572,094, where the Xaaresidue at position 277 is Ala, Val, Ser, or Thr.

SEQ ID NO:23 is the deduced amino acid sequence of a Thermotoga sp. RQ2acetyl xylan esterase variant derived from“RQ2(a)” from co-owned,co-filed, and copending U.S. patent application Ser. No. 12/572,094,where the Xaa residue at position 277 is Ala, Val, Ser, or Thr.

SEQ ID NO:24 is the deduced amino acid sequence of a Thermotoga sp. RQ2acetyl xylan esterase variant derived from “RQ2(b)” from co-owned,co-filed, and copending U.S. patent application Ser. No. 12/572,094,where the Xaa residue at position 278 is Ala, Val, Ser, or Thr.

SEQ ID NO:25 is the deduced amino acid sequence of an acetyl xylanesterase from Thermoanaerobacterium sp. JW/SL YS485.

SEQ ID NO:26 is the coding region of a kanamycin resistance gene (kan)from Streptomyces kanamyceticus.

SEQ ID NO:27 is plasmid pKD13, which contains the kanamycin resistancegene.

SEQ ID NO:28 is a forward primer used to clone katG from plasmid pKD13.

SEQ ID NO:29 is a reverse primer used to clone katG from plasmid pKD13.

SEQ ID NO:30 is the PCR product of the katG amplification from plasmidpKD13 using the primers of SEQ ID NO:28 and SEQ ID NO:29.

SEQ ID NO:31 is the coding region of the catalase-peroxidase gene(katG).

SEQ ID NO:32 is the deduced amino acid sequence of katG.

SEQ ID NO:33 is plasmid pKD46, which contains the λ-Red recombinasegenes.

SEQ ID NO:34 is a forward primer used to confirm disruption of katG.

SEQ ID NO:35 is a reverse primer used to confirm disruption of katG.

SEQ ID NO:36 is the temperature-sensitive plasmid pCP20, which containsthe FLP recombinase.

SEQ ID NO:37 is a forward primer used to clone katE from plasmid pKD13.

SEQ ID NO:38 is a reverse primer used to clone katE from plasmid pKD13.

SEQ ID NO:39 is the PCR product of the katE amplification from plasmidpKD13 using the primers of SEQ ID NO:37 and SEQ ID NO:38.

SEQ ID NO:40 is the coding region of the catalase HPII gene (katE).

SEQ ID NO:41 is the deduced amino acid sequence of katE.

SEQ ID NO:42 is a forward primer used to confirm disruption of katE.

SEQ ID NO:43 is a reverse primer used to confirm disruption of katE.

SEQ ID NO:44 is a coding region of a gene encoding acetyl xylan esterasefrom Thermotoga neapolitana as reported in GENBANK® (accession No.AE000512).

SEQ ID NO:45 is a forward primer used to amplify the acetyl xylanesterase gene from Thermotoga neapolitana.

SEQ ID NO:46 is a reverse primer used to amplify the acetyl xylanesterase gene from Thermotoga neapolitana.

SEQ ID NO:47 is the PCR product of the acetyl xylan esteraseamplification using the primers of SEQ ID NO:45 and SEQ ID NO:46.

SEQ ID NO:48 is a gene encoding acetyl xylan esterase from Thermotogamaritime as reported in GENBANK® (accession No. NP_(—)227893.1).

SEQ ID NO:49 is a forward primer used to amplify the acetyl xylanesterase gene from Thermotoga maritime.

SEQ ID NO:50 is a reverse primer used to amplify the acetyl xylanesterase gene from Thermotoga maritime.

SEQ ID NO:51 is the PCR product of the acetyl xylan esteraseamplification using the primers of SEQ ID NO:49 and SEQ ID NO:50.

SEQ ID NOs: 52 and 53 are forward and reverse primers as described inExample 25.

SEQ NO: 54 is the nucleic acid sequence of the nucleic acid productamplified by SEQ ID NO: 52 and 53 that was used to prepare plasmidpSW207.SEQ ID NOs: 55 and 56 are forward and reverse primers asdescribed in Example 25.

SEQ NO: 57 is the codon optimized Thermotoga maritima coding sequenceused to prepare plasmid pSW228.

SEQ ID NOs 58-65 are forward and reverse primers used to prepare thecoding sequences of the Thermotoga maritima variants in Example 26.

DETAILED DESCRIPTION OF THE INVENTION

In this disclosure, a number of terms and abbreviations are used. Thefollowing definitions apply unless specifically stated otherwise.

As used herein, the articles “a”, “an”, and “the” preceding an elementor component of the invention are intended to be nonrestrictiveregarding the number of instances (i,e., occurrences) of the element orcomponent. Therefore “a”, “an”, and “the” should be read to include oneor at least one, and the singular word form of the element or componentalso includes the plural unless the number is obviously meant to besingular.

As used herein, the term “comprising” means the presence of the statedfeatures, integers, steps, or components as referred to in the claims,but that it does not preclude the presence or addition of one or moreother features, integers, steps, components or groups thereof. The term“comprising” is intended to include embodiments encompassed by the terms“consisting essentially of”and “consisting of”. Similarly, the term“consisting essentially of” is intended to include embodimentsencompassed by the term “consisting of”.

As used herein, the term “about” modifying the quantity of an ingredientor reactant employed refers to variation in the numerical quantity thatcan occur, for example, through typical measuring and liquid handlingprocedures used for making concentrates or use solutions in the realworld; through inadvertent error in these procedures; throughdifferences in the manufacture, source, or purity of the ingredientsemployed to make the compositions or carry out the methods; and thelike. The term “about” also encompasses amounts that differ due todifferent equilibrium conditions for a composition resulting from aparticular initial mixture. Whether or not modified by the term “about”,the claims include equivalents to the quantities.

Where present, all ranges are inclusive and combinable. For example,when a range of “1 to 5” is recited, the recited range should beconstrued as including ranges “1 to 4”, “1 to 3”, “1-2”, “1-2 & 4-5”,“1-3 & 5”, and the like.

As used herein, the terms “substrate”, “suitable substrate”, and“carboxylic acid ester substrate” interchangeably refer specifically to:

-   -   (a) one or more esters having the structure        [X]_(m)R₅    -   wherein    -   X is an ester group of the formula R₆C(O)O;    -   R₆ is a C1 to C7 linear, branched or cyclic hydrocarbyl moiety,        optionally substituted with a hydroxyl group or C1 to C4 alkoxy        group, wherein R₆ optionally comprises one or more ether        linkages where R₆ is C2 to C7;    -   R₅ is a C1 to C6 linear, branched, or cyclic hydrocarbyl moiety        optionally substituted with a hydroxyl group, wherein each        carbon atom in R₅ individually comprises no more than one        hydroxyl group or no more than one ester group, and wherein R₅        optionally comprises one or more ether linkages;    -   m is 1 to the number of carbon atoms in R₅,    -   said one or more esters having solubility in water of at least 5        ppm at 25° C.; or    -   (b) one or more glycerides having the structure

-   -   wherein R₁ is a C1 to C7 straight chain or branched chain alkyl        optionally substituted with an hydroxyl or a C1 to C4 alkoxy        group and R₃ and R₄ are individually H or R₁C(O); or    -   (c) one or more esters of the formula

-   -   wherein R₁ is a C1 to C7 straight chain or branched chain alkyl        optionally substituted with an hydroxyl or a C1 to C4 alkoxy        group and R₂ is a C1 to C10 straight chain or branched chain        alkyl, alkenyl, alkynyl, aryl, alkylaryl, alkylheteroaryl,        heteroaryl, (CH₂CH₂O)_(n), or (CH₂CH(CH₃)—O)_(n)H and n is 1 to        10; or    -   (d) one or more acetylated monosaccharides, acetylated        disaccharides, or acetylated polysaccharides; or    -   (e) any combination of (a) through (d).

Examples of said carboxylic acid ester substrate may include monoacetin;triacetin; monopropionin; dipropionin; tripropionin; monobutyrin;dibutyrin; tributyrin; glucose pentaacetate; xylose tetraacetate;acetylated xylan; acetylated xylan fragments;β-D-ribofuranose-1,2,3,5-tetraacetate; tri-O-acetyl-D-galactal;tri-O-acetyl-glucal; propylene glycol diacetate; ethylene glycoldiacetate; monoesters or diesters of 1,2-ethanediol; 1,2-propanediol;1,3-propanediol; 1,2-butanediol; 1,3-butanediol; 2,3-butanediol;1,4-butanediol; 1,2-pentanediol; 2,5-pentanediol; 1,6-pentanediol,1,2-hexanediol; 2,5-hexanediol; 1,6-hexanediol; or any combinationthereof.

As used herein, the term “peracid” is synonymous with peroxyacid,peroxycarboxylic acid, peroxy acid, percarboxylic acid and peroxoicacid.

As used herein, the term “peracetic acid” is abbreviated as “PAA” and issynonymous with peroxyacetic acid, ethaneperoxoic acid and all othersynonyms of CAS Registry Number 79-21-0.

As used herein, the term “monoacetin” is synonymous with glycerolmonoacetate, glycerin monoacetate, and glyceryl monoacetate.

As used herein, the term “diacetin” is synonymous with glyceroldiacetate; glycerin diacetate, glyceryl diacetate, and all othersynonyms of CAS Registry Number 25395-31-7.

As used herein, the term “triacetin” is synonymous with glycerintriacetate; glycerol triacetate; glyceryl triacetate,1,2,3-triacetoxypropane; 1,2,3-propanetriol triacetate and all othersynonyms of CAS Registry Number 102-76-1.

As used herein, the term “monobutyrin” is synonymous with glycerolmonobutyrate, glycerin monobutyrate, and glyceryl monobutyrate.

As used herein, the term “dibutyrin” is synonymous with glyceroldibutyrate and glyceryl dibutyrate.

As used herein, the term “tributyrin” is synonymous with glyceroltributyrate, 1,2,3-tributyrylglycerol, and all other synonyms of CASRegistry Number 60-01-5.

As used herein, the term “monopropionin” is synonymous with glycerolmonopropionate, glycerin monopropionate, and glyceryl monopropionate.

As used herein, the term “dipropionin” is synonymous with glyceroldipropionate and glyceryl dipropionate.

As used herein, the term “tripropionin” is synonymous with glyceryltripropionate, glycerol tripropionate, 1,2,3-tripropionylglycerol, andall other synonyms of CAS Registry Number 139-45-7.

As used herein, the term “ethyl acetate” is synonymous with aceticether, acetoxyethane, ethyl ethanoate, acetic acid ethyl ester, ethanoicacid ethyl ester, ethyl acetic ester and all other synonyms of CASRegistry Number 141-78-6.

As used herein, the term “ethyl lactate” is synonymous with lactic acidethyl ester and all other synonyms of CAS Registry Number 97-64-3.

As used herein, the terms “acetylated sugar” and “acetylated saccharide”refer to mono-, di- and polysaccharides comprising at least one acetylgroup. Examples include, but are not limited to glucose pentaacetate;xylose tetraacetate; acetylated xylan; acetylated xylan fragments;β-D-ribofuranose-1,2,3,5-tetraacetate; tri-O-acetyl-D-galactal; andtri-O-acetyl-glucal.

As used herein, the terms “hydrocarbyl”, “hydrocarbyl group”, and“hydrocarbyl moiety” is meant a straight chain, branched or cyclicarrangement of carbon atoms connected by single, double, or triplecarbon to carbon bonds and/or by ether linkages, and substitutedaccordingly with hydrogen atoms. Such hydrocarbyl groups may bealiphatic and/or aromatic. Examples of hydrocarbyl groups includemethyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, cyclopropyl,cyclobutyl, pentyl, cyclopentyl, methylcyclopentyl, hexyl, cyclohexyl,benzyl, and phenyl. In a preferred embodiment, the hydrocarbyl moiety isa straight chain, branched or cyclic arrangement of carbon atomsconnected by single carbon to carbon bonds and/or by ether linkages, andsubstituted accordingly with hydrogen atoms.

As used herein, the terms “monoesters” and “diesters” of 1,2-ethanediol;1,2-propanediol; 1,3-propanediol; 1,2-butanediol; 1,3-butanediol;2,3-butanediol; 1,4-butanediol; 1,2-pentanediol; 2,5-pentanediol;1,6-pentanediol; 1,2-hexanediol; 2,5-hexanediol; 1,6-hexanediol; andmixtures thereof, refer to said compounds comprising at least one estergroup of the formula RC(O)O, wherein R is a Cl to C7 linear hydrocarbylmoiety. In one embodiment, the carboxylic acid ester substrate isselected from the group consisting of propylene glycol diacetate (PGDA),ethylene glycol diacetate (EDGA), and mixtures thereof.

As used herein, the term “propylene glycol diacetate” is synonymous with1,2-diacetoxypropane, propylene diacetate, 1,2-propanediol diacetate,and all other synonyms of CAS Registry Number 623-84-7.

As used herein, the term “ethylene glycol diacetate” is synonymous with1,2-diacetoxyethane, ethylene diacetate, glycol diacetate, and all othersynonyms of CAS Registry Number 111-55-7.

As used herein, the terms “suitable enzymatic reaction mixture”,“components suitable for in situ generation of a peroxycarboxylic acid”,“suitable reaction components”, “suitable aqueous reaction mixture”, and“reaction mixture” refer to the materials and water in which thereactants and enzyme catalyst come into contact. The components of thesuitable aqueous reaction mixture are provided herein and those skilledin the art appreciate the range of component variations suitable forthis process. In one embodiment, the suitable enzymatic reaction mixtureproduces peroxycarboxylic acid in situ upon combining the reactioncomponents. As such, the reaction components may be provided as amulti-component system wherein the reaction components remains separateduntil use. The design of systems and means for separating and combiningmultiple active components are known in the art and generally willdepend upon the physical form of the individual reaction components. Forexample, multiple active fluids (liquid-liquid) systems typically usemulti-chamber dispenser bottles or two-phase systems (e.g., U.S. PatentApplication Publication No. 2005/0139608; U.S. Pat. Nos. 5,398,846;5,624,634; 6,391,840; E.P. Patent 0807156B1; U.S. Patent Application.Pub. No. 2005/0008526; and PCT Publication No. WO 00/61713) such asfound in some bleaching applications wherein the desired bleaching agentis produced upon mixing the reactive fluids. Other forms ofmulticomponent systems used to generate peroxycarboxylic acid mayinclude, but are not limited to, those designed for one or more solidcomponents or combinations of solid-liquid components, such as powders(e.g., U.S. Pat. No. 5,116,575), multi-layered tablets (e.g., U.S. Pat.No. 6,210,639), water dissolvable packets having multiple compartments(e.g., U.S. Pat. No. 6,995,125) and solid agglomerates that react uponthe addition of water (e.g., U.S. Pat. No. 6,319,888).

In another embodiment, the carboxylic acid ester in the first componentis selected from the group consisting of monoacetin, diacetin,triacetin, and combinations thereof. In another embodiment, thecarboxylic acid ester in the first component is an acetylatedsaccharide. In another embodiment, the enzyme catalyst in the firstcomponent is a particulate solid. In another embodiment, the firstreaction component is a solid tablet or powder.

As used herein, the term “perhydrolysis” is defined as the reaction of aselected substrate with peroxide to form a peroxycarboxylic acid.Typically, inorganic peroxide is reacted with the selected substrate inthe presence of a catalyst to produce the peroxycarboxylic acid. As usedherein, the term “chemical perhydrolysis” includes perhydrolysisreactions in which a substrate (a peroxycarboxylic acid precursor) iscombined with a source of hydrogen peroxide wherein peroxycarboxylicacid is formed in the absence of an enzyme catalyst.

As used herein, the term “perhydrolase activity” refers to the catalystactivity per unit mass (for example, milligram) of protein, dry cellweight, or immobilized catalyst weight.

As used herein, “one unit of enzyme activity” or “one unit of activity”or “U” is defined as the amount of perhydrolase activity required forthe production of 1 μmol of peroxycarboxylic acid product per minute ata specified temperature.

As used herein, the terms “enzyme catalyst” and “perhydrolase catalyst”refer to a catalyst comprising an enzyme having perhydrolysis activityand may be in the form of a whole microbial cell, permeabilizedmicrobial cell(s), one or more cell components of a microbial cellextract, partially purified enzyme, or purified enzyme. The enzymecatalyst may also be chemically modified (e.g., by pegylation or byreaction with cross-linking reagents). The perhydrolase catalyst mayalso be immobilized on a soluble or insoluble support using methodswell-known to those skilled in the art; see for example, Immobilizationof Enzymes and Cells; Gordon F. Bickerstaff, Editor; Humana Press,Totowa, N.J., USA; 1997. As described herein, all of the present enzymeshaving perhydrolysis activity are structurally members of thecarbohydrate family esterase family 7 (CE-7 family) of enzymes (seeCoutinho, P. M., Henrissat, B. “Carbohydrate-active enzymes: anintegrated database approach” in Recent Advances in CarbohydrateBioengineering, H. J. Gilbert, G. Davies, B. Henrissat and B. Svenssoneds., (1999) The Royal Society of Chemistry, Cambridge, pp. 3-12.). TheCE-7 family of enzymes has been demonstrated to be particularlyeffective for producing peroxycarboxylic acids from a variety ofcarboxylic acid ester substrates when combined with a source ofperoxygen (WO2007/070609 and U.S. Patent Application Publication Nos.2008/0176299, 2008/176783, and 2009/0005590 to DiCosimo et al.; eachherein incorporated by reference in their entirety).

Members of the CE-7 family include cephalosporin C deacetylases (CAHs;E.C. 3.1.1.41) and acetyl xylan esterases (AXEs; E.C. 3,1.1.72). Membersof the CE-7 esterase family share a conserved signature motif (Vincentet al., J. Mol. Biol., 330:593-606 (2003)). Perhydrolases comprising theCE-7 signature motif and/or a substantially similar structure aresuitable for use in the present invention. Means to identifysubstantially similar biological molecules are well known in the art(e.g., sequence alignment protocols, nucleic acid hybridizations and/orthe presence of a conserved signature motif). In one aspect, theperhydrolase includes an enzyme comprising the CE-7 signature motif andat least 30%, preferably at least 33%, more preferably at least 40%,even more preferably at least 42%, even more preferably at least 50%,even more preferably at least 60%, even more preferably at least 70%,even more preferably at least 80%, even more preferably at least 90%,and most preferably at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,98%, or 99% amino acid identity to one of the sequences provided herein.

As used herein, the terms “cephalosporin C deacetylase” and“cephalosporin C acetyl hydrolase” refer to an enzyme (E.C. 3.1.1.41)that catalyzes the deacetylation of cephalosporins such as cephalosporinC and 7-aminocephalosporanic acid (Mitsushima et at., (1995) Appl. Env.Microbiol. 61(6)2224-2229). As described herein, several cephalosporin Cdeacetylases are provided having significant perhydrolysis activity.

As used herein, “acetyl xylan esterases” refers to an enzyme (E.C.3.1.1.72; AXEs) that catalyzes the deacetylation of acetylated xylansand other acetylated saccharides. As illustrated herein, several enzymesclassified as acetyl xylan esterases are provided having significantperhydrolysis activity.

As used herein, the term “Bacillus subtilis ATCC® 31954™” refers to abacterial cell deposited to the American Type Culture Collection (ATCC)having international depository accession number ATCC® 31954™. Bacillussubtilis ATCC® 31954™ has been reported to have an ester hydrolase(“diacetinase”) activity capable of hydrolyzing glycerol esters having 2to 8 carbon acyl groups, especially diacetin (U.S. Pat. No. 4,444,886;herein incorporated by reference in its entirety). As described herein,an enzyme having significant perhydrolase activity has been isolatedfrom B. subtilis ATCC® 31954™ and is provided as SEQ ID NO: 1, The aminoacid sequence of the isolated enzyme has 100% amino acid identity to thecephalosporin C deacetylase provided by GENBANK® Accession No.BAA01729.1 (Mitsushima et al., supra).

As used herein, the term “Bacillus subtilis ATCC® 29233™” refers to astrain of Bacillus subtilis deposited to the American Type CultureCollection (ATCC) having international depository accession number ATCC®29233™. As described herein, an enzyme having significant perhydrolaseactivity has been isolated and sequenced from B. subtilis ATCC® 29233™and is provided as SEQ ID NO:12.

As used herein, the term “Clostridium thermocellum ATCC® 27405™” refersto a strain of Clostridium thermocellum deposited to the American TypeCulture Collection (ATCC) having international depository accessionnumber ATCC® 27405™. The amino acid sequence of the enzyme havingperhydrolase activity from C. thermocellum ATCC® 27405™ is provided asSEQ ID NO:5.

As used herein, the term “Bacillus subtilis ATCC® 6633™” refers to abacterial cell deposited to the American Type Culture Collection (ATCC)having international depository accession number ATCC® 6633™. Bacillussubtilis ATCC® 6633™ has been reported to have cephalosporinacetylhydrolase activity (U.S. Pat. No. 6,465,233). The amino acidsequence of the enzyme having perhydrolase activity from B. subtilisATCC® 6633™ is provided as SEQ ID NO:2.

As used herein, the term “Bacillus licheniformis ATCC® 14580™” refers toa bacterial cell deposited to the American Type Culture Collection(ATCC) having international depository accession number ATCC® 14580™.Bacillus licheniformis ATCC® 14580™ has been reported to havecephalosporin acetylhydrolase activity. The amino acid sequence of theenzyme having perhydrolase activity from B. licheniformis ATCC® 14580™is provided as SEQ ID NO:3.

As used herein, the term “Bacillus pumilus P5213” refers to a bacterialcell reported to have acetyl xylan esterase activity (GENBANK®AJ249957). The amino acid sequence of the enzyme having perhydrolaseactivity from Bacillus pumilus PS213 is provided as SEQ ID NO:4.

As used herein, the term “Thermotoga neapolitana” refers to a strain ofThermotoga neapolitana reported to have acetyl xylan esterase activity(GENBANK® AAB70869). The amino acid sequence of the enzyme havingperhydrolase activity from Thermotoga neapolitana is provided as SEQ IDNO: 6.

As used herein, the term “Thermotoga maritime MSB8” refers to abacterial cell reported to have acetyl xylan esterase activity (GENBANK®NP_(—)227893.1). The amino acid sequence of the enzyme havingperhydrolase activity from Thermotoga maritime MSB8 is provided as SEQID NO: 7.

As used herein, the term “Bacillus clausii KSM-K16” refers to abacterial cell reported to have cephalosporin-C deacetylase activity(GENBANK® YP_(—)175265). The amino acid sequence of the enzyme havingperhydrolase activity from Bacillus clausii KSM-K16 is provided as SEQID NO: 11.

As used herein, the term “Thermoanearobacterium saccharolyticum” refersto a bacterial strain reported to have acetyl xylan esterase activity(GENBANK® S41858). The amino acid sequence of the enzyme havingperhydrolase activity from Thermoanearobacterium saccharolyticum isprovided as SEQ ID NO: 13.

As used herein, the term “Thermotoga lettingae” refers to a bacterialcell reported to have acetyl xylan esterase activity (GENBANK®CP000812). The deduced amino acid sequence of the enzyme havingperhydrolase activity from Thermotoga lettingae is provided as SEQ IDNO: 14.

As used herein, the term “Thermotoga petrophila” refers to a bacterialcell reported to have acetyl xylan esterase activity (GENBANK®CP000702). The deduced amino acid sequence of the enzyme havingperhydrolase activity from Thermotoga petrophila is provided as SEQ IDNO: 15.

As used herein, the term “Thermotoga sp. RQ2” refers to a bacterial cellreported to have acetyl xylan esterase activity (GENBANK® CP000969). Twodifferent acetyl xylan esterases have been identified from Thermotogasp. RQ2 and are referred to herein as “RQ2(a)” (the deduced amino acidsequence provided as SEQ ID NO: 16) and “RQ2(b)” (the deduced amino acidsequence provided as SEQ ID NO: 17).

As used herein, an “isolated nucleic acid molecule”, “isolatedpolynucleotide”, and “isolated nucleic acid fragment” will be usedinterchangeably and refer to a polymer of RNA or DNA that is single- ordouble-stranded, optionally containing synthetic, non-natural or alterednucleotide bases. An isolated nucleic acid molecule in the form of apolymer of DNA may be comprised of one or more segments of cDNA, genomicDNA or synthetic DNA.

The term “amino acid” refers to the basic chemical structural unit of aprotein or polypeptide. The following abbreviations are used herein toidentify specific amino acids:

Three-Letter One-Letter Amino Acid Abbreviation Abbreviation Alanine AlaA Arginine Arg R Asparagine Asn N Aspartic acid Asp D Cysteine Cys CGlutamine Gln Q Glutamic acid Glu E Glycine Gly G Histidine His HIsoleucine Ile I Leucine Leu L Lysine Lys K Methionine Met MPhenylalanine Phe F Proline Pro P Serine Ser S Threonine Thr TTryptophan Trp W Tyrosine Tyr Y Valine Val V Any amino acid or Xaa X asdefined herein

As used herein, “substantially similar” refers to nucleic acid moleculeswherein changes in one or more nucleotide bases results in the addition,substitution, or deletion of one or more amino acids, but does notaffect the functional properties (i.e., perhydrolytic activity) of theprotein encoded by the DNA sequence. As used herein, “substantiallysimilar” also refers to an enzyme having an amino acid sequence that isat least 30%, preferably at least 33%, more preferably at least 40%,more preferably at least 50%, even more preferably at least 60%, evenmore preferably at least 70%, even more preferably at least 80%, yeteven more preferably at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,98%, or 99% identical to the sequences reported herein wherein theresulting enzyme retains the present functional properties (i.e.,perhydrolytic activity). “Substantially similar” may also refer to anenzyme having perhydrolytic activity encoded by nucleic acid moleculesthat hybridize under stringent conditions to the nucleic acid moleculesreported herein. It is therefore understood that the inventionencompasses more than the specific exemplary sequences.

For example, it is well known in the art that alterations in a genewhich result in the production of a chemically equivalent amino acid ata given site, but do not affect the functional properties of the encodedprotein are common. For the purposes of the present inventionsubstitutions are defined as exchanges within one of the following fivegroups:

-   -   1. Small aliphatic, nonpolar or slightly polar residues: Ala,        Ser, Thr (Pro, Gly);    -   2. Polar, negatively charged residues and their amides: Asp,        Asn, Glu, Gln;    -   3. Polar, positively charged residues: His, Arg, Lys;    -   4. Large aliphatic, nonpolar residues: Met, Leu, Ile, Val (Cys);        and    -   5. Large aromatic residues: Phe, Tyr, and Trp.        Thus, a codon for the amino acid alanine, a hydrophobic amino        acid, may be substituted by a codon encoding another less        hydrophobic residue (such as glycine) or a more hydrophobic        residue (such as valine, leucine, or isoleucine). Similarly,        changes which result in substitution of one negatively charged        residue for another (such as aspartic acid for glutamic acid) or        one positively charged residue for another (such as lysine for        arginine) can also be expected to produce a functionally        equivalent product. In many cases, nucleotide changes which        result in alteration of the N-terminal and C-terminal portions        of the protein molecule would also not be expected to alter the        activity of the protein.

Each of the proposed modifications is well within the routine skill inthe art, as is determination of retention of biological activity of theencoded products. Moreover, the skilled artisan recognizes thatsubstantially similar sequences are encompassed by the presentinvention. In one embodiment, substantially similar sequences aredefined by their ability to hybridize, under stringent conditions(0.1×SSC, 0.1% SDS, 65° C. and washed with 2×SSC, 0.1% SDS followed by0.1×SSC, 0.1% SDS, 65° C.) with the sequences exemplified herein.

As used herein, a nucleic acid molecule is “hybridizable” to anothernucleic acid molecule, such as a cDNA, genomic DNA, or RNA, when asingle strand of the first molecule can anneal to the other moleculeunder appropriate conditions of temperature and solution ionic strength.Hybridization and washing conditions are well known and exemplified inSambrook, J. and Russell, D., T. Molecular Cloning: A Laboratory Manual,Third Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor(2001). The conditions of temperature and ionic strength determine the“stringency” of the hybridization. Stringency conditions can be adjustedto screen for moderately similar molecules, such as homologous sequencesfrom distantly related organisms, to highly similar molecules, such asgenes that duplicate functional enzymes from closely related organisms.Post-hybridization washes typically determine stringency conditions. Oneset of preferred conditions uses a series of washes starting with 6×SSC,0.5% SDS at room temperature for 15 min, then repeated with 2×SSC, 0.5%SDS at 45° C. for 30 min, and then repeated twice with 0.2×SSC, 0.5% SDSat 50° C. for 30 min. A more preferred set of conditions uses highertemperatures in which the washes are identical to those above except forthe temperature of the final two 30 min washes in 0.2×SSC, 0.5% SDS wasincreased to 60° C. Another preferred set of stringent hybridizationconditions is 0.1×SSC, 0.1% SDS, 65° C. and washed with 2×SSC, 0.1% SDSfollowed by a final wash of 0.1×SSC, 0.1% SDS, 65° C. with the sequencesexemplified herein.

Hybridization requires that the two nucleic acids contain complementarysequences, although depending on the stringency of the hybridization,mismatches between bases are possible. The appropriate stringency forhybridizing nucleic acids depends on the length of the nucleic acids andthe degree of complementation, variables well known in the art. Thegreater the degree of similarity or homology between two nucleotidesequences, the greater the value of Tm for hybrids of nucleic acidshaving those sequences. The relative stability (corresponding to higherTm) of nucleic acid hybridizations decreases in the following order:RNA:RNA, DNA:RNA, DNA:DNA. For hybrids of greater than 100 nucleotidesin length, equations for calculating Tm have been derived (Sambrook andRussell, supra). For hybridizations with shorter nucleic acids, i.e.,oligonucleotides, the position of mismatches becomes more important, andthe length of the oligonucleotide determines its specificity (Sambrookand Russell, supra). In one aspect, the length for a hybridizablenucleic acid is at least about 10 nucleotides. Preferably, a minimumlength for a hybridizable nucleic acid is at least about 15 nucleotidesin length, more preferably at least about 20 nucleotides in length, evenmore preferably at least 30 nucleotides in length, even more preferablyat least 300 nucleotides in length, and most preferably at least 800nucleotides in length. Furthermore, the skilled artisan will recognizethat the temperature and wash solution salt concentration may beadjusted as necessary according to factors such as length of the probe.

As used herein, the term “percent identity” is a relationship betweentwo or more polypeptide sequences or two or more polynucleotidesequences, as determined by comparing the sequences. In the art,“identity” also means the degree of sequence relatedness betweenpolypeptide or polynucleotide sequences, as the case may be, asdetermined by the match between strings of such sequences. “Identity”and “similarity” can be readily calculated by known methods, includingbut not limited to those described in: Computational Molecular Biology(Lesk, A. M., ed.) Oxford University Press, NY (1988); Biocomputing:Informatics and Genome Projects (Smith, D. W., ed.) Academic Press, NY(1993); Computer Analysis of Sequence Data, Part I(Griffin, A. M., andGriffin, H. G., eds.) Humana Press, NJ (1994); Sequence Analysis inMolecular Biology (von Heinje, G., ed.) Academic Press (1987); andSequence Analysis Primer (Gribskov, M. and Devereux, J., eds.) StocktonPress, NY (1991). Methods to determine identity and similarity arecodified in publicly available computer programs. Sequence alignmentsand percent identity calculations may be performed using the Megalignprogram of the LASERGENE bioinformatics computing suite (DNASTAR Inc.,Madison, Wis.), the AlignX program of Vector NTI v. 7.0 (lnformax, Inc.,Bethesda, Md.), or the EMBOSS Open Software Suite (EMBL-EBI; Rice etal., Trends in Genetics 16,: (6):276-277 (2000)). Multiple alignment ofthe sequences can be performed using the CLUSTAL method (such asCLUSTALW; for example version 1.83) of alignment (Higgins and Sharp,CABIOS, 5:151-153 (1989); Higgins et al., Nucleic Acids Res.22:4673-4680 (1994); and Chenna et al., Nucleic Acids Res 31(13):3497-500 (2003)), available from the European Molecular BiologyLaboratory via the European Bioinformatics Institute) with the defaultparameters. Suitable parameters for CLUSTALW protein alignments includeGAP Existence penalty=15, GAP extension=0.2, matrix=Gonnet (e.g.,Gonnet250), protein ENDGAP=−1, Protein GAPDIST=4, and KTUPLE=1. In oneembodiment, a fast or slow alignment is used with the default settingswhere a slow alignment is preferred. Alternatively, the parameters usingthe CLUSTALW method (e.g., version 1.83) may be modified to also useKTUPLE=1, GAP PENALTY=10, GAP extension=1, matrix=BLOSUM (e.g.,BLOSUM64), WINDOW=5, and TOP DIAGONALS SAVED=5.

In one aspect, suitable isolated nucleic acid molecules encode apolypeptide having an amino acid sequence that is at least about 30%,preferably at least 33%, preferably at least 40%, preferably at least50%, preferably at least 60%, more preferably at least 70%, morepreferably at least 80%, even more preferably at least 85%, even morepreferably at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%identical to the amino acid sequences reported herein. Suitable nucleicacid molecules not only have the above homologies, but also typicallyencode a polypeptide having about 300 to about 340 amino acids, morepreferably about 310 to about 330 amino acids, and most preferably about318 to about 325 amino acids.

As used herein, the terms “signature motif”, “CE-7 signature motif”, and“diagnostic motif” refer to conserved structures shared among a familyof enzymes having a defined activity. The signature motif can be used todefine and/or identify the family of structurally related enzymes havingsimilar enzymatic activity for a defined family of substrates. Thesignature motif can be a single contiguous amino acid sequence or acollection of discontiguous, conserved motifs that together form thesignature motif. Typically, the conserved motif(s) is represented by anamino acid sequence.

As described herein, the present enzymes having perhydrolysis activity(“perhydrolases”) belong to the family of CE-7 carbohydrate esterases(DiCosimo et al., U.S. Patent Application Publication No. 2009/0005590).As used herein, the phrase “enzyme is structurally classified as a CE-7enzyme”, “CE-7 perhydrolase” or “structurally classified as acarbohydrate esterase family 7 enzyme” will be used to refer to enzymeshaving perhydrolysis activity which are structurally classified as aCE-7 carbohydrate esterase. This family of enzymes can be defined by thepresence of a signature motif (Vincent et al., supra). The signaturemotif for CE-7 esterases comprises three conserved motifs (residueposition numbering relative to reference sequence SEQ ID NO: 1):

a) Arg118-Gly119-Gln120;

b) Gly179-Xaa180-Ser181-Gln182-Gly183; and

c) His298-Glu299.

Typically, the Xaa at amino acid residue position 180 is glycine,alanine, proline, tryptophan, or threonine. Two of the three amino acidresidues belonging to the catalytic triad are in bold. In oneembodiment, the Xaa at amino acid residue position 180 is selected fromthe group consisting of glycine, alanine, proline, tryptophan, andthreonine.

Further analysis of the conserved motifs within the CE-7 carbohydrateesterase family indicates the presence of an additional conserved motif(LXD at amino acid positions 267-269 of SEQ ID NO:1) that may be used tofurther define a perhydrolase belonging to the CE-7 carbohydrateesterase family. In a further embodiment, the signature motif definedabove includes a fourth conserved motif defined as:

Leu267-Xaa268-Asp269.

The Xaa at amino acid residue position 268 is typically isoleucine,valine, or methionine. The fourth motif includes the aspartic acidresidue (bold) belonging to the catalytic triad (Ser181-Asp269-His298).

A number of well-known global alignment algorithms (i.e., sequenceanalysis software) may be used to align two or more amino acid sequencesrepresenting enzymes having perhydrolase activity to determine if theenzyme is comprised of the present signature motif. The alignedsequence(s) are compared to the reference sequence (SEQ ID NO:1) todetermine the existence of the signature motif. In one embodiment, aCLUSTAL alignment (such as CLUSTALW) using a reference amino acidsequence (as used herein the perhydrolase sequence (SEQ ID NO:1) fromthe Bacillus subtilis ATCC® 31954™) is used to identify perhydrolasesbelonging to the CE-7 esterase family. The relative numbering of theconserved amino acid residues is based on the residue numbering of thereference amino acid sequence to account for small insertions ordeletions (for example, five amino acids of less) within the alignedsequence.

Examples of other suitable algorithms that may be used to identifysequences comprising the present signature motif (when compared to thereference sequence) include, but are not limited to, Needleman andWunsch (J. Mol. Biol. 48, 443-453 (1970); a global alignment tool) andSmith-Waterman (J. Mol. Biol. 147:195-197 (1981); a local alignmenttool). In one embodiment, a Smith-Waterman alignment is implementedusing default parameters. An example of suitable default parametersinclude the use of a BLOSUM62 scoring matrix with GAP open penalty=10and a GAP extension penalty=0.5.

A comparison of the overall percent identity among perhydrolasesexemplified herein indicates that enzymes having as little as 33%identity to SEQ ID NO: 1 (while retaining the signature motif) exhibitsignificant perhydrolase activity and are structurally classified asCE-7 carbohydrate esterases. In one embodiment, suitable perhydrolasesinclude enzymes comprising the CE-7 signature motif and at least 30%,preferably at least 33%, more preferably at least 40%, even morepreferably at least 42%, even more preferably at least 50%, even morepreferably at least 60%, even more preferably at least 70%, even morepreferably at least 80%, even more preferably at least 90%, and mostpreferably at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%amino acid identity to SEQ ID NO: 1.

Alternatively, a contiguous amino acid sequence comprising the regionencompassing the conserved motifs may also be used to identify CE-7family members.

As used herein, “codon degeneracy” refers to the nature of the geneticcode permitting variation of the nucleotide sequence without affectingthe amino acid sequence of an encoded polypeptide. Accordingly, thepresent invention relates to any nucleic acid molecule that encodes allor a substantial portion of the amino acid sequences encoding thepresent microbial polypeptide. The skilled artisan is well aware of the“codon-bias” exhibited by a specific host cell in usage of nucleotidecodons to specify a given amino acid. Therefore, when synthesizing agene for improved expression in a host cell, it is desirable to designthe gene such that its frequency of codon usage approaches the frequencyof preferred codon usage of the host cell.

As used herein, the term “codon optimized”, as it refers to genes orcoding regions of nucleic acid molecules for transformation of varioushosts, refers to the alteration of codons in the gene or coding regionsof the nucleic acid molecules to reflect the typical codon usage of thehost organism without altering the polypeptide for which the DNA codes.

As used herein, “synthetic genes” can be assembled from oligonucleotidebuilding blocks that are chemically synthesized using procedures knownto those skilled in the art. These building blocks are ligated andannealed to form gene segments that are then enzymatically assembled toconstruct the entire gene. “Chemically synthesized”, as pertaining to aDNA sequence, means that the component nucleotides were assembled invitro. Manual chemical synthesis of DNA may be accomplished usingwell-established procedures, or automated chemical synthesis can beperformed using one of a number of commercially available machines.Accordingly, the genes can be tailored for optimal gene expression basedon optimization of nucleotide sequences to reflect the codon bias of thehost cell. The skilled artisan appreciates the likelihood of successfulgene expression if codon usage is biased towards those codons favored bythe host. Determination of preferred codons can be based on a survey ofgenes derived from the host cell where sequence information isavailable.

As used herein, “gene” refers to a nucleic acid molecule that expressesa specific protein, including regulatory sequences preceding (5′non-coding sequences) and following (3′ non-coding sequences) the codingsequence. “Native gene” refers to a gene as found in nature with its ownregulatory sequences. “Chimeric gene” refers to any gene that is not anative gene, comprising regulatory and coding sequences that are notfound together in nature. Accordingly, a chimeric gene may compriseregulatory sequences and coding sequences that are derived fromdifferent sources, or regulatory sequences and coding sequences derivedfrom the same source, but arranged in a manner different from that foundin nature. “Endogenous gene” refers to a native gene in its naturallocation in the genome of an organism. A “foreign” gene refers to a genenot normally found in the host organism, but that is introduced into thehost organism by gene transfer. Foreign genes can comprise native genesinserted into a non-native organism, or chimeric genes. A “transgene” isa gene that has been introduced into the genome by a transformationprocedure.

As used herein, “coding sequence” refers to a DNA sequence that codesfor a specific amino acid sequence. “Suitable regulatory sequences”refer to nucleotide sequences located upstream (5′ non-codingsequences), within, or downstream (3′ non-coding sequences) of a codingsequence, and which influence the transcription, RNA processing orstability, or translation of the associated coding sequence. Regulatorysequences may include promoters, translation leader sequences, RNAprocessing site, effector binding site and stem-loop structure.

As used herein, “promoter” refers to a DNA sequence capable ofcontrolling the expression of a coding sequence or functional RNA. Ingeneral, a coding sequence is located 3′ to a promoter sequence.Promoters may be derived in their entirety from a native gene, or becomposed of different elements derived from different promoters found innature, or even comprise synthetic DNA segments. It is understood bythose skilled in the art that different promoters may direct theexpression of a gene at different stages of development, or in responseto different environmental or physiological conditions. Promoters thatcause a gene to be expressed at most times are commonly referred to as“constitutive promoters”. It is further recognized that since in mostcases the exact boundaries of regulatory sequences have not beencompletely defined, DNA fragments of different lengths may haveidentical promoter activity.

As used herein, the “3′ non-coding sequences” refer to DNA sequenceslocated downstream of a coding sequence and include polyadenylationrecognition sequences (normally limited to eukaryotes) and othersequences encoding regulatory signals capable of affecting mRNAprocessing or gene expression. The polyadenylation signal is usuallycharacterized by affecting the addition of polyadenylic acid tracts(normally limited to eukaryotes) to the 3′ end of the mRNA precursor.

As used herein, the term “operably linked” refers to the association ofnucleic acid sequences on a single nucleic acid molecule so that thefunction of one is affected by the other. For example, a promoter isoperably linked with a coding sequence when it is capable of affectingthe expression of that coding sequence, i.e., the coding sequence isunder the transcriptional control of the promoter. Coding sequences canbe operably linked to regulatory sequences in sense or antisenseorientation.

As used herein, the term “expression” refers to the transcription andstable accumulation of sense (mRNA) or antisense RNA derived from thenucleic acid molecule of the invention. Expression may also refer totranslation of mRNA into a polypeptide.

As used herein, “transformation” refers to the transfer of a nucleicacid molecule into the genome of a host organism, resulting ingenetically stable inheritance. In the present invention, the hostcell's genome includes chromosomal and extrachromosomal (e.g., plasmid)genes. Host organisms containing the transformed nucleic acid moleculesare referred to as “transgenic” or “recombinant” or “transformed”organisms.

As used herein, the terms “plasmid”, “vector” and “cassette” refer to anextrachromosomal element often carrying genes which are not part of thecentral metabolism of the cell, and usually in the form of circulardouble-stranded DNA molecules. Such elements may be autonomouslyreplicating sequences, genome integrating sequences, phage or nucleotidesequences, linear or circular, of a single- or double-stranded DNA orRNA, derived from any source, in which a number of nucleotide sequenceshave been joined or recombined into a unique construction which iscapable of introducing a promoter fragment and DNA sequence for aselected gene product along with appropriate 3′ untranslated sequenceinto a cell. “Transformation cassette” refers to a specific vectorcontaining a foreign gene and having elements in addition to the foreigngene that facilitate transformation of a particular host cell.“Expression cassette” refers to a specific vector containing a foreigngene and having elements in addition to the foreign gene that allow forenhanced expression of that gene in a foreign host.

As used herein, the term “sequence analysis software” refers to anycomputer algorithm or software program that is useful for the analysisof nucleotide or amino acid sequences. “Sequence analysis software” maybe commercially available or independently developed. Typical sequenceanalysis software will include, but is not limited to, the GCG suite ofprograms (Wisconsin Package Version 9.0, Genetics Computer Group (GCG),Madison, Wis.), BLASTP, BLASTN, BLASTX (Altschul et al., J. Mol. Biol.215:403-410 (1990)), and DNASTAR (DNASTAR, Inc. 1228 S. Park St.Madison, Wis. 53715 USA), CLUSTALW (for example, version 1.83; Thompsonet al., Nucleic Acids Research, 22(22):4673-4680 (1994)), and the FASTAprogram incorporating the Smith-Waterman algorithm (W. R. Pearson,Comput. Methods Genome Res., [Proc. Int. Symp.] (1994), Meeting Date1992, 111-20. Editor(s): Suhai, Sandor. Publisher: Plenum, New York,N.Y.), Vector NTI (Informax, Bethesda, Md.) and Sequencher v. 4.05.Within the context of this application it will be understood that wheresequence analysis software is used for analysis, that the results of theanalysis will be based on the “default values” of the programreferenced, unless otherwise specified. As used herein “default values”will mean any set of values or parameters set by the softwaremanufacturer that originally load with the software when firstinitialized.

As used herein, the term “biological contaminants” refers to one or moreunwanted and/or pathogenic biological entities including, but notlimited to, microorganisms, spores, viruses, prions, and mixturesthereof. The process produces an efficacious concentration of at leastone percarboxylic acid useful to reduce and/or eliminate the presence ofthe viable biological contaminants. In a preferred embodiment, thebiological contaminant is a viable pathogenic microorganism.

As used herein, the term “disinfect” refers to the process ofdestruction of or prevention of the growth of biological contaminants.As used herein, the term “disinfectant” refers to an agent thatdisinfects by destroying, neutralizing, or inhibiting the growth ofbiological contaminants. Typically, disinfectants are used to treatinanimate objects or surfaces. As used herein, the term “disinfection”refers to the act or process of disinfecting. As used herein, the term“antiseptic” refers to a chemical agent that inhibits the growth ofdisease-carrying microorganisms. In one aspect, the biologicalcontaminants are pathogenic microorganisms.

As used herein, the term “sanitary” means of or relating to therestoration or preservation of health, typically by removing, preventingor controlling an agent that may be injurious to health. As used herein,the term “sanitize” means to make sanitary. As used herein, the term“sanitizer” refers to a sanitizing agent. As used herein the term“sanitization” refers to the act or process of sanitizing.

As used herein, the term “virucide” refers to an agent that inhibits ordestroys viruses, and is synonymous with “viricide”. An agent thatexhibits the ability to inhibit or destroy viruses is described ashaving “virucidal” activity. Peroxycarboxylic acids can have virucidalactivity. Typical alternative virucides known in the art which may besuitable for use with the present invention include, for example,alcohols, ethers, chloroform, formaldehyde, phenols, beta propiolactone,iodine, chlorine, mercury salts, hydroxylamine, ethylene oxide, ethyleneglycol, quaternary ammonium compounds, enzymes, and detergents.

As used herein, the term “biocide” refers to a chemical agent, typicallybroad spectrum, which inactivates or destroys microorganisms. A chemicalagent that exhibits the ability to inactivate or destroy microorganismsis described as having “biocidal” activity. Peroxycarboxylic acids canhave biocidal activity. Typical alternative biocides known in the art,which may be suitable for use in the present invention include, forexample, chlorine, chlorine dioxide, chloroisocyanurates, hypochlorites,ozone, acrolein, amines, chlorinated phenolics, copper salts,organo-sulphur compounds, and quaternary ammonium salts.

As used herein, the phrase “minimum biocidal concentration” refers tothe minimum concentration of a biocidal agent that, for a specificcontact time, will produce a desired lethal, irreversible reduction inthe viable population of the targeted microorganisms. The effectivenesscan be measured by the log₁₀ reduction in viable microorganisms aftertreatment. In one aspect, the targeted reduction in viablemicroorganisms after treatment is at least a 3-log reduction, morepreferably at least a 4-log reduction, and most preferably at least a5-log reduction. In another aspect, the minimum biocidal concentrationis at least a 6-log reduction in viable microbial cells.

As used herein, the terms “peroxygen source” and “source of peroxygen”refer to compounds capable of providing hydrogen peroxide at aconcentration of about 1 mM or more when in an aqueous solutionincluding, but not limited to, hydrogen peroxide, hydrogen peroxideadducts (e.g., urea-hydrogen peroxide adduct (carbamide peroxide)),perborates, and percarbonates. As described herein, the concentration ofthe hydrogen peroxide provided by the peroxygen compound in the aqueousreaction formulation is initially at least 1 mM or more upon combiningthe reaction components. In one embodiment, the hydrogen peroxideconcentration in the aqueous reaction formulation is at least 10 mM. Inanother embodiment, the hydrogen peroxide concentration in the aqueousreaction formulation is at least 100 mM. In another embodiment, thehydrogen peroxide concentration in the aqueous reaction formulation isat least 200 mM. In another embodiment, the hydrogen peroxideconcentration in the aqueous reaction formulation is 500 mM or more. Inyet another embodiment, the hydrogen peroxide concentration in theaqueous reaction formulation is 1000 mM or more. The molar ratio of thehydrogen peroxide to enzyme substrate, e.g., triglyceride,(H₂O₂:substrate) in the aqueous reaction formulation may be from about0.002 to 20, preferably about 0.1 to 10, and most preferably about 0.5to 5.

By “oligosaccharide” is meant compounds containing between 2 and atleast 24 monosaccharide units linked by glycosidic linkages. The term“monosaccharide” refers to a compound of empirical formula (CH₂O)_(n),where n≧3, the carbon skeleton is unbranched, each carbon atom exceptone contains a hydroxyl group, and the remaining carbon atom is analdehyde or ketone at carbon atom 2. The term “monosaccharide” alsorefers to intracellular cyclic hemiacetal or hemiketal forms.

As used herein, the term “excipient” refers to an inactive substanceused to stabilize the active ingredient in a formulation, such as thestorage stability of the active ingredient. Excipients are alsosometimes used to bulk up formulations that contain active ingredients.As described herein, the “active ingredient” is an enzyme catalystcomprising at least one enzyme having perhydrolysis activity. In oneembodiment, the active ingredient is at least one CE-7 carbohydrateesterase having perhydrolysis activity.

As used herein, the term “oligosaccharide excipient” means anoligosaccharide that, when added to an aqueous enzyme solution, improvesrecovery/retention of active enzyme (i.e., perhydrolase activity) afterspray drying and/or improves storage stability of the resultingspray-dried enzyme powder or a formulation of the enzyme powder and anorganic substrate. In one embodiment, the addition of theoligosaccharide excipient prior to spray drying improves the storagestability of the enzyme when stored in the carboxylic acid ester (i.e.,a storage mixture substantially free of water). The carboxylic acidester may contain a very low concentration of water, for example,triacetin typically has between 180 ppm and 300 ppm of water. As usedherein, the phrase “substantially free of water” will refer to aconcentration of water in a formulation of the enzyme powder and thecarboxylic acid ester that does not adversely impact the storagestability of enzyme powder when present in the carboxylic acid ester. Ina further embodiment, “substantially free of water” may mean less than2000 ppm, preferably less than 1000 ppm, more preferably less than 500ppm, and even more preferably less than 250 ppm of water in theformulation comprising the enzyme powder and the carboxylic acid ester.

Multicomponent Peroxycarboxylic Acid Generation Systems

Peroxycarboxylic acids are quite reactive and generally decrease inconcentration over time. This is especially true for commercialpre-formed peroxycarboxylic acid compositions that often lack long termstability. Aqueous solutions of pre-formed peroxycarboxylic acids mayalso present handling and/or shipping difficulties, especially whenshipping large containers and/or highly concentrated peroxycarboxylicacid solutions over longer distances. Further, pre-formedperoxycarboxylic acid solutions may not be able to provide the desiredconcentration of peroxycarboxylic acid for a particular targetapplication. As such, it is highly desirable to keep the variousreaction components separated, especially for liquid formulations.

The use of multi-component peroxycarboxylic acid generation systemscomprising two or more components that are combined to produce thedesired peroxycarboxylic acid has been reported. The individualcomponents should be safe to handle, easy to ship, and stable forextended periods of time (i.e., as measured by the concentration ofperoxycarboxylic acid produced upon mixing). In one embodiment, thestorage stability of a multi-component enzymatic peroxycarboxylic acidgeneration system may be measured in terms of enzyme catalyst stability.

The design of systems and means for separating and combining multipleactive components are known in the art and generally will depend uponthe physical form of the individual reaction components. For example,multiple active fluids (liquid-liquid) systems typically usemultichamber dispenser bottles or two-phase systems (e.g., U.S. PatentApplication Pub. No. 2005/0139608; U.S. Pat. Nos. 5,398,846; 5,624,634;6,391,840; E.P. Patent 0807156B1; U.S. Patent Application. Pub. No.2005/0008526; and PCT Publication No. WO 00/61713) such as found in somebleaching applications wherein the desired bleaching agent is producedupon mixing the reactive fluids. Other forms of multicomponent systemsused to generate peroxycarboxylic acid may include, but are not limitedto, those designed for one or more solid components or combinations ofsolid-liquid components, such as powders (e.g., U.S. Pat. No.5,116,575), multi-layered tablets (e.g., U.S. Pat. No. 6,210,639), waterdissolvable packets having multiple compartments (e.g., U.S. Pat. No.6,995,125) and solid agglomerates that react upon the addition of water(e.g., U.S. Pat. No. 6,319,888).

United States Published Patent Application No. 2004-0127381 to Sciallaet al. describes an aqueous two component laundry product. One part ofthe two part laundry product comprises a liquid cleaning compositionwhile the second part comprises a bleaching composition; wherein thebleaching composition comprises an equilibrium peroxycarboxylic acidsolution comprising a carboxylic acid, a source of peroxygen, and thecorresponding peroxycarboxylic acid.

A multi-component peroxycarboxylic acid generation formulation isprovided herein that uses an enzyme catalyst to rapidly produce anaqueous peroxycarboxylic acid solution having a desired peroxycarboxylicacid concentration. The mixing may occur immediately prior to use and/orat the site (in situ) of application. The formulation will be comprisedof at least two components that remain separated until use. Mixing ofthe components rapidly forms an aqueous peroxycarboxylic acid solution.The composition of each component is designed so that the resultingaqueous peroxycarboxylic acid solution comprises an efficaciousperoxycarboxylic acid concentration suitable for the intended end use(e.g., disinfecting, stain removal, odor reduction or bleachingapplications). The composition of the individual components should bedesigned to (1) provide extended storage stability and (2) provide theability to enhance formation of a suitable aqueous reaction formulationcomprised of peroxycarboxylic acid.

In one embodiment, the multi-component peroxycarboxylic acid generationformulation comprises a two component formulation. Various two componentformulations have been reported. In another embodiment, the twocomponent formulation is substantially a two liquid componentformulation. At a minimum, the present multi-component peroxycarboxylicacid formulation comprises (1) at least one enzyme catalyst havingperhydrolysis activity, wherein said at least one enzyme is structurallyclassified as a CE-7 esterase, (2) a carboxylic acid ester substrate,and (3) an aqueous source of peroxygen wherein the formulationenzymatically produces the desired peroxycarboxylic acid upon combiningthe components.

The ingredients and concentration of the ingredients within twocomponent formulation should to be carefully selected and balanced toprovide (1) storage stability of each component, especially theperhydrolysis activity of the enzyme catalyst and (2) physicalcharacteristics that enhance solubility and/or the ability toeffectively form the desired aqueous peroxycarboxylic acid solution(e.g., ingredients that enhance the solubility of the ester substrate inthe aqueous reaction mixture and/or ingredients that modify theviscosity and/concentration of at least one of the liquid components[i.e., at least one cosolvent that does not have a significant, adverseeffect on the enzymatic perhydrolysis activity]).

A multi-component peroxycarboxylic acid formulation is provided herein.The multi-component formulation is comprised of at least twosubstantially liquid components. In one embodiment, the multi-componentformulation is a two component formulation comprises a first liquidcomponent and a second liquid component. The use of the terms “first” or“second” liquid component is relative provided that two different liquidcomponents comprising the specified ingredients remain separated untiluse.

Co-owned, co-filed, and copending U.S. patent application Ser. No.12/572,059 entitled “ENZYMATIC PERACID PRODUCTION USING A COSOLVENT”describes the use of at least one cosolvent to enhance solubility and/orthe mixing characteristics of the ester substrate. The componentcomprising the carboxylic acid ester substrate and the perhydrolasecatalyst comprises an organic solvent having a Log P value of less thanabout 2, wherein Log P is defined as the logarithm of the partitioncoefficient of a substance between octanol and water, expressed asP=[solute]_(octanol)/[solute]_(water). Several cosolvents having a log Pvalue of 2 or less that do not have a significant adverse impact onenzyme activity are described. In one embodiment, the cosolvent is about20 wt % to about 70 wt % within the reaction component comprising thecarboxylic acid ester substrate and the enzyme.

Co-owned, co-filed, and copending U.S. patent application Ser. No.12/572,070 entitled “STABILIZATION OF PERHYDROLASES” describes the useof a two component system wherein the first component comprises aformulation of a liquid carboxylic acid ester and solid enzyme powdercomprising a formulation of (a) at least one CE-7 esterase havingperhydrolysis activity and (b) at least one oligosaccharide excipient;and the second component comprises water having a source of peroxygenand a hydrogen peroxide stabilizer. In one embodiment, the at least oneoligosaccharide has a number average molecular weight of at least about1250 and a weight average molecular weight of at least about 9000. Inanother embodiment, the oligosaccharide excipient has a number averagemolecular weight of at least about 1700 and a weight average molecularweight of at least about 15000. In another embodiment, theoligosaccharide is maltodextrin.

Co-owned, co-filed, and copending U.S. patent application Ser. No.12/572,086 entitled “STABILIZATION OF PERHYDROLASES” describes the useof a two component system wherein the first component comprises aformulation of a liquid carboxylic acid ester and solid enzyme powdercomprising a formulation of (a) an enzyme powder comprising at least oneCE-7 esterase having perhydrolysis activity and at least oneoligosaccharide excipient and at least one surfactant; and (b) at leastone buffer, where in a preferred embodiment the buffer is added as aseparate (i.e. separate from the enzyme powder) insoluble component tothe carboxylic acid ester substrate; and the second component compriseswater having a source of peroxygen and a hydrogen peroxide stabilizer.In one embodiment, the at least one excipient is an oligosaccharide thathas a number average molecular weight of at least about 1250 and aweight average molecular weight of at least about 9000. In anotherembodiment, the at least one excipient is an oligosaccharide that has anumber average molecular weight of at least about 1700 and a weightaverage molecular weight of at least about 15000. In another embodiment,the oligosaccharide is maltodextrin. In a further embodiment, the pHbuffer is a bicarbonate buffer. In yet a further embodiment, thehydrogen peroxide stabilizer is TURPINAL® SL.

Compositions and methods of using enzymes having perhydrolysis activitythat are structurally classified as being members of the CE-7carbohydrate esterase family have reported. These “perhydrolase” enzymesare particularly effective in producing peroxycarboxylic acids from avariety of ester substrates when combined with a source of peroxygen(See co-pending and co-owned published International Patent Applicationno. WO2007/070609 and U.S. Patent Application Publication Nos.2008-0176299, 2008-176783, and 2009/0005590 to DiCosimo et al.; eachherein incorporated by reference in their entirety). The perhydrolasesdescribed in the published patent applications to DiCosimo et al. wereall based on amino acid sequences reported from previously reported CE-7esterases (this group includes acetyl xylan esterases (AXEs) andcephalosporin acetyl hydrolases (CAHs)). Co-owned, co-filed, andcopending U.S. patent application Ser. No. 12/572,094 discloses variantsof several Thermotoga sp. CE-7 esterases having improved perhydrolysisactivity and/or improved perhydrolysis activity to hydrolysis activityratios (i.e., P/H ratios). In one embodiment, the two variant CE-7perhydrolases have an amino acid sequence selected from the groupconsisting of SEQ ID NO: 19 and SEQ ID NO: 20.

Enzyme Powder

In one embodiment, the multi-component formulation comprises an enzymepowder comprising a formulation of at least one enzyme structurallyclassified as a CE-7 enzyme and having perhydrolysis activity and atleast one excipient. In one embodiment, the enzyme powder is formed byspray drying (i.e., a spray-dried formulation). In one embodiment, theexcipient is present in the enzyme powder in an amount ranging fromabout 95 wt % to about 25 wt % of the enzyme powder. In a furtheraspect, the excipient is an oligosaccharide excipient. In a furtheraspect, the oligosaccharide excipient has a number average molecularweight of at least about 1250 and a weight average molecular weight ofat least about 9000, and optionally at least one surfactant.

The at least one enzyme can be any of the CE-7 carbohydrate esterasesdescribed herein or can be any of the CE-7 carbohydrate esterasesdescribed in co-owned, copending Published U.S. Patent Application No.2008/0176299 (incorporated herein by reference in its entirety). In someembodiments, the at least one enzyme is selected from the groupconsisting of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,15, 16, 17, 19, 20, 21, 22, 23, 24, and 25. In one embodiment, the atleast one enzyme comprises an amino acid sequence substantially similarto SEQ ID NOs: 6, 7, 19, or 20. In a preferred embodiment, the at leastone enzyme comprises an amino acid sequence selected from the groupconsisting of SEQ ID NOs: 6, 7, 19, and 20.

The at least one enzyme is present in the enzyme powder in an amount ina range of from about 5 weight percent (wt %) to about 75 wt % based onthe dry weight of the enzyme powder. A preferred weight percent range ofthe enzyme in the enzyme powder/spray-dried mixture is from about 10 wt% to 50 wt %, and a more preferred weight percent range of the enzyme inthe enzyme powder/spray-dried mixture is from about 20 wt % to 33 wt %

In one embodiment, the enzyme powder further comprises an excipient. Inone aspect, the excipient is provided in an amount in a range of fromabout 95 wt % to about 25 wt % based on the dry weight of the enzymepowder. A preferred wt % range of excipient in the enzyme powder is fromabout 90 wt % to 50 wt %, and a more preferred wt % range of excipientin the enzyme powder is from about 80 wt % to 67 wt %.

In yet a further embodiment, the excipient is at least oneoligosaccharide excipieint. In still a further embodiment, at least oneoligosaccharide excipient has a number average molecular weight of atleast about 1250 and a weight average molecular weight of at least about9000. In some embodiments, the oligosaccharide excipient has a numberaverage molecular weight of at least about 1700 and a weight averagemolecular weight of at least about 15000. Specific oligosaccharidesuseful in the present invention include, but are not limited to,maltodextrin, xylan, mannan, fucoidan, galactomannan, chitosan,raffinose, stachyose, pectin, insulin, levan, graminan, amylopectin,sucrose, lactulose, lactose, maltose, trehalose, cellobiose,nigerotriose, maltotriose, melezitose, maltotriulose, raffinose,kestose, and mixtures thereof. In a preferred embodiment, theoligosaccharide excipient is maltodextrin. Oligosaccharide-basedexcipients useful in the present invention may include, but are notlimited to, water-soluble non-ionic cellulose ethers, such ashydroxymethyl-cellulose and hydroxypropylmethylcellulose, and mixturesthereof. In yet a further embodiment, the excipient is selected from,but not limited to, one or more of the following compounds: trehalose,lactose, sucrose, mannitol sorbitol, glucose, cellobiose,a-cyclodextrin, carboxymethylcellulose.

In some embodiments, the formulation used to prepare the enzyme powderoptionally comprises at least one surfactant. In a preferred aspect, atleast one surfactant is present. Useful surfactants may include, but arenot limited to, ionic and nonionic surfactants or wetting agents, suchas ethoxylated castor oil, polyglycolyzed glycerides, acetylatedmonoglycerides, sorbitan fatty acid esters, poloxamers, polyoxyethylenesorbitan fatty acid esters, polyoxyethylene derivatives, monoglyceridesor ethoxylated derivatives thereof, diglycerides or polyoxyethylenederivatives thereof, sodium docusate, sodium laurylsulfate, cholic acidor derivatives thereof, lecithins, phospholipids, block copolymers ofethylene glycol and propylene glycol, and non-ionic organosilicones.Preferably, the surfactant is a polyoxyethylene sorbitan fatty acidester, with polysorbate 80 being more preferred.

When part of the formulation used to prepare the enzyme powder, thesurfactant is present in an amount in a range of from about 5 wt % to0.1 wt % based on the weight of protein present in the enzyme powder,preferably from about 2 wt % to 0.5 wt % based on the weight of proteinpresent in the enzyme powder.

The enzyme powder may additionally comprise one or more buffers (e.g.,sodium and/or potassium salts of bicarbonate, citrate, acetate,phosphate, pyrophosphate, methylphosphonate, succinate, malate,fumarate, tartrate, and maleate), and an enzyme stabilizer (e.g.,ethylenediaminetetraacetic acid, (1-hydroxyethylidene)bisphosphonicacid)).

Spray drying of the formulation to form the enzyme powder is carriedout, for example, as described generally in Spray Drying Handbook,5^(th) ed., K. Masters, John Wiley & Sons, Inc., NY, N.Y. (1991), and inPCT Patent Publication Nos. WO 97/41833 and WO 96/32149 to Platz, R. etat.

In general spray drying consists of bringing together a highly dispersedliquid, and a sufficient volume of hot air to produce evaporation anddrying of the liquid droplets. Typically the feed is sprayed into acurrent of warm filtered air that evaporates the solvent and conveys thedried product to a collector. The spent air is then exhausted with thesolvent. Those skilled in the art will appreciate that several differenttypes of apparatus may be used to provide the desired product. Forexample, commercial spray dryers manufactured. by Buchi Ltd. (Postfach,Switzerland) or GEA Niro Corp. (Copenhagen, Denmark) will effectivelyproduce particles of desired size. It will further be appreciated thatthese spray dryers, and specifically their atomizers, may be modified orcustomized for specialized applications, such as the simultaneousspraying of two solutions using a double nozzle technique. Morespecifically, a water-in-oil emulsion can be atomized from one nozzleand a solution containing an anti-adherent such as mannitol can beco-atomized from a second nozzle. In other cases it may be desirable topush the feed solution though a custom designed nozzle using a highpressure liquid chromatography (HPLC) pump. Provided thatmicrostructures comprising the correct morphology and/or composition areproduced the choice of apparatus is not critical and would be apparentto the skilled artisan in view of the teachings herein.

The temperature of both the inlet and outlet of the gas used to dry thesprayed material is such that it does not cause degradation of theenzyme in the sprayed material. Such temperatures are typicallydetermined experimentally, although generally, the inlet temperaturewill range from about 50° C. to about 225° C., while the outlettemperature will range from about 30° C. to about 150° C. Preferredparameters include atomization pressures ranging from about 20-150 psi(0.14 MPa-1.03 MPa), and preferably from about 30-40 to 100 psi(0.21-0.28 MPa to 0.69 MPa). Typically the atomization pressure employedwill be one of the following (MPa) 0.14, 0.21, 0.28, 0.34, 0.41, 0.48,0.55, 0.62, 0.69, 0.76, 0.83 or above.

The enzyme powder or a formulation of the enzyme powder in carboxylicacid ester is required to substantially retain its enzymatic activityfor an extended period of time when stored at ambient temperature. Theenzyme powder or a formulation of the enzyme powder in carboxylic acidester substantially retains its enzymatic activity at elevatedtemperatures for short periods of time. In one embodiment,“substantially retains its enzymatic activity” is meant that the enzymepowder or a formulation of the enzyme powder in carboxylic acid esterretains at least about 75 percent of the enzyme activity of the enzymein the enzyme powder or a formulation of the enzyme powder after anextended storage period at ambient temperature and/or after a shortstorage period at an elevated temperature (above ambient temperature) ina formulation comprised of a carboxylic acid ester and the enzyme powderas compared to the initial enzyme activity of the enzyme powder prior tothe preparation of a formulation comprised of the carboxylic acid esterand the enzyme powder. The extended storage period is a period of timeof from about one year to about two years at ambient temperature. In oneembodiment, the short storage period is at an elevated temperature is aperiod of time of from when the formulation comprised of a carboxylicacid ester and the enzyme powder is produced at 40° C. to about eightweeks at 40° C. In another embodiment, the elevated temperature is in arange of from about 30° C. to about 52° C. In a preferred embodiment,the elevated temperature is in a range of from about 30° C. to about 40°C.

In some embodiments, the enzyme powder has at least 75 percent of theenzyme activity of the at least one enzyme after eight weeks storage at40° C. in a formulation comprised of a carboxylic acid ester and theenzyme powder as compared to the initial enzyme activity of the enzymepowder prior to the preparation of a formulation comprised of thecarboxylic acid ester and the enzyme powder at 40° C. In otherembodiments, the enzyme powder has at least 76, 77, 78, 79, 80, 81, 82,83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or100 percent of the enzyme activity of the at least one enzyme aftereight weeks storage at 40° C. in a formulation comprised of a carboxylicacid ester and the enzyme powder as compared to the initial enzymeactivity of the enzyme powder prior to the preparation of a formulationcomprised of the carboxylic acid ester and the enzyme powder at 40° C.Preferably, perhydrolysis activity is measured as described in Example8-13, infra, but any method of measuring perhydrolysis activity can beused in the practice of the present invention.

In some embodiments, further improvement in enzyme activity over thestated periods of time can be achieved by adding a buffer having abuffering capacity in a pH range of from about 5.5 to about 9.5 to theformulation comprised of the carboxylic acid ester and the spray-driedenzyme powder. Suitable buffer for use in the formulation may include,but is not limited to, sodium salt, potassium salt, or mixtures ofsodium or potassium salts of bicarbonate, pyrophosphate, phosphate,methylphosphonate, citrate, acetate, malate, fumarate, tartrate maleateor succinate. Preferred buffers for use in the formulation comprised ofthe carboxylic acid ester and the spray-dried enzyme powder include thesodium salt, potassium salt, or mixtures of sodium or potassium salts ofbicarbonate, pyrophosphate, phosphate, methylphosphonate, citrate,acetate, malate, fumarate, tartrate maleate or succinate. In preferredembodiment, the buffer comprises the sodium and/or potassium salts ofbicarbonate.

In embodiments where a buffer is present in the carboxylic acid esterand enzyme powder formulation, the buffer may be present in an amount ina range of from about 0.01 wt % to about 50 wt % based on the weight ofcarboxylic acid ester in the formulation comprised of carboxylic acidester and enzyme powder. The buffer may be present in a more preferredrange of from about 0.10% to about 10% based on the weight of carboxylicacid ester in the formulation comprised of carboxylic acid ester andenzyme powder. Further, in these embodiments, the comparison betweenperhydrolysis activity of the enzyme is determined as between an enzymepowder which retains at least 75 percent of the perhydrolysis activityof the at least one enzyme after eight weeks storage at 40° C. in aformulation comprised of a carboxylic acid ester, a buffer having abuffering capacity in a pH range of from about 5.5 to about 9.5, and theenzyme powder as compared to the initial perhydrolysis activity of theenzyme powder prior to the preparation of a formulation comprised of thecarboxylic acid ester, the buffer having a buffering capacity in a pHrange of from about 5.5 to about 9.5, and the enzyme powder.

It is intended that the spray-dried enzyme powder be stored as aformulation in the organic compound that is a substrate for the at leastone enzyme, such as triacetin. In the absence of added hydrogenperoxide, triacetin is normally hydrolyzed in aqueous solution by a CE-7carbohydrate esterase to produce diacetin and acetic acid, and theproduction of acetic acid results in a decrease in the pH of thereaction mixture. One requirement for long term storage stability of theenzyme in triacetin is that there is not a significant reaction of thetriacetin with any water that might be present in the triacetin; thespecification for water content in one commercial triacetin (supplied byTessenderlo Group, Brussels, Belgium) is 0.03 wt % water (300 ppm). Anyhydrolysis of triacetin that occurs during storage of the enzyme intriacetin would produce acetic acid, which could result in a decrease inactivity or inactivation of the CE-7 perhydrolases; the perhydrolasesare typically inactivated at or below a pH of 5.0 (see U.S. PatentApplication Publication No. 2009/0005590 to DiCosimo, R., et al.). Theexcipient selected for use in the present application must providestability of the enzyme in the organic substrate for the enzyme underconditions where acetic acid might be generated due to the presence oflow concentrations of water in the formulation.

Suitable Reaction Conditions for the Enzyme-Catalyzed Preparation ofPeroxycarboxylic Acids from Carboxylic Acid Esters and Hydrogen Peroxide

In one aspect of the invention, a process is provided to produce anaqueous formulation comprising a peroxycarboxylic acid by reactingcarboxylic acid esters with a source of peroxygen including, but notlimited to, hydrogen peroxide, sodium perborate or sodium percarbonate,in the presence of an enzyme catalyst having perhydrolysis activity. Inone embodiment, the enzyme catalyst comprises at least one enzyme havingperhydrolase activity, wherein said enzyme is structurally classified asa member of the CE-7 carbohydrate esterase family (CE-7; see Coutinho,P. M., and Henrissat, B., supra). In another embodiment, theperhydrolase catalyst is structurally classified as a cephalosporin Cdeacetylase. In another embodiment, the perhydrolase catalyst isstructurally classified as an acetyl xylan esterase.

In one embodiment, the perhydrolase catalyst comprises an enzyme havingperhydrolysis activity and a signature motif comprising:

-   -   a) an RGQ motif at amino acid residues 118-120;    -   b) a GXSQG motif at amino acid residues 179-183; and    -   c) an HE motif at amino acid residues 298-299 when aligned to        reference sequence SEQ ID NO:1 using CLUSTALW.

In a further embodiment, the signature motif additional comprises afourth conserved motif defined as an LXD motif at amino acid residues267-269 when aligned to reference sequence SEQ ID NO:1 using CLUSTALW.

In another embodiment, the perhydrolase catalyst comprises an enzymehaving the present signature motif and at least 30% amino acid to SEQ 1DNO:1.

In another embodiment, the perhydrolase catalyst comprises an enzymehaving perhydrolase activity selected from the group consisting of SEQID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 19,20, 21, 22, 23, 24, and 25.

In another embodiment, the perhydrolase catalyst comprises an enzymehaving at least 40% amino acid identity to a contiguous signature motifdefined as SEQ ID NO:18 wherein the conserved motifs described above(i.e., RGQ, GXSQG, and HE, and optionally, LXD) are conserved.

In another embodiment, the perhydrolase catalyst comprises an enzymehaving an amino acid sequence selected from the group consisting of SEQID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 19,20, 21, 22, 23, 24, and 25, wherein said enzyme may have one or moreadditions, deletions, or substitutions so long as the signature motif isconserved and perhydrolase activity is retained.

Suitable carboxylic acid ester substrates may include esters having thefollowing formula:

-   -   (a) one or more esters having the structure        [X]_(m)R₅    -   wherein    -   X is an ester group of the formula R₆C(O)O;    -   R₆ is a C1 to C7 linear, branched or cyclic hydrocarbyl moiety,        optionally substituted with a hydroxyl group or C1 to C4 alkoxy        group, wherein R₆ optionally comprises one or more ether        linkages where R₆ is C2 to C7;    -   R₅ is a C1 to C6 linear, branched, or cyclic hydrocarbyl moiety        optionally substituted with a hydroxyl group, wherein each        carbon atom in R₅ individually comprises no more than one        hydroxyl group or no more than one ester group, and wherein R₅        optionally comprises one or more ether linkages;    -   m is 1 to the number of carbon atoms in R₅,    -   said one or more esters having solubility in water of at least 5        ppm at 25° C.; or    -   (b) one or more glycerides having the structure

-   -   wherein R₁ is a C1 to C7 straight chain or branched chain alkyl        optionally substituted with an hydroxyl or a C1 to C4 alkoxy        group and R₃ and R₄ are individually H or R₁C(O); or    -   (c) one or more esters of the formula

-   -   wherein R₁ is a C1 to C7 straight chain or branched chain alkyl        optionally substituted with an hydroxyl or a C1 to C4 alkoxy        group and R₂ is a C1 to C10 straight chain or branched chain        alkyl, alkenyl, alkynyl, aryl, alkylaryl, alkylheteroaryl,        heteroaryl, (CH₂CH₂O)_(n), or (CH₂CH(CH₃)—O)_(n)H and n is 1 to        10; or    -   (d) one or more acetylated monosaccharides, acetylated        disaccharides, or acetylated polysaccharides; or    -   (e) any combination of (a) through (d).

Examples of said carboxylic acid ester substrate may include monoacetin;triacetin; monopropionin; dipropionin; tripropionin; monobutyrin;dibutyrin; tributyrin; glucose pentaacetate; xylose tetraacetate;acetylated xylan; acetylated xylan fragments;β-D-ribofuranose-1,2,3,5-tetraacetate; tri-O-acetyl-D-galactal;tri-O-acetyl-glucal; propylene glycol diacetate; ethylene glycoldiacetate; monoesters or diesters of 1,2-ethanediol; 1,2-propanediol;1,3-propanediol; 1,2-butanediol; 1,3-butanediol; 2,3-butanediol;1,4-butanediol; 1,2-pentanediol; 2,5-pentanedial; 1,6-pentanediol,1,2-hexanediol; 2,5-hexanediol; 1,6-hexanediol; or any combinationthereof.

In a preferred embodiment, the carboxylic acid ester is a liquidsubstrate selected from the group consisting of monoacetin, diacetin,triacetin, and combinations (i.e., mixtures) thereof. The carboxylicacid ester is present in the reaction formulation at a concentrationsufficient to produce the desired concentration of peroxycarboxylic acidupon enzyme-catalyzed perhydrolysis. The carboxylic acid ester need notbe completely soluble in the reaction formulation, but has sufficientsolubility to permit conversion of the ester by the perhydrolasecatalyst to the corresponding peroxycarboxylic acid. The carboxylic acidester is present in the reaction formulation at a concentration of 0.05wt % to 40 wt % of the reaction formulation, preferably at aconcentration of 0.1 wt % to 20 wt % of the reaction formulation, andmore preferably at a concentration of 0.5 wt % to 10 wt % of thereaction formulation.

The peroxygen source may include, but is not limited to, hydrogenperoxide, hydrogen peroxide adducts (e.g., urea-hydrogen peroxide adduct(carbamide peroxide)) perborate salts and percarbonate salts. Theconcentration of peroxygen compound in the reaction formulation mayrange from 0.0033 wt % to about 50 wt %, preferably from 0.033 wt % toabout 40 wt %, more preferably from 0.33 wt % to about 30 wt %.

Many perhydrolase catalysts (whole cells, permeabilized whole cells, andpartially purified whole cell extracts) have been reported to havecatalase activity (EC 1.11.1.6). Catalases catalyze the conversion ofhydrogen peroxide into oxygen and water. In one aspect, theperhydrolysis catalyst lacks catalase activity. In another aspect, acatalase inhibitor is added to the reaction formulation. Examples ofcatalase inhibitors include, but are not limited to, sodium azide andhydroxylamine sulfate. One of skill in the art can adjust theconcentration of catalase inhibitor as needed. The concentration of thecatalase inhibitor typically ranges from 0.1 mM to about 1 M; preferablyabout 1 mM to about 50 mM; more preferably from about 1 mM to about 20mM. In one aspect, sodium azide concentration typically ranges fromabout 20 mM to about 60 mM while hydroxylamine sulfate is concentrationis typically about 0.5 mM to about 30 mM, preferably about 10 mM.

In another embodiment, the enzyme catalyst lacks significant catalaseactivity or is engineered to decrease or eliminate catalase activity.The catalase activity in a host cell can be down-regulated or eliminatedby disrupting expression of the gene(s) responsible for the catalaseactivity using well known techniques including, but not limited to,transposon mutagenesis, RNA antisense expression, targeted mutagenesis,and random mutagenesis. In a preferred embodiment, the gene(s) encodingthe endogenous catalase activity are down-regulated or disrupted (i.e.,knocked-out). As used herein, a “disrupted” gene is one where theactivity and/or function of the protein encoded by the modified gene isno longer present. Means to disrupt a gene are well-known in the art andmay include, but are not limited to, insertions, deletions, or mutationsto the gene so long as the activity and/or function of the correspondingprotein is no longer present. In a further preferred embodiment, theproduction host is an E. coli production host comprising a disruptedcatalase gene selected from the group consisting of katG and katE (seePublished U.S. Patent Application No. 2008/0176299). In anotherembodiment, the production host is an E. coli strain comprising adown-regulation and/or disruption in both katG and a katE catalasegenes.

The concentration of the catalyst in the aqueous reaction formulationdepends on the specific catalytic activity of the catalyst, and ischosen to obtain the desired rate of reaction. The weight of catalyst inperhydrolysis reactions typically ranges from 0.0001 mg to 10 mg per mLof total reaction volume, preferably from 0.001 mg to 2.0 mg per mL. Thecatalyst may also be immobilized on a soluble or insoluble support usingmethods well-known to those skilled in the art; see for example,Immobilization of Enzymes and Cells; Gordon F. Bickerstaff, Editor;Humana Press, Totowa, N.J., USA; 1997. The use of immobilized catalystspermits the recovery and reuse of the catalyst in subsequent reactions.The enzyme catalyst may be in the form of whole microbial cells,permeabilized microbial cells, microbial cell extracts,partially-purified or purified enzymes, and mixtures thereof.

In one aspect, the concentration of peroxycarboxylic acid generated bythe combination of chemical perhydrolysis and enzymatic perhydrolysis ofthe carboxylic acid ester is sufficient to provide an effectiveconcentration of peroxycarboxylic acid for bleaching, stain removal,odor reduction, sanitization or disinfection at a desired pH. In anotheraspect, the present methods provide combinations of enzymes and enzymesubstrates to produce the desired effective concentration ofperoxycarboxylic acid, where, in the absence of added enzyme, there is asignificantly lower concentration of peroxycarboxylic acid produced.Although there may in some cases be substantial chemical perhydrolysisof the enzyme substrate by direct chemical reaction of inorganicperoxide with the enzyme substrate, there may not be a sufficientconcentration of peroxycarboxylic acid generated to provide an effectiveconcentration of peroxycarboxylic acid in the desired applications, anda significant increase in total peroxycarboxylic acid concentration isachieved by the addition of an appropriate perhydrolase catalyst to thereaction formulation.

The concentration of peroxycarboxylic acid generated (e.g. peraceticacid) by the perhydrolysis of at least one carboxylic acid ester is atleast about 20 ppm, preferably at least 100 ppm, more preferably atleast about 200 ppm peroxycarboxylic acid, more preferably at least 300ppm, more preferably at least 500 ppm, more preferably at least 700 ppm,more preferably at least about 1000 ppm peroxycarboxylic acid, mostpreferably at least 2000 ppm peroxycarboxylic acid within 10 minutes,preferably within 5 minutes, of initiating the perhydrolysis reaction.The product formulation comprising the peroxycarboxylic acid may beoptionally diluted with water, or a solution predominantly comprised ofwater, to produce a formulation with the desired lower concentration ofperoxycarboxylic acid. In one aspect, the reaction time required toproduce the desired concentration of peroxycarboxylic acid is notgreater than about two hours, preferably not greater than about 30minutes, more preferably not greater than about 10 minutes, and mostpreferably in about 5 minutes or less. In other aspects, a hard surfaceor inanimate object contaminated with a concentration of biologicalcontaminant(s) is contacted with the peroxycarboxylic acid formed inaccordance with the processes described herein within about 5 minutes toabout 168 hours of combining said reaction components, or within about 5minutes to about 48 hours, or within about 5 minutes to 2 hours ofcombining said reaction components, or any such time interval therein.

In another aspect, the peroxycarboxylic acid formed in accordance withthe processes describe herein is used in a laundry care applicationwherein the peroxycarboxylic acid is contacted with a textile to providea benefit, such as disinfecting, bleaching, destaining, sanitizing,deodorizing/odor reduction or a combination thereof. Theperoxycarboxylic acid may be used in a variety of laundry care productsincluding, but not limited to, textile pre-wash treatments, laundrydetergents, stain removers, bleaching compositions, deodorizingcompositions, and rinsing agents. In one embodiment, the present processto produce a peroxycarboxylic acid for a target surface is conducted insitu.

In connection with the present formulations for laundry care where theperacid is generated for one or more of bleaching, stain removal, andodor reduction, the concentration of peracid generated (e.g., peraceticacid) by the perhydrolysis of at least one carboxylic acid ester may beat least about 2 ppm, preferably at least 20 ppm, preferably at least100 ppm, and more preferably at least about 200 ppm peracid. Inconnection with the present systems and methods for laundry care wherethe peracid is generated for disinfection or sanitization, theconcentration of peracid generated (e.g., peracetic acid) by theperhydrolysis of at least one carboxylic acid ester may be at leastabout 2 ppm, more preferably at least 20 ppm, more preferably at least200 ppm, more preferably at least 500 ppm, more preferably at least 700ppm, more preferably at least about 1000 ppm peracid, most preferably atleast 2000 ppm peracid within 10 minutes, preferably within 5 minutes,and most preferably within 1 minute of initiating the perhydrolysisreaction. The product mixture comprising the peracid may be optionallydiluted with water, or a solution predominantly comprised of water, toproduce a mixture with the desired lower concentration of peracid. Inone aspect of the present methods and systems, the reaction timerequired to produce the desired concentration of peracid is not greaterthan about two hours, preferably not greater than about 30 minutes, morepreferably not greater than about 10 minutes, even more preferably notgreater than about 5 minutes, and most preferably in about 1 minute orless.

The temperature of the reaction is chosen to control both the reactionrate and the stability of the enzyme catalyst activity. The temperatureof the reaction may range from just above the freezing point of thereaction formulation (approximately 0° C.) to about 95° C., with apreferred range of 5° C. to about 75° C., and a more preferred range ofreaction temperature of from about 5° C. to about 55° C.

The pH of the final reaction formulation containing peroxycarboxylicacid is from about 2 to about 9, preferably from about 3 to about 8,more preferably from about 5 to about 8, even more preferably about 5.5to about 8, and yet even more preferably about 6.0 to about 7.5. Inanother embodiment, the pH of the reaction formulation is acidic (pH<7).The pH of the reaction, and of the final reaction formulation, mayoptionally be controlled by the addition of a suitable buffer including,but not limited to, phosphate, pyrophosphate, bicarbonate, acetate, orcitrate. The concentration of buffer, when employed, is typically from0.1 mM to 1.0 M, preferably from 1 mM to 300 mM, most preferably from 10mM to 100 mM.

In another aspect, the enzymatic perhydrolysis reaction formulation maycontain an organic solvent that acts as a dispersant to enhance the rateof dissolution of the carboxylic acid ester in the reaction formulation.Such solvents include, but are not limited to, propylene glycol methylether, acetone, cyclohexanone, diethylene glycol butyl ether,tripropylene glycol methyl ether, diethylene glycol methyl ether,propylene glycol butyl ether, dipropylene glycol methyl ether,cyclohexanol, benzyl alcohol, isopropanol, ethanol, propylene glycol,and mixtures thereof.

In another aspect, the enzymatic perhydrolysis product may containadditional components that provide desirable functionality. Theseadditional components include, but are not limited to buffers, detergentbuilders, thickening agents, emulsifiers, surfactants, wetting agents,corrosion inhibitors (e.g., benzotriazole), enzyme stabilizers, andperoxide stabilizers (e.g., metal ion chelating agents). Many of theadditional components are well known in the detergent industry (see, forexample, U.S. Pat. No. 5,932,532; hereby incorporated by reference).Examples of emulsifiers include, but are not limited to, polyvinylalcohol or polyvinylpyrrolidone. Examples of thickening agents include,but are not limited to, LAPONITE® RD, corn starch, PVP, CARBOWAX®,CARBOPOL®, CABOSIL®, polysorbate 20, PVA, and lecithin. Examples ofbuffering systems include, but are not limited to, sodium phosphatemonobasic/sodium phosphate dibasic; sulfamic acid/triethanolamine;citric acid/triethanolamine; tartaric acid/triethanolamine; succinicacid/triethanolamine; and acetic acid/triethanolamine. Examples ofsurfactants include, but are not limited to, a) non-ionic surfactantssuch as block copolymers of ethylene oxide or propylene oxide,ethoxylated or propoxylated linear and branched primary and secondaryalcohols, and aliphatic phosphine oxides; b) cationic surfactants suchas quaternary ammonium compounds, particularly quaternary ammoniumcompounds having a C8-C20 alkyl group bound to a nitrogen atomadditionally bound to three C1-C2 alkyl groups; c) anionic surfactantssuch as alkane carboxylic acids (e.g., C8-C20 fatty acids), alkylphosphonates, alkane sulfonates (e.g., sodium dodecylsulphate “SDS”) orlinear or branched alkyl benzene sulfonates, alkene sulfonates; and d)amphoteric and zwitterionic surfactants such as aminocarboxylic acids,aminodicarboxylic acids, alkybetaines, and mixtures thereof. Additionalcomponents may include fragrances, dyes, stabilizers of hydrogenperoxide (e.g., metal chelators such as1-hydroxyethylidene-1,1-diphosphonic acid (DEQUEST® 2010, Solutia Inc.,St. Louis, Mo. and ethylenediaminetetraacetic acid (EDTA)), TURPINAL® SL(CAS #2809-21-4), DEQUEST® 0520, DEQUEST® 0531, stabilizers of enzymeactivity (e.g., polyethylene glycol (PEG)), and detergent builders.

In Situ Production of Peroxycarboxylic Acids using a PerhydrolaseCatalyst

Cephalosporin C deacetylases (E.C. 3.1.1.41; systematic namecephalosporin C acetylhydrolases; CAHs) are enzymes having the abilityto hydrolyze the acetyl ester bond on cephalosporins such ascephalosporin C, 7-aminocephalosporanic acid, and7-(thiophene-2-acetamido)cephalosporanic acid (Abbott, B. and Fukuda,D., Appl. Microbiol. 30(3):413-419 (1975)). CAHs belong to a largerfamily of structurally related enzymes referred to as the carbohydrateesterase family seven (CE-7; see Coutinho, P. M., Henrissat, B., supra).

The CE-7 family includes both CAHs and acetyl xylan esterases (AXEs;E.C. 3.1.1.72). CE-7 family members share a common structural motif andare quite unusual in that they typically exhibit ester hydrolysisactivity for both acetylated xylooligosaccharides and acetylatedcephalosporin C, suggesting that the CE-7 family represents a singleclass of proteins with a multifunctional deacetylase activity against arange of small substrates (Vincent et al., supra). Vincent et al.describes the structural similarity among the members of this family anddefines a signature sequence motif characteristic of the CE-7 family.

Members of the CE-7 family are found in plants, fungi (e.g.,Cephalosporidium acremonium), yeasts (e.g., Rhodosporidium toruloides,Rhodotorula glutinis), and bacteria such as Thermoanaerobacterium sp.;Norcardia lactamdurans, and various members of the genus Bacillus(Politino et a., Appl. Environ. Microbiol., 63(12):4807-4811 (1997);Sakai et al., J. Ferment. Bioeng. 85:53-57 (1998); Lorenz, W. andWiegel, J., J. Bacteriol 179:5436-5441 (1997); Cardoza et al., Appl.Microbiol. Biotechnol., 54(3):406-412 (2000); Mitsushima et al., supra;Abbott, B. and Fukuda, D., Appl. Microbiol. 30(3):413-419 (1975);Vincent et al., supra ; Takami et al., NAR, 28(21):4317-4331 (2000); Reyet at, Genome Biol., 5(10): article 77 (2004); Degrassi et al.,Microbiology., 146:1585-1591 (2000); U.S. Pat. Nos. 6,645,233;5,281,525; 5,338,676; and WO 99/03984.

WO2007/070609 and U.S. Patent Application Publication Nos. 2008/0176299,2008/176783 and 2009/0005590 to DiCosimo et al. disclose various enzymesstructurally classified as CE-7 enzymes that have perhydrolysis activitysuitable for producing efficacious concentrations of peroxycarboxylicacids from a variety of carboxylic acid ester substrates when combinedwith a source of peroxygen. Variant CE-7 enzymes having improvedperhydrolysis activity are also described in a co-filed, co-owned, andcopending U.S. patent application Ser. No. 12/572,094 entitled “IMPROVEDPERHYDROLASES FOR ENZYMATIC PERACID GENERATION”, incorporated herein byreference in its entirety).

The present method produces industrially-useful, efficaciousconcentrations of peroxycarboxylic acids in situ under aqueous reactionconditions using the perhydrolase activity of an enzyme belonging to theCE-7 family of carbohydrate esterases.

HPLC Assay Method for Determining the Concentration of PeroxycarboxylicAcid and Hydrogen Peroxide.

A variety of analytical methods can be used in the present methods toanalyze the reactants and products including, but not limited to,titration, high performance liquid chromatography (HPLC), gaschromatography (GC), mass spectroscopy (MS), capillary electrophoresis(CE), the analytical procedure described by U. Karst et al., (Anal.Chem., 69(17):3623-3627 (1997)), and the 2,2′-azino-bis(3-ethylbenzothazoline)-6-sulfonate (ABTS) assay (S. Minning, et al.,Analytica Chimica Acta 378:293-298 (1999) and WO 2004/058961 A1) asdescribed in the present examples.

Determination of Minimum Biocidal Concentration of PeroxycarboxylicAcids

The method described by J. Gabrielson, et al. (J. Microbiol. Methods 50:63-73 (2002)) can be employed for determination of the Minimum BiocidalConcentration (MBC) of peroxycarboxylic acids, or of hydrogen peroxideand enzyme substrates. The assay method is based on XTT reductioninhibition, where XTT((2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-5-[(phenylamino)carbonyl]-2H-tetrazolium,inner salt, monosodium salt) is a redox dye that indicates microbialrespiratory activity by a change in optical density (OD) measured at 490nm or 450 nm. However, there are a variety of other methods availablefor testing the activity of disinfectants and antiseptics including, butnot limited to, viable plate counts, direct microscopic counts, dryweight, turbidity measurements, absorbance, and bioluminescence (see,for example Brock, Semour S., Disinfection, Sterilization, andPreservation, 5^(th) edition, Lippincott Williams & Wilkins,Philadelphia, Pa., USA; 2001).

Uses of Enzymatically-Prepared Peroxycarboxylic Acid Compositions

The enzyme catalyst-generated peroxycarboxylic acid produced accordingto the present method can be used in a variety of hard surface/inanimateobject applications for reduction of concentrations of biologicalcontaminants, such as decontamination of medical instruments (e.g.,endoscopes), textiles (e.g., articles of clothing, garments, carpets),food preparation surfaces, food storage and food-packaging equipment,materials used for the packaging of food products, chicken hatcheriesand grow-out facilities, animal enclosures, and spent process watersthat have microbial and/or virucidal activity. The enzyme-generatedperoxycarboxylic acids may be used in formulations designed toinactivate prions (e.g., certain proteases) to additionally providebiocidal activity. In a preferred aspect, the present peroxycarboxylicacid compositions are particularly useful as a disinfecting agent fornon-autoclavable medical instruments and food packaging equipment. Asthe peroxycarboxylic acid-containing formulation may be prepared usingGRAS or food-grade components (enzyme, enzyme substrate, hydrogenperoxide, and buffer), the enzyme-generated peroxycarboxylic acid mayalso be used for decontamination of animal carcasses, meat, fruits andvegetables, or for decontamination of prepared foods. Theenzyme-generated peroxycarboxylic acid may be incorporated into aproduct whose final form is a powder, liquid, gel, film, solid oraerosol. The enzyme-generated peroxycarboxylic acid may be diluted to aconcentration that still provides an efficacious decontamination.

The compositions comprising an efficacious concentration ofperoxycarboxylic acid can be used to disinfect or sanitize surfacesand/or objects contaminated (or suspected of being contaminated) withbiological contaminants by contacting the surface or object with theproducts produced by the present processes. As used herein, “contacting”refers to placing a disinfecting composition comprising an effectiveconcentration of peroxycarboxylic acid in contact with the surface orinanimate object suspected of contamination with a biologicalcontaminant for a period of time sufficient to clean and disinfect.Contacting includes spraying, treating, immersing, flushing, pouring onor in, mixing, combining, painting, coating, applying, affixing to andotherwise communicating a peroxycarboxylic acid solution or compositioncomprising an efficacious concentration of peroxycarboxylic acid, or asolution or composition that forms an efficacious concentration ofperoxycarboxylic acid, with the surface or inanimate object suspected ofbeing contaminated with a concentration of a microbial population. Thedisinfectant compositions may be combined with a cleaning composition toprovide both cleaning and disinfection. Alternatively, a cleaning agent(e.g., a surfactant or detergent) may be incorporated into theformulation to provide both cleaning and disinfection in a singlecomposition.

The compositions comprising an efficacious concentration ofperoxycarboxylic acid can also contain at least one additionalantimicrobial agent, combinations of prion-degrading proteases, avirucide, a sporicide, or a biocide. Combinations of these agents withthe peroxycarboxylic acid produced by the claimed processes can providefor increased and/or synergistic effects when used to clean anddisinfect surfaces and/or objects contaminated (or suspected of beingcontaminated) with biological contaminants. Suitable antimicrobialagents include carboxylic esters (e.g., p-hydroxy alkyl benzoates andalkyl cinnamates); sulfonic acids (e.g., dodecylbenzene sulfonic acid);iodo-compounds or active halogen compounds (e.g., elemental halogens,halogen oxides (e.g., NaOCl, HOCl, HOBr, ClO₂), iodine, interhalides(e.g., iodine monochloride, iodine dichloride, iodine trichloride,iodine tetrachloride, bromine chloride, iodine monobromide, or iodinedibromide), polyhalides, hypochlorite salts, hypochlorous acid,hypobromite salts, hypobromous acid, chloro- and bromo-hydantoins,chlorine dioxide, and sodium chlorite); organic peroxides includingbenzoyl peroxide, alkyl benzoyl peroxides, ozone, singlet oxygengenerators, and mixtures thereof; phenolic derivatives (e.g., o-phenylphenol, o-benzyl-p-chlorophenol, Pert-amyl phenol and C₁-C₆ alkylhydroxy benzoates); quaternary ammonium compounds (e.g.,alkyldimethylbenzyl ammonium chloride, dialkyldimethyl ammonium chlorideand mixtures thereof); and mixtures of such antimicrobial agents, in anamount sufficient to provide the desired degree of microbial protection.Effective amounts of antimicrobial agents include about 0.001 wt % toabout 60 wt % antimicrobial agent, about 0.01 wt % to about 15 wt %antimicrobial agent, or about 0.08 wt % to about 2.5 wt % antimicrobialagent.

In one aspect, the peroxycarboxylic acids formed by the present processcan be used to reduce the concentration of biological contaminants (suchas a viable microbial population) when applied on and/or at a locus. Asused herein, a “locus” of the invention comprises part or all of atarget surface suitable for disinfecting or bleaching. Target surfacesinclude all surfaces that can potentially be contaminated withbiological contaminants. Non-limiting examples include equipmentsurfaces found in the food or beverage industry (such as tanks,conveyors, floors, drains, coolers, freezers, equipment surfaces, walls,valves, belts, pipes, drains, joints, crevasses, combinations thereof,and the like); building surfaces (such as walls, floors and windows);non-food-industry related pipes and drains, including water treatmentfacilities, pools and spas, and fermentation tanks; hospital orveterinary surfaces (such as walls, floors, beds, equipment (such asendoscopes), clothing worn in hospital/veterinary or other healthcaresettings, including clothing, scrubs, shoes, and other hospital orveterinary surfaces); restaurant surfaces; bathroom surfaces; toilets;clothes and shoes; surfaces of barns or stables for livestock, such aspoultry, cattle, dairy cows, goats, horses and pigs; hatcheries forpoultry or for shrimp; and pharmaceutical or biopharmaceutical surfaces(a g., pharmaceutical or biopharmaceutical manufacturing equipment,pharmaceutical or biopharmaceutical ingredients, pharmaceutical orbiopharmaceutical excipients). Additional hard surfaces may also includefood products, such as beef, poultry, pork, vegetables, fruits, seafood,combinations thereof, and the like. The locus can also include waterabsorbent materials such as infected linens or other textiles. The locusalso includes harvested plants or plant products including seeds, corms,tubers, fruit, and vegetables, growing plants, and especially cropgrowing plants, including cereals, leaf vegetables and salad crops, rootvegetables, legumes, berried fruits, citrus fruits and hard fruits.

Non-limiting examples of hard surface materials are metals (e.g., steel,stainless steel, chrome, titanium, iron, copper, brass, aluminum, andalloys thereof), minerals (e.g., concrete), polymers and plastics (e.g.,polyolefins, such as polyethylene, polypropylene, polystyrene,poly(meth)acrylate, polyacrylonitrile, polybutadiene,poly(acrylonitrile, butadiene, styrene), poly(acrylonitrile, butadiene),acrylonitrile butadiene; polyesters such as polyethylene terephthalate;and polyamides such as nylon). Additional surfaces may include brick,tile, ceramic, porcelain, wood, vinyl, linoleum, and carpet.

The peroxycarboxylic acids formed by the present process may be used toprovide a benefit to an article of clothing or a textile including, butnot limited to, bleaching, odor reduction, stain removal, sanization,and disinfection. The peroxycarboxylic acids formed by the presentprocess may be used in any number of laundry care products including,but not limited to, textile/clothing pre-wash treatments, laundrydetergents, stain removers, bleaching compositions, deodorizingcompositions, and rinsing agents.

In the context of laundry care applications, the term “contacting anarticle of clothing or textile” means that the article of clothing ortextile is exposed to a formulation disclosed herein. To this end, thereare a number of formats the formulation may be used to treat articles ofclothing or textiles including, but not limited to, liquid, solids, gel,paste, bars, tablets, spray, foam, powder, or granules and can bedelivered via hand dosing, unit dosing, dosing from a substrate,spraying and automatic dosing from a laundry washing or drying machine.Granular compositions can also be in compact form; liquid compositionscan also be in a concentrated form.

When the formulations disclosed herein are used in a laundry machine,the formulation can further contain components typical to laundrydetergents. For example, typical components included, but are notlimited to, surfactants, bleaching agents, bleach activators, additionalenzymes, suds suppressors, dispersants, lime-soap dispersants, soilsuspension and anti-redeposition agents, softening agents, corrosioninhibitors, tarnish inhibitors, germicides, pH adjusting agents,non-builder alkalinity sources, chelating agents, organic and/orinorganic fillers, solvents, hydrotropes, optical brighteners, dyes, andperfumes.

The formulations disclosed herein can also be used as detergent additiveproducts in solid or liquid form. Such additive products are intended tosupplement or boost the performance of conventional detergentcompositions and can be added at any stage of the cleaning process.

Recombinant Microbial Expression

The genes and gene products of the instant sequences may be produced inheterologous host cells, particularly in the cells of microbial hosts.Preferred heterologous host cells for expression of the instant genesand nucleic acid molecules are microbial hosts that can be found withinthe fungal or bacterial families and which grow over a wide range oftemperature, pH values, and solvent tolerances. For example, it iscontemplated that any of bacteria, yeast, and filamentous fungi maysuitably host the expression of the present nucleic acid molecules. Theperhydrolase may be expressed intracellularly, extracellularly, or acombination of both intracellularly and extracellularly, whereextracellular expression renders recovery of the desired protein from afermentation product more facile than methods for recovery of proteinproduced by intracellular expression. Transcription, translation and theprotein biosynthetic apparatus remain invariant relative to the cellularfeedstock used to generate cellular biomass; functional genes will beexpressed regardless. Examples of host strains include, but are notlimited to, bacterial, fungal or yeast species such as Aspergillus,Trichoderma, Saccharomyces, Pichia, Phaffia, Kluyveromyces, Candida,Hansenula, Yarrowia, Salmonella, Bacillus, Acinetobacter, Zymomonas,Agrobacterium, Erythrobacter, Chlorobium, Chromatium, Flavobacterium,Cytophaga, Rhodobacter, Rhodococcus, Streptomyces, Brevibacterium,Corynebacteria, Mycobacterium, Deinococcus, Escherichia, Erwinia,Pantoea, Pseudomonas, Sphingomonas, Methylomonas, Methylobacter,Methylococcus, Methylosinus, Methylomicrobium, Methylocystis,Alcaligenes, Synechocystis, Synechococcus, Anabaena, Thiobacillus,Methanobacterium, Klebsiella, and Myxococcus. In one embodiment,bacterial host strains include Escherichia, Bacillus, Kluyveromyces, andPseudomonas. In a preferred embodiment, the bacterial host cell isEscherichia coli.

Large-scale microbial growth and functional gene expression may use awide range of simple or complex carbohydrates, organic acids andalcohols or saturated hydrocarbons, such as methane or carbon dioxide inthe case of photosynthetic or chemoautotrophic hosts, the form andamount of nitrogen, phosphorous, sulfur, oxygen, carbon or any tracemicronutrient including small inorganic ions. The regulation of growthrate may be affected by the addition, or not, of specific regulatorymolecules to the culture and which are not typically considered nutrientor energy sources.

Vectors or cassettes useful for the transformation of suitable hostcells are well known in the art. Typically the vector or cassettecontains sequences directing transcription and translation of therelevant gene, a selectable marker, and sequences allowing autonomousreplication or chromosomal integration. Suitable vectors comprise aregion 5′ of the gene which harbors transcriptional initiation controlsand a region 3′ of the DNA fragment which controls transcriptionaltermination. It is most preferred when both control regions are derivedfrom genes homologous to the transformed host cell and/or native to theproduction host, although such control regions need not be so derived.

Initiation control regions or promoters which are useful to driveexpression of the present cephalosporin C deacetylase coding region inthe desired host cell are numerous and familiar to those skilled in theart. Virtually any promoter capable of driving these genes is suitablefor the present invention including but not limited to, CYC1, H1S3,GAL1, GAL10, ADH1, PGK, PHO5, GAPDH, ADC1, TRP1, URA3, LEU2, ENO, TPI(useful for expression in Saccharomyces); AOX1 (useful for expression inPichia); and lac, araB, tet, trp, IP_(L), IP_(R), T7, tac, and trc(useful for expression in Escherichia coli) as well as the amy, apr, nprpromoters and various phage promoters useful for expression in Bacillus.

Termination control regions may also be derived from various genesnative to the preferred host cell. In one embodiment, the inclusion of atermination control region is optional. In another embodiment, thechimeric gene includes a termination control region derived from thepreferred host cell.

Industrial Production

A variety of culture methodologies may be applied to produce theperhydrolase catalyst. For example, large-scale production of a specificgene product overexpressed from a recombinant microbial host may beproduced by batch, fed-batch, and continuous culture methodologies.Batch and fed-batch culturing methods are common and well known in theart and examples may be found in Thomas D. Brock in Biotechnology: ATextbook of Industrial Microbiology, Second Edition, Sinauer Associates,Inc., Sunderland, Mass. (1989) and Deshpande, Mukund V., Appl. Biochem.Biotechnol., 36:227-234 (1992).

Commercial production of the desired perhydrolase catalyst may also beaccomplished with a continuous culture. Continuous cultures are an opensystem where a defined culture media is added continuously to abioreactor and an equal amount of conditioned media is removedsimultaneously for processing. Continuous cultures generally maintainthe cells at a constant high liquid phase density where cells areprimarily in log phase growth. Alternatively, continuous culture may bepracticed with immobilized cells where carbon and nutrients arecontinuously added, and valuable products, by-products or waste productsare continuously removed from the cell mass. Cell immobilization may beperformed using a wide range of solid supports composed of naturaland/or synthetic materials.

Recovery of the desired perhydrolase catalysts from a batchfermentation, fed-batch fermentation, or continuous culture, may beaccomplished by any of the methods that are known to those skilled inthe art. For example, when the enzyme catalyst is producedintracellularly, the cell paste is separated from the culture medium bycentrifugation or membrane filtration, optionally washed with water oran aqueous buffer at a desired pH, then a suspension of the cell pastein an aqueous buffer at a desired pH is homogenized to produce a cellextract containing the desired enzyme catalyst. The cell extract mayoptionally be filtered through an appropriate filter aid such as celiteor silica to remove cell debris prior to a heat-treatment step toprecipitate undesired protein from the enzyme catalyst solution. Thesolution containing the desired enzyme catalyst may then be separatedfrom the precipitated cell debris and protein by membrane filtration orcentrifugation, and the resulting partially-purified enzyme catalystsolution concentrated by additional membrane filtration, then optionallymixed with an appropriate carrier (for example, maltodextrin, phosphatebuffer, citrate buffer, or mixtures thereof) and spray-dried to producea solid powder comprising the desired enzyme catalyst,

When an amount, concentration, or other value or parameter is giveneither as a range, preferred range, or a list of upper preferable valuesand lower preferable values, this is to be understood as specificallydisclosing all ranges formed from any pair of any upper range limit orpreferred value and any lower range limit or preferred value, regardlessof whether ranges are separately disclosed. Where a range of numericalvalues is recited herein, unless otherwise stated, the range is intendedto include the endpoints thereof, and all integers and fractions withinthe range. It is not intended that the scope be limited to the specificvalues recited when defining a range.

General Methods

The following examples are provided to demonstrate preferred aspects ofthe invention. It should be appreciated by those of skill in the artthat the techniques disclosed in the examples follow techniques tofunction well in the practice of the invention, and thus can beconsidered to constitute preferred modes for its practice. However,those of skill in the art should, in light of the present disclosure,appreciate that many changes can be made in the specific embodimentswhich are disclosed and still obtain a like or similar result withoutdeparting from the spirit and scope of the presently disclosed methodsand examples.

All reagents and materials were obtained from DIFCO Laboratories(Detroit, Mich.), GIBCO/BRL (Gaithersburg, Md.), TCI America (Portland,Oreg.), Roche Diagnostics Corporation (Indianapolis, Ind.) orSigma/Aldrich Chemical Company (St. Louis, Mo.), unless otherwisespecified.

The following abbreviations in the specification correspond to units ofmeasure, techniques, properties, or compounds as follows: “sec” or “s”means second(s), “min” means minute(s), “h” or “hr” means hour(s), “μL”means microliter(s), “mL” means milliliter(s), “L” means liter(s), “mM”means millimolar, “M” means molar, “mmol” means millimole(s), “ppm”means part(s) per million, “wt” means weight, “wt %” means weightpercent, “g” means gram(s), “mg” means milligram(s), “μg” meansmicrogram(s), “ng” means nanogram(s), “g” means gravity, “HPLC” meanshigh performance liquid chromatography, “dd H₂O” means distilled anddeionized water, “dcw” means dry cell weight, “ATCC” or “ATCC®” meansthe American Type Culture Collection (Manassas, Va.), “U” means unit(s)of perhydrolase activity, “rpm” means revolution(s) per minute, “Tg”means glass transition temperature, and “EDTA” meansethylenediaminetetraacetic acid.

EXAMPLE 1 Construction of a katG Catalase Disrupted E. Coli Strain

The coding region of the kanamycin resistance gene (kan; SEQ ID NO:26)was amplified from the plasmid pKD13 (SEQ ID NO:27) by PCR (0.5 min at94° C., 0.5 min at 55° C., 1 min at 70° C., 30 cycles) using primersidentified as SEQ ID NO:28 and SEQ ID NO:29 to generate the PCR productidentified as SEQ ID NO:30. The katG nucleic acid sequence is providedas SEQ ID NO:31 and the corresponding amino acid sequence is SEQ IDNO:32. E. coli MG1655 (ATCC® 47076™) was transformed with thetemperature-sensitive plasmid pKD46 (SEQ ID NO:33), which contains theλ-Red recombinase genes (Datsenko and Wanner, (2000), PNAS USA97:6640-6645), and selected on LB-amp plates for 24 h at 30° C.MG1655/pKD46 was transformed with 50-500 ng of the PCR product byelectroporation (BioRad Gene Pulser, 0.2 cm cuvette, 2.5 kV, 200 W, 25μF), and selected on LB-kan plates for 24 h at 37° C. Several colonieswere streaked onto LB-kan plates and incubated overnight at 42° C. tocure the pKD46 plasmid. Colonies were checked to confirm a phenotype ofkanR/ampS. Genomic DNA was isolated from several colonies using thePUREGENE® DNA purification system (Gentra Systems, Minneapolis, Minn.),and checked by PCR to confirm disruption of the katG gene using primersidentified as SEQ ID NO:34 and SEQ ID NO:35. Several katG-disruptedstrains were transformed with the temperature-sensitive plasmid pCP20(SEQ 1D NO:36), which contains the FLP recombinase, used to excise thekan gene, and selected on LB-amp plates for 24 h at 37° C. Severalcolonies were streaked onto LB plates and incubated overnight at 42° C.to cure the pCP20 plasmid. Two colonies were checked to confirm aphenotype of kanS/ampS, and called MG1655 KatG1 and MG1655 KatG2.

EXAMPLE 2 Construction of a katE Catalase Disrupted E. Coli Strain

The kanamycin resistance gene (SEQ ID NO:26) was amplified from theplasmid pKD13 (SEQ ID NO:27) by PCR (0.5 min at 94° C., 0.5 min at 55°C., 1 min at 70° C., 30 cycles) using primers identified as SEQ ID NO:37and SEQ ID NO:38 to generate the PCR product identified as SEQ ID NO:39.The katE nucleic acid sequence is provided as SEQ ID NO:40 and thecorresponding amino acid sequence is SEQ ID NO:41. E. coli MG1655 (ATCC®47076™) was transformed with the temperature-sensitive plasmid pKD46(SEQ ID NO:33), which contains the A-Red recombinase genes, and selectedon LB-amp plates for 24 h at 30° C. MG1655/pKD46 was transformed with50-500 ng of the PCR product by electroporation (BioRad Gene Pulser, 0.2cm cuvette, 2.5 kV, 200 W, 25 μF), and selected on LB-kan plates for 24h at 37° C. Several colonies were streaked onto LB-kan plates andincubated overnight at 42° C. to cure the pKD46 plasmid. Colonies werechecked to confirm a phenotype of kanR/ampS. Genomic DNA was isolatedfrom several colonies using the PUREGENE® DNA purification system, andchecked by PCR to confirm disruption of the katE gene using primersidentified as SEQ ID NO: 42 and SEQ ID NO: 43. Several katE-disruptedstrains were transformed with the temperature-sensitive plasmid pCP20(SEQ ID NO:36), which contains the FLP recombinase, used to excise thekan gene, and selected on LB-amp plates for 24 h at 37° C. Severalcolonies were streaked onto LB plates and incubated overnight at 42° C.to cure the pCP20 plasmid. Two colonies were checked to confirm aphenotype of kanS/ampS, and called MG1655 KatE1 and MG 1655 KatE2.

EXAMPLE 3 Construction of a katG Catalase and katE Catalase Disrupted E.Coli Strain (KLP18)

The kanamycin resistance gene (SEQ ID NO:26) was amplified from theplasmid pKD13 (SEQ ID NO:27) by PCR (0.5 min at 94° C., 0.5 min at 55°C., 1 min at 70° C., 30 cycles) using primers identified as SEQ ID NO:37and SEQ ID NO:38 to generate the PCR product identified as SEQ ID NO:39.E. coli MG1655 KatG1 (EXAMPLE 1) was transformed with thetemperature-sensitive plasmid pKD46 (SEQ ID NO:33), which contains theλ-Red recombinase genes, and selected on LB-amp plates for 24 h at 30°C. MG1655 KatG1/pKD46 was transformed with 50-500 ng of the PCR productby electroporation (BioRad Gene Pulser, 0.2 cm cuvette, 2.5 kV, 200 W,25 μF), and selected on LB-kan plates for 24 h at 37° C. Severalcolonies were streaked onto LB-kan plates and incubated overnight at 42°C. to cure the pKD46 plasmid. Colonies were checked to confirm aphenotype of kanR/ampS. Genomic DNA was isolated from several coloniesusing the PUREGENE® DNA purification system, and checked by PCR toconfirm disruption of the katE gene using primers identified as SEQ IDNO:42 and SEQ ID NO:43. Several katE-disrupted strains (Δ katE) weretransformed with the temperature-sensitive plasmid pCP20 (SEQ ID NO:36),which contains the FLP recombinase, used to excise the kan gene, andselected on LB-amp plates for 24 h at 37° C. Several colonies werestreaked onto LB plates and incubated overnight at 42° C. to cure thepCP20 plasmid. Two colonies were checked to confirm a phenotype ofkanS/ampS, and called MG1655 KatG1KatE18.1 and MG1655 KatG1KatE23.MG1655 KatG1KatE18.1 is designated E. coli KLP18.

EXAMPLE 4 Cloning and Expression of Perhydrolase from ThermotogaNeapolitana

The coding region of the gene encoding acetyl xylan esterase fromThermotoga neapolitana as reported in GENBANK® (accession numberAE000512; region 80481-81458; SEQ ID NO:44) was synthesized using codonsoptimized for expression in E. coli (DNA 2.0, Menlo Park, Calif.). Thecoding region of the gene was subsequently amplified by PCR (0.5 min at94° C., 0.5 min at 55° C., 1 min at 70° C., 30 cycles) using primersidentified as SEQ ID NO: 45 and SEQ ID NO: 46. The resulting nucleicacid product (SEQ ID NO: 47) was subcloned into pTrcHis2-TOPO® togenerate the plasmid identified as pSW196. The plasmid pSW196 was usedto transform E. coli KLP18 (EXAMPLE 3) to generate the strainKLP18/pSW196. KLP18/pSW196 was grown in LB media at 37° C. with shakingup to OD_(600nm)=0.4-0.5, at which time IPTG was added to a finalconcentration of 1 mM, and incubation continued for 2-3 h. Cells wereharvested by centrifugation and SDS-PAGE was performed to confirmexpression of the perhydrolase at 20-40% of total soluble protein.

EXAMPLE 5 Cloning and Expression of Perhydrolase from ThermotogaMaritima MSB8

The coding region of the gene encoding acetyl xylan esterase fromThermotoga maritima MSB8 as reported in GENBANK® (accession#NP_(—)227893.1; SEQ ID NO: 48) was synthesized (DNA 2.0, Menlo Park,Calif.). The coding region of the gene was subsequently amplified by PCR(0.5 min @94° C., 0.5 min @55° C., 1 min @70° C., 30 cycles) usingprimers identified as SEQ ID NO: 49 and SEQ ID NO: 50. The resultingnucleic acid product (SEQ ID NO: 51) was cut with restriction enzymesPstI and XbaI and subcloned between the PstI and XbaI sites in pUC19 togenerate the plasmid identified as pSW207. The plasmid pSW207 was usedto transform E. coli KLP18 (EXAMPLE 3) to generate the strain identifiedas KLP18/pSW207. KLP18/pSW207 was grown in LB media at 37° C. withshaking up to OD_(600nm)=0.4-0.5, at which time IPTG was added to afinal concentration of 1 mM, and incubation continued for 2-3 h. Cellswere harvested by centrifugation and SDS-PAGE was performed to confirmexpression of the perhydrolase enzyme at 20-40% of total solubleprotein.

EXAMPLE 6 Fermentation of E. coli KLP18 Transformants ExpressingPerhydrolase

A fermentor seed culture was prepared by charging a 2-L shake flask with0.5 L seed medium containing yeast extract (Amberex 695, 5.0 g/L),K₂HPO₄ (10.0 g/L), KH₂PO₄(7.0 g/L), sodium citrate dihydrate (1.0 g/L),(NH₄)₂SO₄ (4.0 g/L), MgSO₄ heptahydrate (1.0 g/L) and ferric ammoniumcitrate (0.10 g/L). The pH of the medium was adjusted to 6.8 and themedium was sterilized in the flask. Post sterilization additionsincluded glucose (50 wt %, 10.0 mL) and 1 mL ampicillin (25 mg/mL) stocksolution. The seed medium was inoculated with a 1-mL culture of E. coliKLP18/pSW196 or E. coli KLP18/pSW207 in 20% glycerol, and cultivated at35° C. and 300 rpm. The seed culture was transferred at ca. 1-2OD_(550nm) to a 14-L fermentor (Braun Biotech, Allentown, Pa.) with 8 Lof medium at 35° C. containing KH₂PO₄ (3.50 g/L), FeSO₄ heptahydrate(0.05 g/L), MgSO₄ heptahydrate (2.0 g/L), sodium citrate dihydrate (1.90g/L), yeast extract (Amberex 695, 5.0 g/L), Biospumex153K antifoam (0.25mL/L, Cognis Corporation, Monheim, Germany), NaCl (1.0 g/L), CaCl₂dihydrate (10 g/L), and NIT trace elements solution (10 mL/L). The traceelements solution contained citric acid monohydrate (10 g/L), MnSO₄hydrate (2 g/L), NaCl (2 g/L), FeSO₄ heptahydrate (0.5 g/L), ZnSO₄heptahydrate (0.2 g/L), CuSO₄ pentahydrate (0.02 g/L) and NaMoO₄dihydrate (0.02 g/L). Post sterilization additions included glucosesolution (50% w/w, 80.0 g) and ampicillin (25 mg/mL) stock solution(16.00 mL). Glucose solution (50% w/w) was used for fed batch. Glucosefeed was initiated when glucose concentration decreased to 0.5 g/L,starting at 0.31 g feed/min and increasing progressively each hour to0.36, 0.42, 0.49, 0.57, 0.66, 0.77, 0.90, 1,04, 1.21, 1.41, and 1.63g/min respectively; the rate remained constant afterwards. Glucoseconcentration in the medium was monitored and if the concentrationexceeded 0.1 g/L the feed rate was decreased or stopped temporarily.Induction was initiated between OD_(550nm)56 and OD_(550nm)=80 withaddition of 16 mL IPTG (0.5 M) for the various strains. The dissolvedoxygen (DO) concentration was controlled at 25% of air saturation. TheDO was controlled first by impeller agitation rate (400 to 1400 rpm) andlater by aeration rate (2 to 10 slpm). The pH was controlled at 6.8.NH₄OH (29% w/w) and H₂SO₄ (20% w/v) were used for pH control. The headpressure was 0.5 bars. The cells were harvested by centrifugation 16 hpost IPTG addition.

EXAMPLE 7 Preparation of Heat-Treated Cell Extracts of CE-7Esterases/Perhydrolases

A cell extract of an E. coli transformant expressing perhydrolase fromThermotoga neapolitana (KLP18/pSW196) or Thermotoga maritima MSB8(KLP18/pSW207) was prepared by passing a suspension of cell paste (20 wt% wet cell weight) in 0.05 M potassium phosphate buffer (pH 7.0)containing dithiothreitol (1 mM) twice through a French press having aworking pressure of 16,000 psi (˜110 MPa). The crude extract was thencentrifuged at 20,000×g to remove cellular debris, producing a clarifiedcell extract that was assayed for total soluble protein (BicinchoninicAcid Kit for Protein Determination, Sigma Aldrich catalog #BCA1-KT). Theclarified Thermotoga maritima MSB8 or Thermotoga neapolitanaperhydrolase-containing extract was heated for 20 min at 75° C.,followed immediately by cooling in an ice/water bath to 5° C. Theresulting mixture was centrifuged to remove precipitated protein, andthe supernatant collected and assayed for total soluble protein asbefore. SDS-PAGE of the heat-treated supernatant indicated that theperhydrolase constituted at least ca. 90% of the total soluble proteinpresent in the supernatant.

EXAMPLE 8 Temperature Stability of T. Neapolitana Perhydrolase/TrehaloseSpray-Dried Enzyme Powders

A set of ten aqueous mixtures were prepared that contained varyingconcentrations of the heat-treated cell extract protein of E. coliKLP18/pSW196 (≧90% T. neapolitana perhydrolase by PAGE), trehalose(Cargill), and, optionally, polysorbate 80 (p80) as surfactant in sodiumbicarbonate buffer (50 mM, pH=8.1) (Table 1). These solutions werespray-dried using a Buchi B-290 glass-chamber spray dryer (inlettemperature=170° C., exit temperature=90° C., feed rate=3 mL/min to 10mL/min) to produce ten spray-dried enzyme powders; the weight percentprotein in the powders was determined using the BCA (Bicinchoninic acid)protein assay, and the glass transition temperatures (Tg) of thesepowders were measured using modulated differential scanning calorimetry(Table 1).

TABLE 1 Composition of protein/excipient solutions used to produce T.neapolitana perhydrolase/trehalose spray-dried enzyme powders, and Tg ofcorresponding powders. wt % protein Tg of in protein/ protein/ protein/protein/ excipient excipient trehalose protein excipient/ p80 excipientexcipient powder solution (g/L) (g/L) protein (g/L) powder powder (° C.)S1-1 52.5 35 1.5 0.25 P1-2 39.2 42 S2-1 100 50 2.0 0 P2-2 32.5 48 S3-1100 50 2.0 0.50 P3-2 33.2 40 S4-1 50 50 1.0 0 P4-2 45.1 40 S5-1 50 501.0 0.50 P5-2 46.7 54 S6-1 40 20 2.0 0 P6-2 31.4 44 S7-1 40 20 2.0 0.50P7-2 32.5 45 S8-1 20 20 1.0 0 P8-2 47.8 38 S9-1 20 20 1.0 0.50 P9-2 46.658 S10-1 52.5 35 1.5 0.25 P10-2 37.8 21

The spray-dried enzyme powders were stored in sealed vials at 40° C. andsampled at one-week intervals, and the samples assayed for theconcentration of peracetic acid produced in 5 minutes in reactionscontaining T. neapolitana perhydrolase (50 μg protein/mL), H₂O₂ (100mM), triacetin (100 mM) and TURPINAL® SL (500 ppm) in sodium bicarbonatebuffer (50 mM, pH 7.2) at 25° C., and analyzed for production ofperacetic acid using a modification of the analytical method reported byKarst et al. (below).

A sample (0.040 mL) of the reaction mixture was removed at apredetermined time (5 min) and immediately mixed with 0.960 mL of 5 mMphosphoric acid in water to terminate the reaction by adjusting the pHof the diluted sample to less than pH 4. The resulting solution wasfiltered using an ULTRAFREE® MC-filter unit (30,000 Normal MolecularWeight Limit (NMWL), Millipore Corp., Billerica, Mass.; cat #UFC3LKT 00)by centrifugation for 2 min at 12,000 rpm. An aliquot (0.100 mL) of theresulting filtrate was transferred to a 1.5-mL screw cap HPLC vial(Agilent Technologies, Palo Alto, Calif.; #5182-0715) containing 0.300mL of deionized water, then 0.100 mL of 20 mM MTS (methyl-p-tolylsulfide) in acetonitrile was added, the vial capped, and the contentsbriefly mixed prior to a 10 min incubation at ca. 25° C. in the absenceof light. To the vial was then added 0.400 mL of acetonitrile and 0.100mL of a solution of triphenylphosphine (TPP, 40 mM) in acetonitrile, thevial re-capped, and the resulting solution mixed and incubated at ca.25° C. for 30 min in the absence of light. To the vial was then added0.100 mL of 10 mM N,N-diethyl-m-toluamide (DEET; HPLC external standard)and the resulting solution analyzed by HPLC for MTSO (methyl-p-tolylsulfoxide), the stoichiometric oxidation product produced by reaction ofMTS with peracetic acid. A control reaction was run in the absence ofadded extract protein or triacetin to determine the rate of oxidation ofMTS in the assay mixture by hydrogen peroxide, for correction of therate of peracetic acid production for background MTS oxidation. HPLCmethod: Supelco Discovery C8 column (10-cm×4.0-mm, 5 μm) (cat.#569422-U) with Supelco Supelguard Discovery C8 precolumn(Sigma-Aldrich; catalog #59590-U); 10 microliter injection volume;gradient method with CH₃CN (Sigma-Aldrich; catalog #270717) anddeionized water at 1.0 mL/min and ambient temperature.

TABLE 2 HPLC Gradient for analysis of peracetic acid. Time (min:sec) (%CH₃CN) 0:00 40 3:00 40 3:10 100 4:00 100 4:10 40 7:00 (stop) 40

The perhydrolytic activity of the T. neapolitana perhydrolase/trehalosespray-dried powder was stable over eight weeks of storage at 40° C.(Table 2).

TABLE 3 Temperature stability of T. neapolitana perhydrolase/trehalosespray- dried enzyme powders during storage at 40° C. PAA (ppm) producedin 5 min at 25° C. by reaction of triacetin (100 mM) and H₂O₂ (100 mM)in sodium bicarbonate buffer (50 mM, pH 7.2) containing T. neapolitanaperhydrolase/ trehalose spray-dried powder (50 μg protein/mL) andTURPINAL ® SL (500 ppm). PAA (ppm) in 5 minutes time at 40° C. P1-2 P2-2P3-2 P4-2 P5-2 P6-2 P7-2 P8-2 P9-2 P10-2 initial 1855 1983 2075 20251769 1891 1902 1777 1880 1945 week 1 1872 2019 2060 1785 1776 1887 20131903 2046 2204 week 2 1830 1899 1870 1771 1833 1930 1987 1933 2146 2222week 3 1888 1974 1887 1973 1977 2223 2102 1924 2080 2104 week 4 18941878 2035 1881 1712 1918 1902 1793 1720 1988 week 5 1595 1744 1706 15651871 2052 1933 1783 1908 1985 week 6 1908 1760 1538 1545 1825 1864 17561675 1659 1758 week 7 1562 1797 1614 1487 1551 1774 1879 1927 1866 1957week 8 1881 1959 1792 1753 1939 2123 1972 1907 1902 2095

EXAMPLE 9 Temperature Stability of T. Neapolitana Perhydrolase/TrehaloseSpray-Dried Enzyme Powders in a Mixture of Enzyme Powder and Triacetin

The spray-dried enzyme powders prepared as described in Example 8 wereevaluated for stability when stored for eight weeks at 40° C. as amixture of the spray-dried powder in triacetin. Spray-dried enzymepowders were added to triacetin to produce a mixture containing 0.200 gof protein in 87.2 g of triacetin. The resulting mixtures were stored at40° C., and a 2.19 g sample of the well-stirred mixture was assayedweekly at 25° C. in a 100-mL reaction containing 100 mM hydrogenperoxide and TURPINAL® SL (500 ppm) in 50 mM sodium bicarbonate bufferat pH 7.2, where the resulting concentration of triacetin and proteinwas 100 mM and 50 μg/mL, respectively. Comparison of the data in Table 4with the data in Example 8, Table 3, demonstrates the instability of T.neapolitana perhydrolase/trehalose spray-dried enzyme powders whenstored as a mixture with triacetin.

TABLE 4 Temperature stability of T. neapolitana perhydrolase/trehalosespray- dried enzyme powders during storage in a mixture of enzyme powderand triacetin at 40° C. PAA (ppm) produced in 5 min at 25° C. byreaction of triacetin (100 mM) and H₂O₂ (100 mM) in sodium bicarbonatebuffer (50 mM, pH 7.2) containing T. neapolitana perhydrolase (50 μgprotein/mL) and TURPINAL ® SL (500 ppm). PAA (ppm) in 5 minutes time at40° C. P1-2 P2-2 P3-2 P4-2 P5-2 P6-2 P7-2 P8-2 P9-2 P10-2 initial 16501495 1539 1569 1666 1735 1552 1327 1712 1816 week 1 1214 1359 1597 15991589 1632 1515 1469 1421 1577 week 2 1303 1609 1580 1316 1293 1682 1353971 1402 1483 week 3 1092 1573 1568 1233 1293 1245 1268 849 1324 1388week 4 828 1563 1420 1226 1199 1608 1361 961 1172 1273 week 5 622 13401114 1294 1154 1663 1163 739 815 667 week 6 636 1301 990 970 895 1318514 313 699 372 week 7 281 998 1140 841 798 962 259 188 831 521 week 8254 569 659 563 567 483 414 323 494 321

EXAMPLE 10 Temperature Stability of T. NeapolitanaPerhydrolase/Maltodextrin Spray-Dried Enzyme Powder

An aqueous mixture was prepared containing heat-treated cell extractprotein of E. coli KLP18/pSW196 (34 g protein/L, ≧90% T. neapolitanaperhydrolase by PAGE) and maltodextrin (66.7 g/L MALTRIN® M100maltodextrin, 14.7 g/L MALTRIN® M250, 14.7 g/L MALTRIN® M040, GrainProcessing Corporation, Muscatine, Iowa) as excipient in 50 mM sodiumbicarbonate (pH 8.1). This solution was spray-dried using a spray dryer(GEA Niro, 3-ft diameter, inlet temperature=226° C., exittemperature=76° C., feed rate=60 g/min) to produce a spray-dried enzymepowder; the weight percent protein in the powder (20.3 wt %) wasdetermined using the BCA (Bicinchoninic acid) protein assay, and theglass transition temperature of this powder (Tg=54° C.) was measuredusing modulated differential scanning calorimetry. This solution wasspray-dried to produce a powder that was then tested for stabilityduring storage at 40° C. for 9 weeks. The spray-dried enzyme powder(stored at 40° C.) was sampled at one-week intervals and assayed foractivity using 50 μg protein/mL of T. neapolitana perhydrolase, H₂O₂(100 mM), triacetin (100 mM) and TURPINAL® SL (500 ppm) in 50 mMbicarbonate buffer (pH 7.2) at 25° C., and analyzed for production ofperacetic acid using a modification of the analytical method reported byKarst et al., supra. The perhydrolytic activity of the T. neapolitanaperhydrolase/maltodextrin spray-dried powder was stable over eight weeksof storage at 40° C. (Table 5).

TABLE 5 Temperature stability of T. neapolitanaperhydrolase/maltodextrin spray-dried enzyme powder during storage at40° C. PAA (ppm) produced in 5 min at 25° C. by reaction of triacetin(100 mM) and H₂O₂ (100 mM) in sodium bicarbonate buffer (50 mM, pH 7.2)containing T. neapolitana perhydrolase (50 μg protein/mL) and TURPINAL ®SL (500 ppm). time PAA (ppm) at 40° C. in 5 min initial 1142 week 1 1117week 2 1135 week 3 1087 week 4 964 week 5 1153 week 6 930 week 7 1025week 8 964

EXAMPLE 11 Temperature Stability of T. NeapolitanaPerhydrolase/Maltodextrin Spray-Dried Enzyme Powder Stored in a Mixtureof Enzyme Powder and Triacetin

The spray-dried enzyme powder prepared as described in Example 10 wasevaluated for stability when stored for twenty-one weeks at 40° C. as amixture of the spray-dried powder in triacetin. The spray-dried enzymepowder (1.235 g, 20.3 wt % protein) was added to 109 g of triacetin. Theresulting mixture was stored at 40° C., and a 2.19 g sample of thewell-stirred mixture assayed in duplicate at 25° C. in a 100-mL reactioncontaining hydrogen peroxide (100 mM) and TURPINAL® SL (500 ppm) in 50mM sodium bicarbonate buffer at pH 7.2, where the resultingconcentration of triacetin and protein was 100 mM and 50 μg/mL,respectively. Comparison of the data in Table 6 with the data in Example10, Table 5, demonstrates the stability of T. neapolitanaperhydrolase/maltodextrin spray-dried enzyme powders when stored as amixture with triacetin.

TABLE 6 Temperature stability of T. neapolitanaperhydrolase/maltodextrin spray-dried enzyme powder during storage in amixture of enzyme powder and triacetin at 40° C. PAA (ppm) produced in 5min at 25° C. by reaction of triacetin (100 mM) and H₂O₂ (100 mM) insodium bicarbonate buffer (50 mM, pH 7.2) containing T. neapolitanaperhydrolase (50 μg protein/mL) and TURPINAL ® SL (500 ppm). time PAA(ppm) in 5 min at 40° C. duplicate A duplicate B average initial 10101019 1015 week 1 983 1054 1019 week 2 897 927 912 week 3 1194 1137 1166week 4 1139 1088 1114 week 5 1099 1069 1084 week 6 1098 978 1038 week 71018 1006 1012 week 8 907 892 900 week 12 925 936 931 week 18 824 NDweek 21 792 ND ND = a duplicate assay was not done

EXAMPLE 12 Temperature Stability of T. NeapolitanaPerhydrolase/Maltodextrin Spray-Dried Enzyme Powder Stored in a Mixtureof Enzyme Powder, Sodium Bicarbonate and Triacetin

The spray-dried enzyme powder prepared as described in Example 10 wasevaluated for stability when stored for 21 weeks at 40° C. as a mixtureof the spray-dried powder in a mixture of triacetin and sodiumbicarbonate. The spray-dried enzyme powder (0.988 g, 20.3 wt % protein)was added to a mixture of 87.2 g of triacetin and 16.8 g of sodiumbicarbonate (Grade 3DF (powder), Church & Dwight). The resulting mixturewas stored at 40° C., and a 2.62 g sample of the well-stirred mixturewas assayed in duplicate at 25° C. in a 100-mL reaction containinghydrogen peroxide (100 mM) and TURPINAL® SL (500 ppm), where theresulting concentrations of triacetin, sodium bicarbonate and proteinwere 100 mM, 50 mM (pH 7.2) and 50 μg/mL, respectively. Comparison ofthe data in Table 7 with the data in Example 11, Table 6, demonstratesthe stability of T. neapolitana perhydrolase/maltodextrin spray-driedenzyme powders when stored for twenty-one weeks at 40° C. as a mixturewith triacetin and solid sodium bicarbonate is improved when compared tothe stability of T. neapolitana perhydrolase/maltodextrin spray-driedenzyme powders when stored for twenty-one weeks at 40° C. as a mixturewith triacetin alone. At the longer storage times, such as 21 weeks, theperhydrolase still retains ca. 100% of initial activity in a mixture oftriacetin and sodium bicarbonate.

TABLE 7 Temperature stability of T. neapolitanaperhydrolase/maltodextrin spray-dried enzyme powder during storage in amixture of enzyme powder, sodium bicarbonate and triacetin at 40° C. PAA(ppm) produced in 5 min at 25° C. by reaction of triacetin (100 mM) andH₂O₂ (100 mM) in sodium bicarbonate buffer (50 mM, pH 7.2) containing T.neapolitana perhydrolase (50 μg protein/mL) and TURPINAL ® SL (500 ppm).time PAA (ppm) in 5 min at 40° C. duplicate A duplicate B averageinitial 950 1032 991 week 1 1060 1096 1078 week 2 1114 1114 1114 week 41044 974 1009 week 8 1085 1046 1066 week 12 1101 1122 1112 week 17 1013ND week 21 1162 ND ND = a duplicate assay was not done

EXAMPLE 13 Temperature Stability of T. MaritimaPerhydrolase/Maltodextrin Spray-Dried Enzyme Powder

An aqueous mixture was prepared containing heat-treated cell extractprotein of E. coli KLP18/pSW207 (21 g protein/L, ≧90% T. maritimaperhydrolase by PAGE) and maltodextrin (31 g/L maltodextrin DE 13-17 and31 g/L maltodextrin DE 4-7, Aldrich) as excipient in 50 mM sodiumbicarbonate (pH 8.1). This solution was spray-dried using a Buchi B-290glass-chamber spray dryer (inlet temperature=170° C., exittemperature=90° C., feed rate=4.5 mL/min) to produce a spray-driedenzyme powder; the weight percent protein in the powder (18.0 wt %) wasdetermined using the BCA (Bicinchoninic acid) protein assay, and theglass transition temperature of this powder (Tg=90° C.) was measuredusing modulated differential scanning calorimetry. This solution wasspray-dried to produce a powder that was then tested for stabilityduring storage at 40° C. for 7 weeks. The spray-dried enzyme powder(stored at 40° C.) was sampled at one-week intervals and assayed foractivity using 50 μg protein/mL of T. maritima perhydrolase, H₂O₂ (H₂O₂(100 mM)), triacetin (100 mM) and TURPINAL® SL (500 ppm) in 50 mMbicarbonate buffer (pH 7.2) at 25° C., and analyzed for production ofperacetic acid using a modification of the analytical method reported byKarst et al., supra. The perhydrolytic activity of the T. maritimaperhydrolase/maltodextrin spray-dried powder was stable over seven weeksof storage at 40° C. (Table 8).

TABLE 8 Temperature stability of T. maritima perhydrolase/maltodextrinspray- dried enzyme powder during storage at 40° C. PAA (ppm) producedin 5 min at 25° C. by reaction of triacetin (100 mM) and H₂O₂ (100 mM)in sodium bicarbonate buffer (50 mM, pH 7.2) containing T. maritimaperhydrolase (50 μg protein/mL) and TURPINAL ® SL (500 ppm). time PAA(ppm) at 40° C. in 5 min initial 1373 week 1 1262 week 2 1548 week 31317 week 4 1316 week 5 1378 week 6 1296 week 7 1475

EXAMPLE 14 Temperature Stability of T. MaritimaPerhydrolase/Maltodextrin Spray-Dried Enzyme Powder Stored in a Mixtureof Enzyme Powder and Triacetin

The spray-dried enzyme powder prepared as described in Example 13 wasevaluated for stability when stored for seven weeks at 40° C. as amixture of the spray-dried powder in triacetin. The spray-dried enzymepowder (0.556 g, 18.0 wt % protein) was added to 43.6 g of triacetin.The resulting mixture was stored at 40° C., and a 2.21 g sample of thewell-stirred mixture assayed in duplicate at 25° C. in a 100-mL reactioncontaining hydrogen peroxide (100 mM) and TURPINAL® SL (500 ppm) in 50mM sodium bicarbonate buffer at pH 7.2, where the resultingconcentration of triacetin and protein was 100 mM and 50 μg/mL,respectively. Comparison of the data in Table 9 with the data in Example13, Table 8, demonstrates the stability of T. maritimaperhydrolase/maltodextrin spray-dried enzyme powders when stored as amixture with triacetin.

TABLE 9 Temperature stability of T. maritima perhydrolase/maltodextrinspray- dried enzyme powder during storage in a mixture of enzyme powderand triacetin at 40° C. PAA (ppm) produced in 5 min at 25° C. byreaction of triacetin (100 mM) and H₂O₂ (100 mM) in sodium bicarbonatebuffer (50 mM, pH 7.2) containing T. maritima perhydrolase (50 μgprotein/mL) and TURPINAL ® SL (500 ppm). time PAA (ppm) at 40° C. in 5min initial 1137 week 1 1089 week 2 1138 week 3 1213 week 4 1130 week 5872 week 6 858 week 7 1004

EXAMPLE 15 Temperature Stability of T. MaritimaPerhydrolase/Maltodextrin Spray-Dried Enzyme Powder Stored in a Mixtureof Enzyme Powder, Sodium Bicarbonate and Triacetin

The spray-dried enzyme powder prepared as described in Example 13 wasevaluated for stability when stored for seven weeks at 40° C. as amixture of the spray-dried powder in a mixture of triacetin and sodiumbicarbonate. The spray-dried enzyme powder (0.556 g, 18.0 wt % protein)was added to 43.6 g of triacetin and 8.4 g of sodium bicarbonate (Grade3DF (powder), Church & Dwight). The resulting mixture was stored at 40°C., and a 2.63 g sample of the well-stirred mixture assayed in duplicateat 25° C. in a 100-mL reaction containing hydrogen peroxide (100 mM) andTURPINAL® SL (500 ppm), where the resulting concentrations of triacetin,sodium bicarbonate buffer (pH 7.2) and protein were 100 mM, 50 mM and 50μg/mL, respectively. Comparison of the data in Table 10 with the data inExample 14, Table 9, demonstrates the improved stability of T. maritimaperhydrolase/maltodextrin spray-dried enzyme powders when stored forfive, six and seven weeks at 40° C. as a mixture with triacetin andsolid sodium bicarbonate when compared to the stability of T.neapolitana perhydrolase/maltodextrin spray-dried enzyme powders whenstored for five, six and seven weeks at 40° C. as a mixture withtriacetin alone.

TABLE 10 Temperature stability of T. maritima perhydrolase/maltodextrinspray- dried enzyme powder during storage in a mixture of enzyme powder,sodium bicarbonate and triacetin at 40° C. PAA (ppm) produced in 5 minat 25° C. by reaction of triacetin (100 mM) and H₂O₂ (100 mM) in sodiumbicarbonate buffer (50 mM, pH 7.2) containing T. maritima perhydrolase(50 μg protein/mL) and TURPINAL ® SL (500 ppm). time PAA (ppm) at 40° C.in 5 min initial 1153 week 1 1138 week 2 1343 week 3 1242 week 4 1111week 5 1149 week 6 1184 week 7 1109

EXAMPLE 16 Effect of Added Solvent on Peracetic Acid Production byThermotoga Neapolitana Perhydrolase

A first mixture of 90.0 g of deionized water, 0.350 g of TURPINAL® SL((1-hydroxy-1-phosphonoethyl)phosphonic acid, 60 wt % in water;Thermphos International), and 3.20 g of 30 wt % hydrogen peroxide inwater was adjusted to pH 7.2 with 50% aqueous sodium hydroxide, and thefinal weight of the mixture adjusted to 100.0 g with deionized water. Asecond mixture of 55.76 g triacetin, 4.20 g of sodium bicarbonate, 2.50g of CAB-O-SIL® M5 (Cabot), 0.270 g of spray-dried Thermotoganeapolitana perhydrolase (Example 10), and 37.43 g of one organicsolvent selected from the group consisting of tripropylene glycol methylether (DOWANOL® TPM), dipropylene glycol methyl ether (DOWANOL® DPM),propylene glycol methyl ether (DOWANOL® PM), Diethylene glycol butylether (DOWANOL® DB), dipropylene glycol (DOWANOL® DPG), triethyleneglycol, 1,2-propanediol, N-ethyl-2-pyrroldinone, isopropanol, ethanol,ethyl lactate, or 1,3-propanediol was prepared. A 1.0 g aliquot of thesecond mixture was removed with rapid stirring (to suspend theundissolved solids) and mixed with 9.00 mL of the first mixture ofhydrogen peroxide and TURPINAL® SL in water (pH 7.2) was added to withstirring at 25° C.; the resulting mixture contained 255 mM triacetin,254 mM hydrogen peroxide and 0.055 mg protein/mL of spray-driedperhydrolase. A control reaction for each solvent was also run todetermine the concentration of peracetic acid produced by chemicalperhydrolysis of triacetin by hydrogen peroxide in the absence of addedprotein.

Determination of the concentration of peracetic acid in the reactionmixtures was performed according to the method described by Karst et al.Aliquots (0.040 mL) of the reaction mixture were removed atpredetermined times and mixed with 0.960 mL of 5 mM phosphoric acid inwater; adjustment of the pH of the diluted sample to less than pH 4immediately terminated the reaction. The resulting solution was filteredusing an ULTRAFREE® MC-filter unit (30,000 Normal Molecular Weight Limit(NMWL), Millipore cat #UFC3LKT 00) by centrifugation for 2 min at 12,000rpm. An aliquot (0.100 mL) of the resulting filtrate was transferred to1.5-mL screw cap HPLC vial (Agilent Technologies, Palo Alto, Calif.;#5182-0715) containing 0.300 mL of deionized water, then 0.100 mL of 20mM MTS (methyl-p-tolyl-sulfide) in acetonitrile was added, the vialscapped, and the contents briefly mixed prior to a 10 min incubation atca. 25° C. in the absence of light. To each vial was then added 0.400 mLof acetonitrile and 0.100 mL of a solution of triphenylphosphine (TPP,40 mM) in acetonitrile, the vials re-capped, and the resulting solutionmixed and incubated at ca. 25° C. for 30 min in the absence of light. Toeach vial was then added 0.100 mL of 10 mM N,N-diethyl-m-toluamide(DEET; HPLC external standard) and the resulting solution analyzed byHPLC as described in Table 2.

HPLC Method:

Supelco Discovery C8 column (10-cm×4.0-mm, 5 μm) (cat. #569422-U)w/precolumn Supelco Supelguard Discovery C8 (Sigma-Aldrich; cat#59590-U); 10 microliter injection volume; gradient method with CH₃CN(Sigma-Aldrich; #270717) and deionized water at 1.0 mL/min and ambienttemperature:

Time (min:sec) (% CH₃CN) 0:00 40 3:00 40 3:10 100 4:00 100 4:10 40 7:00(stop) 40

The peracetic acid concentrations produced in 0.5 min, 1 min, 2 min, 5min and 10 min for the reactions described above are listed in Table 11,below.

TABLE 11 Dependence of peracetic acid (PAA) concentration on solventaddition using 255 mM triacetin, 254 mM hydrogen peroxide and 0.055mg/mL of spray-dried Thermotoga neapolitana perhydrolase. Enzyme PAA(ppm) Solvent (μg/mL) 0.5 min 1 min 2 min 5 min 10 min DOWANOL ® PM 0 3954 52 81 137 DOWANOL ® DPM 0 136 41 106 386 ND DOWANOL ® TPM 0 23 25 11193 180 DOWANOL ® DB 0 107 102 105 157 218 DOWANOL ® DPG 0 19 40 101 156207 Triethylene glycol 0 36 53 110 76 307 1,2-propanediol 0 101 96 122226 347 N-ethyl-2- 0 37 49 60 77 133 pyrroldinone isopropanol 0 70 13147 150 242 ethanol 0 68 33 150 356 479 ethyl lactate 0 88 91 98 121 1371,3-propanediol 0 54 48 48 62 107 DOWANOL ® PM 55 355 1327 1632 31565378 DOWANOL ® DPM 55 846 972 1587 3209 4494 DOWANOL ® TPM 55 439 5391303 2710 3740 DOWANOL ® DB 55 475 827 1719 3222 4863 DOWANOL ® DPG 55583 769 1211 2784 4522 Triethylene glycol 55 325 834 1634 3229 51161,2-propanediol 55 507 903 1428 2921 4364 N-ethyl-2- 55 243 837 14703033 4839 pyrroldinone isopropanol 55 326 656 1175 2229 2860 ethanol 55408 584 1109 2235 2858 ethyl lactate 55 180 337 5736 1420 25541,3-propanediol 55 163 269 510 1086 1657

To demonstrate the stability of the spray-dried enzyme in a mixture oftriacetin and an organic solvent, the mixtures of triacetin, sodiumbicarbonate, CAB-O-SIL® M5 (Cabot), spray-dried Thermotoga neapolitanaperhydrolase (Example 10), and either tripropylene glycol methyl ether(DOWANOL® TPM) or 1,2-propanediol described above were stored for 24 hat ambient temperature, then a 1.0 g aliquot of each of these mixtureswas removed with rapid stirring (to suspend the undissolved solids) andmixed with 9.0 mL of a freshly prepared (as described above) mixture ofhydrogen peroxide and TURPINAL® SL in water (pH 7.2) with stirring at25° C.; the resulting mixture contained 255 mM triacetin, 254 mMhydrogen peroxide and 0.055 mg protein/mL of spray-dried perhydrolase. Acontrol reaction for each solvent was also run to determine theconcentration of peracetic acid produced by chemical perhydrolysis oftriacetin by hydrogen peroxide in the absence of added protein.Determination of the concentration of peracetic acid in the reactionmixtures was performed according to the method described by Karst et al.(Table 12).

TABLE 12 Stability of perhydrolase in triacetin solvent suspension,measured in reactions containing 255 mM triacetin and 254 mM hydrogenperoxide. Enzyme PAA (ppm) Solvent (μg/mL) 0.5 min 1 min 2 min 5 min 10min DOWANOL ® TPM 0 0 95 58 172 276 1,2-propanediol 0 16 38 35 171 397DOWANOL ® TPM 55 386 557 1078 2014 2717 1,2-propanediol 55 566 768 14673093 4649

EXAMPLE 16 Comparison of Peracetic Acid Production by ThermotogaNeapolitana Perhydrolase in Presence or Absence of Added Solvent

A first mixture of 40.0 g of deionized water, 0.1575 g of TURPINAL® SL((1-hydroxy-1-phosphonoethyl)phosphonic acid, 60 wt % in water;Thermphos International), and 1.44 g of 30 wt % hydrogen peroxide inwater was adjusted to pH 7.2 with 50% aqueous sodium hydroxide, and thefinal weight of the mixture adjusted to 46.87 g with deionized water. Asecond mixture of 2.78 g triacetin, 0.210 g of sodium bicarbonate, 0.125g of CAB-O-SIL® M5 (Cabot) and 0.0135 g of spray-dried Thermotoganeapolitana perhydrolase (Example 10) was prepared, and the firstmixture of hydrogen peroxide and TURPINAL® SL in water (pH 7.2) wasadded to the second mixture with stirring at 25° C.; the resultingmixture contained 255 mM triacetin, 254 mM hydrogen peroxide and 0.055mg protein/mL of spray-dried perhydrolase. Determination of theconcentration of peracetic acid in the reaction mixtures was performedaccording to the method described by Karst et al., supra. A controlreaction was also run to determine the concentration of peracetic acidproduced by chemical perhydrolysis of triacetin by hydrogen peroxide inthe absence of added perhydrolase.

The reaction described above was repeated, where 1.872 g of eitherpropylene glycol monomethyl ether (DOWANOL® PM) or dipropyleneglycolmonomethyl ether (DOWANOL® DPM), was substituted for an equivalentweight of water in the reaction mixture. A first mixture of 40.0 g ofdeionized water, 0.175 g of TURPINAL® SL, and 1.60 g of 30 wt % hydrogenperoxide in water was adjusted to pH 7.2 with 50% aqueous sodiumhydroxide, and the final weight of the mixture adjusted to 50.0 g withdeionized water. A second mixture of 2.78 g triacetin, 1.872 g of eitherpropylene glycol monomethyl ether (DOWANOL® PM) or dipropyleneglycolmonomethyl ether (DOWANOL® DPM), 0.210 g of sodium bicarbonate, 0.125 gof CAB-O-SIL® M5 (Cabot) and 0.0135 g of spray-dried Thermotoganeapolitana perhydrolase (Example 10) was prepared, and 45.0 g of thefirst mixture of hydrogen peroxide and TURPINAL® SL in water (pH 7.2)was added to the second mixture with stirring at 25° C.; the resultingmixture (pH 6.5) contained 255 mM triacetin, 254 mM hydrogen peroxideand 0.055 mg protein/mL of spray-dried perhydrolase. A control reactionwas also run to determine the concentration of peracetic acid producedby chemical perhydrolysis of triacetin by hydrogen peroxide in theabsence of added extract protein. The peracetic acid concentrationsproduced in 0.5 min, 1 min, 2 min, 5 min and 10 min for the threereactions described above are listed in Table 13, below.

TABLE 13 Dependence of peracetic acid (PAA) concentration on solventaddition using 255 mM triacetin, 254 mM hydrogen peroxide and 55 μg/mLof spray-dried Thermotoga neapolitana perhydrolase. Enzyme PAA (ppm)Solvent (μg/mL) 0.5 min 1 min 2 min 5 min 10 min none 0 ND ND ND ND NDDOWANOL ® PM 0 89 90 205 318 498 DOWANOL ® DPM 0 104 178 184 373 535none 55 629 1359 2020 4274 6019 DOWANOL ® PM 55 807 1390 2331 4439 5917DOWANOL ® DPM 55 787 1373 2566 5122 6528

EXAMPLE 17 Use of Solvent for In-Situ Peroxycarboxylic acid GenerationUsing a Two-Compartment Spray-Bottle Compared to Stirred Reactions

A first mixture of 100 g of 0.20 M sodium citrate buffer containing 2000ppm TURPINAL® SL ((1-hydroxy-1-phosphonoethyl)phosphonic acid, 60 wt %in water; Thermphos International), 280 g of deionized water, and 5.20 gof 30 wt % hydrogen peroxide in water was adjusted to pH 7.2 with 50%aqueous sodium hydroxide, and the final weight of the mixture adjustedto 400 g with deionized water. A second mixture was separately prepared,containing 83.4 g of triacetin, 3.75 g of CAB-O-SIL® M5 (Cabot), 0.750 gof spray-dried Thermotoga neapolitana perhydrolase (Example 10), and62.1 g of a single solvent selected from: propylene glycol methyl ether(DOWANOL® PM), tripropylene glycol methyl ether (DOWANOL® TPM),diethylene glycol methyl ether (DOWANOL® DM), propylene glycol n-butylether (DOWANOL® PNB), propylene glycol n-propyl ether (DOWANOL® PnP),propylene glycol monomethyl ether acetate (DOWANOL® PMA), dipropyleneglycol, ethanol, isopropanol, and 1,2-propanediol. In a first reactionat 25° C., 1.0 g of the first mixture was stirred with 9.0 g of thesecond mixture for the first 30-60 seconds of the reaction (reaction pHof 6.5-6.0), and samples were withdrawn and analyzed for peracetic acidproduction; the resulting reaction mixture contained 255 mM triacetin,103 mM hydrogen peroxide and 100 μg protein/mL of spray-driedperhydrolase. Determination of the concentration of. peracetic acid inthe reaction mixtures (TABLE 14, below) was performed according to themethod described by Karst et al., supra. A control reaction was also runto determine the concentration of peracetic acid produced by chemicalperhydrolysis of triacetin by hydrogen peroxide in the absence of addedperhydrolase.

The first mixture and second mixture prepared as described above wereeach separately charged to one of the two compartments of atwo-compartment spray bottle (Custom Dual-Liquid Variable-Ratio Sprayer,Model DLS 200, manufactured by Take5 (Rogue River, Oreg.)), where thebottle was set up to spray a mixture of 9 parts by weight of the firstmixture with 1 part by weight of the second mixture. The two mixtureswere sprayed into a 12.5 cm diameter crystallizing dish, and theresulting reaction mixture (reaction pH of 6.5-6.0) contained 255 mMtriacetin, 100 mM hydrogen peroxide and 0.100 mg protein/mL ofspray-dried perhydrolase. The sprayed reaction mixture was sampled atpredetermined times and analyzed for peracetic acid (TABLE 14, below)according to the method described by Karst et al., supra.

TABLE 14 Dependence of peracetic acid (PAA) concentration on solventaddition using 255 mM triacetin, 103 mM hydrogen peroxide and 100 μg/mLof spray-dried Thermotoga neapolitana perhydrolase in stirred batchreactions and in a sprayed two-component mixture. PAA Enzyme (ppm)Solvent (μg/mL) 20 sec 40 sec 60 sec 120 sec 300 sec 600 sec DOWANOL ®PM, 0 101 106 106 82 90 166 stirred reaction DOWANOL ® PM, 100 319 587622 648 889 976 stirred reaction DOWANOL ® PM, 100 375 454 515 671 873994 sprayed reaction DOWANOL ® TPM, 0 0 72 19 25 44 69 stirred reactionDOWANOL ® TPM, 100 445 548 726 980 1378 1560 stirred reaction DOWANOL ®TPM, 100 433 575 1385 806 1089 1250 sprayed reaction DOWANOL ® DM, 0 287261 287 261 255 234 stirred reaction DOWANOL ® DM, 100 667 875 927 14101640 1876 stirred reaction DOWANOL ® DM, 100 540 613 866 914 1112 1276sprayed reaction DOWANOL ® PNB, 0 76 70 40 58 0 11 stirred reactionDOWANOL ® PNB, 100 344 488 654 932 1166 1357 stirred reaction DOWANOL ®PNB, 100 394 514 586 715 963 1141 sprayed reaction DOWANOL ® PnP, 0 173163 223 215 213 253 stirred reaction DOWANOL ® PnP, 100 611 716 857 12771468 1516 stirred reaction DOWANOL ® PnP, 100 371 657 737 928 1090 1195sprayed reaction DOWANOL ® PMA, 0 0 0 14 0 128 166 stirred reactionDOWANOL ® PMA, 100 335 510 756 1218 2178 3132 stirred reaction DOWANOL ®PMA, 100 541 745 1042 1472 ND 3236 sprayed reaction dipropylene glycol,0 26 54 73 79 40 38 stirred reaction dipropylene glycol, 100 318 539 7081423 1241 946 stirred reaction dipropylene glycol, 100 371 414 464 618756 863 sprayed reaction ethanol, 0 144 184 152 161 167 170 stirredreaction ethanol, 100 398 553 694 919 1227 1311 stirred reactionethanol, 100 504 677 685 766 968 1125 sprayed reaction isopropanol, 0149 167 180 207 180 236 stirred reaction isopropanol, 100 564 691 7831114 1395 1533 stirred reaction isopropanol, 100 621 767 882 1014 12391435 sprayed reaction 1,2-propanediol, 0 32 14 19 33 ND 108 stirredreaction 1,2-propanediol, 100 427 665 921 1485 1941 3466 stirredreaction 1,2-propanediol, 100 376 554 704 1376 1873 2517 sprayedreaction cyclohexanone, 0 136 133 153 138 152 114 stirred reactioncyclohexanone, 100 97 153 185 351 329 459 stirred reactioncyclohexanone, 100 128 196 338 368 416 489 sprayed reaction

EXAMPLE 18 Peroxycarboxylic Acid Production Using Thermotoga MaritimaPerhydrolase as an Enzyme Catalyst

Cloning and expression of perhydrolase from Thermotoga maritima isaccomplished in accordance with the methods described in Examples 1-3and 5. Fermentation of bacterial transformants expressing Thermotogamaritima perhydrolase is performed in accordance with preceding Example6, and preparation of spray-dried Thermotoga maritima perhydrolase isaccomplished using methods described in Example 13. Additionalinformation regarding techniques for cloning, expressing, andpreparation of Thermotoga maritima perhydrolase is available in U.S.Ser. No. 12/143,375, filed Jun. 20, 2008.

A comparison of peracetic acid production by Thermotoga maritimaperhydrolase in the presence and absence of added solvent is performed.A first mixture of 40.0 g of deionized water, 0.1575 g of TURPINAL® SL((1-hydroxy-1-phosphonoethyl)phosphonic acid, 60 wt % in water; Thermphos International), and 1.44 g of 30 wt % hydrogen peroxide in water isadjusted to pH 7.2 with 50% aqueous sodium hydroxide, and the finalweight of the mixture adjusted to 46.87 g with deionized water. A secondmixture of 2.78 g triacetin, 0.210 g of sodium bicarbonate, 0.125 g ofCAB-O-SIL® M5 (Cabot) and 0.0135 g of spray-dried Thermotoga maritimaperhydrolase is prepared, and the first mixture of hydrogen peroxide andTURPINAL® SL in water (pH 7.2) is added to the second mixture withstirring at 25° C.; the resulting mixture containing 255 mM triacetin,254 mM hydrogen peroxide and 0.055 mg protein/mL of spray-driedperhydrolase. Determination of the concentration of peracetic acid inthe reaction mixtures is performed according to the method described byKarst et al., supra. A control reaction is also run to determine theconcentration of peracetic acid produced by chemical perhydrolysis oftriacetin by hydrogen peroxide in the absence of added perhydrolase.

The reaction described above is repeated, where 1.872 g of eitherpropylene glycol monomethyl ether (DOWANOL® PM) or dipropyleneglycolmonomethyl ether (DOWANOL® DPM), is substituted for an equivalent weightof water in the reaction mixture. A first mixture of 40.0 g of deionizedwater, 0.175 g of TURPINAL® SL, and 1.60 g of 30 wt % hydrogen peroxidein water is adjusted to pH 7.2 with 50% aqueous sodium hydroxide, andthe final weight of the mixture adjusted to 50.0 g with deionized water.A second mixture of 2.78 g triacetin, 1.872 g of either propylene glycolmonomethyl ether (DOWANOL® PM) or dipropyleneglycol monomethyl ether(DOWANOL® DPM), 0.210 g of sodium bicarbonate, 0.125 g of CAB-O-SIL® M5(Cabot) and 0.0135 g of spray-dried Thermotoga maritima perhydrolase isprepared, and 45.0 g of the first mixture of hydrogen peroxide andTURPINAL® SL in water (pH 7.2) is added to the second mixture withstirring at 25° C.; the resulting mixture (pH 6.5) contained 255 mMtriacetin, 254 mM hydrogen peroxide and 0.055 mg protein/mL ofspray-dried perhydrolase. A control reaction is also run to determinethe concentration of peracetic acid produced by chemical perhydrolysisof triacetin by hydrogen peroxide in the absence of added extractprotein. The peracetic acid concentrations produced in 0.5 min, 1 min, 2min, 5 min and 10 min for the three reactions described above aremeasured and recorded.

EXAMPLE 19 Use of Solvent for In Situ Peroxycarboxylic Acid GenerationUsing Two-Compartment Spray Device Compared to Stirred Reaction andUsing Thermotoga Maritima Perhydrolase

A first mixture of 100 g of 0.20 M sodium citrate buffer containing 2000ppm TURPINAL® SL ((1-hydroxy-1-phosphonoethyl)phosphonic acid, 60 wt %in water; Thermphos International), 280 g of deionized water, and 5.20 gof 30 wt % hydrogen peroxide in water is adjusted to pH 7.2 with 50%aqueous sodium hydroxide, and the final weight of the mixture adjustedto 400 g with deionized water. A second mixture is separately prepared,containing 83.4 g of triacetin, 3.75 g of CAB-O-SIL® M5 (Cabot), 0.750 gof spray-dried Thermotoga maritima perhydrolase (Example 13), and 62.1 gof a single solvent selected from: propylene glycol methyl ether(DOWANOL® PM), tripropylene glycol methyl ether (DOWANOL® TPM),diethylene glycol methyl ether (DOWANOL® DM), propylene glycol n-butylether (DOWANOL® PNB), propylene glycol n-propyl ether (DOWANOL® PnP),propylene glycol monomethyl ether acetate (DOWANOL® PMA), dipropyleneglycol, ethanol, isopropanol, and 1,2-propanediol. In a first reactionat 25° C., 1.0 g of the first mixture is stirred with 9.0 g of thesecond mixture for the first 30-60 seconds of the reaction (reaction pHof 6.5-6.0), and samples are withdrawn and analyzed for peracetic acidproduction; the resulting reaction mixture containing 255 mM triacetin,103 mM hydrogen peroxide and 100 μg protein/mL of spray-driedperhydrolase. Determination of the concentration of peracetic acid inthe reaction mixtures is performed according to the method described byKarst et al., supra. A control reaction is also run to determine theconcentration of peracetic acid produced by chemical perhydrolysis oftriacetin by hydrogen peroxide in the absence of added perhydrolase.

The first mixture and second mixture prepared as described above areeach separately charged to one of the two compartments of atwo-compartment spray bottle (Custom Dual-Liquid Variable-Ratio Sprayer,Model DLS 200, manufactured by Take5 (Rogue River, Oreg.)), where thebottle is set up to spray a mixture of 9 parts by weight of the firstmixture with 1 part by weight of the second mixture. The two mixturesare sprayed into a 12.5 cm diameter crystallizing dish, and theresulting reaction mixture (reaction pH of 6.5-6.0) containing 255 mMtriacetin, 100 mM hydrogen peroxide and 0.100 mg protein/mL ofspray-dried perhydrolase. The sprayed reaction mixture is sampled atpredetermined times and analyzed for peracetic acid according to themethod described by Karst et al., supra.

Example 20 Exemplary Two-Component System

One example of a two-component in situ peroxycarboxylic aciddisinfectant formulation is described below,

mol/L grams Component A triacetin 0.100 21.82 T. neapolitanaperhydrolase/excipient 0.20 sodium bicarbonate 0.050 4.20 Component BH₂O₂ (30 wt %): 0.100 11.33 TURPINAL ® SL (60 wt %, 0.1% final) 1.67water (deionized) 960.78 Total weight (grams) 1000.00

For the two-component in situ peroxycarboxylic acid disinfectantformulation described above, Component A comprises ca. 2.6 wt % of thecombined weight of Components A and B, and the weight ratio of ComponentB to Component A is ca. 38:1. In certain applications for atwo-component in-situ peroxycarboxylic acid disinfectant formulation, itmay be desirable for the ratio of Component B to Component A to bewithin a range of from 1:1 to 10:1, where from 10 parts to 1 part (byweight) of Component B is mixed with one part (by weight) of Component Ato produce a peroxycarboxylic acid at a concentration efficacious fordisinfection. For example, in a first application a two-compartmentspray bottle such as a dual-liquid fixed ratio sprayer (Model DLS100,Take5) or a dual-liquid variable ratio sprayer (Model DLS200, Take5) isutilized, where a maximum ratio of Component B to Component A of 10:1 isemployed. In a second application, a single bottle containing twoseparate compartments separated by a breakable seal is employed, wherethe ratio of the volume of the two separate compartments is 1:1, or 5:1or 10:1. In each of these applications, the two-component formulationcannot be mixed at the desired ratio of Component A to Component B toprovide the desired concentration of reactants and final concentrationof products.

Example 21 Perhydrolase Activity Assay of Thermotoga Neapolitana AcetylXylan Esterase Variants

Libraries of Thermotoga neapolitana mutants were prepared as describedin Example 4 of co-owned, co-filed, and copending U.S. PatentApplication having attorney docket number CL4392 US NA entitled“Improved Perhydrolases for Enzymatic Peracid Production”. Briefly,saturation mutagenesis was conducted at amino acid residues F213, I276,C277, and N93 of SEQ ID NO: 6 so that each of the other 19 possibleamino acids were individually introduced to each specified position.

The mutations were made using QUIKCHANGE® (Stratagene, La Jolla, Calif.)kit according to the manufacturer's instructions. Amplified plasmidswere treated with 1U of DpnI at 37° C. for 1 hour. Treated plasmids wereused to transform chemically competent E. coli XL1-Blue (Stratagene)(residues 213, 276 and 277) or chemically competent E. coli TOP10F′(Invitrogen, Carlsbad, Calif.) (residue 93). Transformants were platedon LB-agar supplemented with 0.1 mg ampicillin/mL and grown overnight at37° C. Up to five individual colonies were picked and the plasmid DNAsequenced to confirm the expected mutations.

Individual colonies of mutants were picked into 96-well platescontaining 0.1 mL LB with 0.1 mg ampicillin/mL, and grown overnight at37° C. without shaking. 0.003 mL of overnight culture was transferred toan “Induction plate” (96 deep-well) containing 0.3 mL LB, 0.5 mM IPTGand 0.1 mg ampicillin/mL. Induction plates were grown overnight at 37°C. with shaking. 0.01 mL of Induction culture was transferred to “Lysisplate” (96-well) containing 0.09 mL of 56 mg/mL CELYTIC™ Express (SigmaAldrich, St. Louis, Mo.). Plates were slightly agitated first, beforeincubating at 25° C. for 30 minutes. Approximately 0.01 mL of Lysisculture was transferred to “Assay plate” (96-well) containing 0.09 mL“Assay solution pH 5.0” (100 mM triacetin, 100 mM hydrogen peroxide, 50mM acetic acid pH 5.0). Approximately 0.01 mL of Lysis culture was alsotransferred to “Assay plate pH 7.5” (96-well) containing 0.09 mL “Assaysolution pH 7.5” (100 mM triacetin, 100 mM hydrogen peroxide, 50 mMsodium phosphate pH 7.5). Plates were gently agitated for 30 secondsbefore incubating at ambient temperature for 10 minutes. The assay wasquenched by addition of 0.1 mL of “Stop buffer” (100 mMortho-phenylenediamine (OPD), 500 mM NaH₂PO₄ pH 2.0). Plates were gentlyagitated for 30 seconds before incubating at 25° C. for 30 minutes. Theabsorbance was read at 458 nm without a lid using a SPECTRAMAX® Plus384plus (Molecular Devices, Sunnyvale, Calif.). Analysis of the resultsindicated four variants that demonstrated significantly greaterperhydrolase activity compared to the native enzyme (Tables 15 and 16).All four are changes of the cysteine at residue 277 (C277A, C277V,C277S, and C277T; see SEQ ID NO: 19).

TABLE 15 Perhydrolase activity (U/mL) at pH 5.0 of T. neapolitana acetylxylan esterase variants. Variant U/mL Variant U/mL Variant U/mL VariantU/mL F213S 0.17 I276W 0.18 C277N 0.17 N093R 0.11 F213N 0.18 I276R 0.18C277I 0.17 N093I 0.10 F213G 0.17 I276L 0.18 C277S 0.43 N093Q 0.10 F213C0.21 I276K 0.18 C277A 0.51 N093K 0.11 F213V 0.17 I276M 0.18 C277Q 0.17N093M 0.10 F213M 0.17 I276V 0.26 C277L 0.17 N093C 0.12 F213T 0.17 I276S0.17 C277K 0.17 N093D 0.10 F213Y 0.23 I276N 0.18 C277V 0.35 N093S 0.12F213I 0.18 I276C 0.29 C277E 0.17 N093G 0.11 F213Q 0.17 I276Q 0.17 C277P0.17 N093V 0.10 F213H 0.22 I276F 0.27 C277D 0.17 N093L 0.13 F213R 0.20I276H 0.18 C277M 0.17 N09E 0.10 F213W 0.17 I276D 0.17 C277F 0.17 N093F0.10 F213P 0.17 I276E 0.18 C277T 0.33 N09A 0.11 F213D 0.17 I276G 0.17C277Y 0.17 N093H 0.11 F213K 0.17 I276Y 0.23 C277H 0.17 N093W 0.10 F213L0.18 I276T 0.29 C277W N/A N093P 0.10 F213E N/A I276A N/A C277R N/A N093Y0.10 F213A N/A I276P N/A C277G N/A N093T N/A native 0.16

TABLE 16 Perhydrolase activity at pH 7.5 of T. neapolitana acetyl xylanesterase variants. Variant U/mL Variant U/mL Variant U/mL Variant U/mLF213S 1.80 I276W 2.00 C277N 3.50 N093R 0.13 F213N 1.90 I276R 1.90 C277I3.60 N093I 0.10 F213G 1.70 I276L 2.00 C277S 9.30 N093Q 0.11 F213C 3.00I276K 1.90 C277A 7.50 N093K 0.13 F213V 1.70 I276M 1.90 C277Q 3.50 N093M0.12 F213M 1.90 I276V 3.40 C277L 3.60 N093C 0.15 F213T 1.80 I276S 1.90C277K 3.50 N093D 0.10 F213Y 2.60 I276N 2.10 C277V 6.10 N093S 0.23 F213I1.80 I276C 3.40 C277E 3.50 N093G 0.18 F213Q 1.80 I276Q 2.00 C277P 3.60N093V 0.10 F213H 2.30 I276F 2.70 C277D 3.70 N093L 0.22 F213R 2.20 I276H2.10 C277M 3.60 N09E 0.12 F213W 1.80 I276D 1.90 C277F 3.60 N093F 0.10F213P 3.50 I276E 1.90 C277T 9.60 N09A 0.13 F213D 3.60 I276G 3.60 C277Y3.60 N093H 0.18 F213K 3.60 I276Y 4.40 C277H 3.60 N093W 0.16 F213L 5.00I276T 3.00 C277W N/A N093P 0.12 F213E N/A I276A N/A C277R N/A N093Y 0.15F213A N/A I276P N/A C277G N/A N093T N/A native 0.23

Example 22 Expression of Thermotoga Neapolitana Acetyl Xylan EsteraseVariants in E. Coli KLP18

Plasmids with confirmed acetyl xylan esterase mutations were used totransform E. coli KLP18 (Example 3). Transformants were plated ontoLB-ampicillin (100 μg/mL) plates and incubated overnight at 37° C. Cellswere harvested from a plate using 2.5 mL LB media supplemented with 20%(v/v) glycerol, and 1.0 mL aliquots of the resulting cell suspensionfrozen at −80° C. One mL of the thawed cell suspension was transferredto a 1-L APPLIKON® Bioreactor (Applikon® Biotechnology, Foster City,Calif.) with 0.7 L medium containing KH₂PO₄ (5.0 g/L), FeSO₄heptahydrate (0.05 g/L), MgSO₄ heptahydrate (1.0 g/L), sodium citratedihydrate (1.90 g/L), yeast extract (Amberex 695, 5.0 g/L),Biospumex153K antifoam (0.25 mL/L, Cognis Corporation), NaCl (1.0 g/L),CaCl₂ dihydrate (0.1 g/L), and NIT trace elements solution (10 mL/L).The trace elements solution contained citric acid monohydrate (10 g/L),MnSO₄ hydrate (2 g/L), NaCl (2 g/L), FeSO₄ heptahydrate (0.5 g/L), ZnSO₄heptahydrate (0.2 g/L), CuSO₄ pentahydrate (0.02 g/L) and NaMoO₄dihydrate (0.02 g/L). Post sterilization additions included glucosesolution (50% w/w, 6.5 g) and ampicillin (25 mg/mL) stock solution (2.8mL). Glucose solution (50% w/w) was also used for fed batch. Glucosefeed was initiated 40 min after glucose concentration decreased below0.5 g/L, starting at 0.03 g feed/min and increasing progressively eachhour to 0.04, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.12, and 0.14 g/minrespectively; the rate remaining constant afterwards. Glucoseconcentration in the medium was monitored, and if the concentrationexceeded 0.1 g/L the feed rate was decreased or stopped temporarily.Induction was initiated at OD₅₅₀=50 with addition of 0.8 mL IPTG (0.05M). The dissolved oxygen (DO) concentration was controlled at 25% of airsaturation, first by agitation (400-1000 rpm), and following by aeration(0.5-2 slpm). The temperature was controlled at 37° C., and the pH wascontrolled at 6.8; NH₄OH (29% w/w) and H₂SO₄ (20% w/v) were used for pHcontrol. The cells were harvested by centrifugation (5,000×g for 15minutes) at 20 h post IPTG addition.

Example 23 Preparation of Cell Lysates Containing Semi-Purified T.Neapolitana Acetyl Xylan Esterase or T. Neapolitana Variant Acetyl XylanEsterases

A cell culture of E. coli KLP18/pSW196 (Thermotoga neapolitana wild-typeperhydrolase) was grown as described in Example 6. The resulting cellpaste was resuspended (20% w/v) in 50 mM phosphate buffer pH 7.0supplemented with 1.0 mM DTT. Resuspended cells were passed through aFrench pressure cell twice to ensure >95% cell lysis. Lysed cells werecentrifuged for 30 minutes at 12,000×g, and the supernatant was heatedat 75° C. for 20 minutes, followed by quenching in an ice bath for 2minutes. Precipitated protein was removed by centrifugation for 10minutes at 11,000×g. SDS-PAGE indicated that the CE-7 enzyme comprisedapproximately 85-90% of the total protein in the heat-treated extractsupernatant.

Cell cultures of E. coli KLP18/pSW196/C277S (Thermotoga neapolitanaC277S variant perhydrolase), E. coli KLP18/pSW196/C277V (Thermotoganeapolitana C277V variant perhydrolase), E. coli KLP18/pSW196/C277A(Thermotoga neapolitana C277A variant perhydrolase), and E. coliKLP18/pSW196/C277T (Thermotoga neapolitana C277T variant perhydrolase)were each grown as described in Example 22. The resulting cell pasteswere resuspended (20% w/v) in 50 mM phosphate buffer pH 7.0 supplementedwith 1.0 mM DTT. Resuspended cells were passed through a French pressurecell twice to ensure >95% cell lysis. Lysed cells were centrifuged for30 minutes at 12,000×g, and the supernatant was heated at 75° C. for 20minutes, followed by quenching in an ice bath for 2 minutes.Precipitated protein was removed by centrifugation for 10 minutes at11,000×g. SDS-PAGE indicated that the CE-7 enzyme comprisedapproximately 85-90% of the total protein in the heat-treated extractsupernatant.

Example 24 Specific Activity and Perhydrolysis/Hydrolysis Ratio of T.Neapolitana Acetyl Xylan Wild-Type Esterase and C277 Esterase Variantss

Reactions (40 mL total volume) were run at 25° C. in phosphate buffer(50 mM, pH 7.2) containing triacetin (100 mM), hydrogen peroxide (100mM) and one of the following acetyl xylan esterase mutants: T.neapolitana C277S variant perhydrolase (0.010 mg/mL of heat-treatedextract total protein from E. coli KLP18/pSW196/C277S), T. neapolitanaC277T variant perhydrolase (0.010 mg/mL of heat-treated extract totalprotein from E. coli KLP18/pSVV196/C277T), T. neapolitana C277Avariantperhydrolase (0.0125 mg/mL of heat-treated extract total proteinfrom E. coli KLP18/pSW196/C277A), and T. neapolitana C277Vvariantperhydrolase (0.0125 mg/mL of heat-treated extract total proteinfrom E. coli KLP18/pSW196/C277V) (prepared as described in Example 23).Reactions were stirred for only the first 30 seconds of reaction toinitially mix the reactants and enzyme.

A reaction was also run under indentical conditions to that describedimmediately above using 0.050 mg/mL of heat-treated extract totalprotein isolated from E. coli KLP18/pSW196 (expressing Thermotoganeapolitana wild-type acetyl xylan esterase (Example 1)), where theheat-treated extract supernatant was prepared according to the procedureof Example 23.

Two samples from each of the reaction mixtures described above weresimultaneously withdrawn after the first minute of each reaction, andevery two minutes thereafter for fifteen minutes, where one of the twosamples was analyzed for peracetic acid, and the second sample wasanalyzed for total acetic acid produced from both enzymatic hydrolysisof triacetin and from subsequent conversion of peracetic acid in sampleto acetic add by reaction with methyl-p-tolyl sulfide (MTS, see below).

Measurement of the rate of peracetic acid production in the reactionmixture was performed using a modification of the method described byKarst et al., supra. A sample (0.040 mL) of the reaction mixture wasremoved at a predetermined time and immediately mixed with 0.960 mL of 5mM phosphoric acid in water to terminate the reaction by adjusting thepH of the diluted sample to less than pH 4. The resulting solution wasfiltered using an ULTRAFREE® MC-filter unit (30,000 Normal MolecularWeight Limit (NMWL), Millipore Corp., Billerica, Mass.; cat #UFC3LKT 00)by centrifugation for 2 min at 12,000 rpm. An aliquot (0.100 mL) of theresulting filtrate was transferred to a 1.5-mL screw cap HPLC vial(Agilent Technologies, Palo Alto, Calif.; #5182-0715) containing 0.300mL of deionized water, then 0.100 mL of 20 mM MTS (methyl-p-tolylsulfide) in acetonitrile was added, the vial capped, and the contentsbriefly mixed prior to a 10 min incubation at ca. 25° C. in the absenceof light. To the vial was then added 0.400 mL of acetonitrile and 0.100mL of a solution of triphenylphosphine (TPP, 40 mM) in acetonitrile, thevial re-capped, and the resulting solution mixed and incubated at ca.25° C. for 30 min in the absence of light. To the vial was then added0.100 mL of 10 mM N,N-diethyl-m-toluamide (DEET; HPLC external standard)and the resulting solution analyzed by HPLC for MTSO (methyl-p-tolylsulfoxide), the stoichiometric oxidation product produced by reaction ofMTS with peracetic acid. A control reaction was run in the absence ofadded extract protein or triacetin to determine the rate of oxidation ofMTS in the assay mixture by hydrogen peroxide, for correction of therate of peracetic acid production for background MTS oxidation. HPLCmethod: Supelco Discovery C8 column (10-cm×4.0-mm, 5 μm) (catalog#569422-U) with Supelco Supelguard Discovery C8 precolumn(Sigma-Aldrich; catalog #59590-U); 10 microliter injection volume;gradient method with CH₃CN (Sigma-Aldrich; catalog #270717) anddeionized water at 1.0 mL/min and ambient temperature (Table 17).

TABLE 17 HPLC Gradient for analysis of peracetic acid. Time (min:sec) (%CH₃CN) 0:00 40 3:00 40 3:10 100 4:00 100 4:10 40 7:00 (stop) 40

For determination of the rate of perhydrolase-catalyzed acetic acidproduction in the reaction, a sample (0.900 mL) of the reaction mixturewas removed at a predetermined time and immediately added to a 1.5mL-microcentrifuge tube containing 0.040 mL of 0.75 M H₃PO₄, and theresulting solution briefly mixed to terminate the reaction at pH3.0-4.0. To the tube was then added 0.020 mL of a solution of 10 mg/mLof Aspergillus niger catalase (Sigma-Aldrich; C3515) in 50 mM phosphatebuffer pH (7.2), and the resulting solution mixed and allowed to reactfor 15 minutes at ambient temperature to disproportionate unreactedhydrogen peroxide to water and oxygen. To the tube was then added 0.040mL of 0.75 M H₃PO₄ and the resulting solution mixed and filtered usingan ULTRAFREE® MC-filter unit (30,000 Normal Molecular Weight Limit(NMWL), Millipore Corp., cat #UFC3LKT 00) by centrifugation for 2 min at12,000 rpm. An aliquot (0.100 mL) of the resulting filtrate was mixedwith 0.150 mL of 20 mM MTS (methyl-p-tolyl sulfide) in acetonitrile, andthe resulting solution was incubated for 10 min at ca. 25° C. in theabsence of light. The concentration of acetic acid in the sampleproduced by both enzymatic hydrolysis of triacetin and conversion ofperacetic acid to acetic acid by reaction with MTS was determined usinga gas chromatograph (GC) equipped with a flame ionization detector (FID)and a DB-FFAP column (length, 15 m; 1D, 0.530 mm; film thickness, 1.00μm); a fresh injection port liner was employed for each ratedetermination (total of eight sample analyses) to avoid build up ofphosphoric acid in the injection port liner over time.

The Thermotoga neapolitana acetyl xylan esterase variants had asignificantly-higher specific activity for perhydrolysis of triacetinthan the wild-type esterase (Table 18). The perhydrolysis/hydrolysisratios for the T. neapolitana acetyl xylan esterase variants weredetermined by dividing the rate of PAA production (perhydrolysis rate)by the rate of hydrolysis of triacetin to acetic acid (hydrolysis rate)(calculated from the rate of total acetic acid production in the assaymethod from both PAA and acetic acid, and corrected for the rate ofperacetic acid production); the P/H ratio of the T. neapolitana acetylxylan esterase variants were ca. equal to or greater than the P/H ratiofor the T. neapolitana wild-type acetyl xylan esterase (Table 18).

TABLE 18 specific Thermotoga enzyme perhydrolysis hydrolysis activityneapolitana concen. rate rate P/H (U/ perhydrolase (μg/mL) (mM/min)(mM/min) ratio mg protein) wild type 50 3.61 1.22 3.0 72 C277S 10 4.401.61 2.7 440 C277T 10 4.24 0.81 5.2 424 C277A 12.5 4.14 1.43 2.9 331C277V 12.5 3.70 0.88 4.2 296

Example 25 Cloning and Expression of Acetyl Xylan Esterase fromThermotoga Maritima

A gene encoding acetyl xylan esterase from T. maritima as reported inGENBANK® (accession #NP_(—)227893.1) was synthesized (DNA 2.0, MenloPark Calif.). The gene was subsequently amplified by PCR (0.5 min at 94°C., 0.5 min at 55° C., 1 min at 70° C., 30 cycles) using primersidentified as SEQ ID NO: 52 and SEQ ID NO: 53. The resulting nucleicacid product (SEQ ID NO: 54) was cut with restriction enzymes PstI andXbaI and subcloned between the PstI and XbaI sites in pUC19 to generatethe plasmid identified as pSW207. A gene encoding an acetyl xylanesterase from T. maritima MSB8 as reported in GENBANK® (Accession no.NP_(—)227893.1) was synthesized using codons optimized for expression inE. coli (DNA 2.0, Menlo Park Calif.). The gene was subsequentlyamplified by PCR (0.5 min at 94° C., 0.5 min at 55° C., 1 min at 70° C.,30 cycles) using primers identified as SEQ ID NO:55 and SEQ ID NO:56.The resulting nucleic acid product was cut with restriction enzymesEcoRI and PstI and subcloned between the EcoRI and PstI sites in pTrc99A(GENBANK® Accession no. M22744) to generate the plasmid identified aspSW228 (containing the codon-optimized T. maritima coding sequence SEQID NO: 57). The plasmids pSW207 and pSW228 were used to transform E.coli KLP18 (U.S. Patent Application Pub. No. 2008/0176299) to generatethe strain identified as KLP18/pSW207 and KLP18/pSW228, respectively.KLP18/pSW207 and KLP18/pSW228 were gown in LB media at 37° C. withshaking up to OD_(600nm)=0.4-0.5, at which time IPTG was added to afinal concentration of 1 mM, and incubation continued for 2-3 h. Cellswere harvested by centrifugation and SDS-PAGE was performed to confirmexpression of the perhydrolase at 20-40% of total soluble protein.

Example 26 Construction of Thermotoga Maritima Acetyl Xylan EsteraseVariants at Residue C277

The C277 (Cys277) position of T. maritima acetyl xylan esterase waschanged to each of Val, Ala, Ser and Thr using oligonucleotide primerpairs (Table 19) that were designed based on the codon optimizedsequence of T. maritima acetyl xylan esterase (SEQ ID NO:57) in theplasmid pSW228. The mutations were made using QUIKCHANGE® (Stratagene)according to the manufacturer's instructions. Amplified plasmids weretreated with 1U of DpnI at 37° C. for 1 hour. Treated plasmids were usedto transform chemically competent E. coli XL1-Blue (Stratagene).Transformants were plated on LB-agar supplemented with 0.1 mgampicillin/mL and grown overnight at 37° C. Up to five individualcolonies were picked and the plasmid DNA sequenced to confirm theexpected mutations.

TABLE 19 Oligonucleotides used to change residue 277 in T. maritima.forward 5′ to 3′ reverse 5′ to 3′ Tma_C277Vf ggacaacatcGTGcctccttctaTma_C277Vr TAGAAGGAGGCACGATGTTGTCC (SEQ ID NO: 58) (SEQ ID NO: 59)Tma_C277Af ggacaacatcGCGcctccttcta Tma_C277Ar TAGAAGGAGGCGCGATGTTGTCC(SEQ ID NO: 60) (SEQ ID NO: 61) Tma_C277Sf ggacaacatcTCAcctccttctaTma_C277Sr TAGAAGGAGGTGAGATGTTGTCC (SEQ ID NO: 62) (SEQ ID NO: 63)Tma_C277Tf ggacaacatcACCcctccttcta Tma_C277Tr TAGAAGGAGGGGTGATGTTGTCC(SEQ ID NO: 64) (SEQ ID NO: 65)

Example 27 Expression of Thermotoga Maritima Acetyl Xylan EsteraseVariants in E. Coli KLP18

Plasmids with confirmed acetyl xylan esterase mutations were used totransform E. coli KLP18 (Example 3). Transformants were grown in LBmedia at 37° C. with shaking up to OD_(600nm)=0.4-0.5, at which timeIPTG was added to a final concentration of 1 mM, and incubationcontinued for 2-3 h. Cells were harvested by centrifugation and SDS-PAGEwas performed to confirm expression of the acetyl xylan esterase at20-40% of total soluble protein.

Example 28 Preparation of Cell Lysates Containing Semi-Purified T.Maritima Acetyl Xylan Esterase Mutants

Cell cultures (prepared as described in Example 27) were grown using afermentation protocol similar to that described in Example 7 at a 1-Lscale (Applikon). Cells were harvested by centrifugation at 5,000×g for15 minutes then resuspended (20% w/v) in 50 mM phosphate buffer pH 7.0supplemented with 1.0 mM DTT. Resuspended cells were passed through aFrench pressure cell twice to ensure >95% cell lysis. Lysed cells werecentrifuged for 30 minutes at 12,000×g, and the supernatant was heatedat 75° C. for 20 minutes, followed by quenching in an ice bath for 2minutes. Precipitated protein was removed by centrifugation for 10minutes at 11,000×g. SDS-PAGE indicated that the CE-7 enzyme comprisedapproximately 85-90% of the total protein in the preparation.

Example 28 Specific Activity and Perhydrolysis/Hydrolysis ratio of T.Maritima Acetyl Xylan Wild-Type Esterase and C277 Esterase Variants

Reactions (40 mL total volume) were run at 25° C. in phosphate buffer(50 mM, pH 7.2) containing triacetin (100 mM), hydrogen peroxide (100mM) and one of the following acetyl xylan esterase variants: T. maritimaC277S variant perhydrolase (0.010 mg/mL of heat-treated extract totalprotein from E. coli KLP18/pSW228/C277S), T. maritima C277Tvariantperhydrolase (0.010 mg/mL of heat-treated extract total proteinfrom E. coli KLP181 pSW228/C277T), T. maritima C277A variantperhydrolase (0.0125 mg/mL of heat-treated extract total protein from E.coli KLP18/pSW228/C277A), and T. maritima C277V variant perhydrolase(0.0125 mg/mL of heat-treated extract total protein from E. coliKLP18/pSW2281C277V) (prepared as described in Example 27). Reactionswere stirred for only the first 30 seconds of reaction to initially mixthe reactants and enzyme.

A reaction was also run under indentical conditions to that describedimmediately above using 0.050 mg/mL of heat-treated extract totalprotein isolated from E. coli KLP18/pSW228 (expressing Thermotogamaritima wild-type acetyl xylan esterase (Example 25)), where theheat-treated extract supernatant was prepared according to the procedureof Example 27.

Two samples from each of the reaction mixtures described above weresimultaneously withdrawn after the first minute of each reaction, andevery two minutes thereafter for fifteen minutes, where one of the twosamples was analyzed for peracetic acid using a modification of themethod described by Karst et al., supra, and the second sample wasanalyzed for total acetic acid produced from both enzymatic hydrolysisof triacetin and from subsequent conversion of peracetic acid in sampleto acetic acid by reaction with methyl-p-tolyl sulfide (MTS) (seeExample 8).

The Thermotoga maritima acetyl xylan esterase mutants had asignificantly-higher specific activity for perhydrolysis of triacetinthan the wild-type esterase (Table 20). The perhydrolysis/hydrolysisratios for the T. maritima acetyl xylan esterase variants weredetermined by dividing the rate of PAA production (perhydrolysis rate)by the rate of hydrolysis of triacetin to acetic acid (hydrolysis rate)(calculated from the rate of total acetic acid production in the assaymethod from both PAA and acetic acid, and corrected for the rate ofperacetic acid production); the PIH ratio of the T. maritima acetylxylan esterase variants were ca. equal to or greater than the P/H ratiofor the T. neapolitana wild-type acetyl xylan esterase (Table 20).

TABLE 20 specific Thermotoga enzyme perhydrolysis hydrolysis activitymaritima concen. rate rate P/H (U/ perhydrolase (μg/mL) (mM/min)(mM/min) ratio mg protein) wild type 50 3.06 0.47 6.5 61 C277S 10 7.770.48 16 777 C277T 10 6.93 1.05 6.6 693 C277A 10 4.27 0.088 48 427 C277V10 4.25 0.062 68 425

Example 29 Peracetic Acid Production Using Perhydrolases

Reactions (100 mL total volume) containing triacetin (2 mM), hydrogenperoxide (10 mM) and from 0.1 pg/mL to 2.0 μg/mL heat-treated cellextract protein (prepared as described above, where the heat-treatmentwas performed at 85° C. for 20 min) were run in 10 mM sodium bicarbonatebuffer (initial pH 8.1) at 20° C. Determination of the concentration ofperacetic acid in the reaction mixtures was performed according to themethod described by Karst et al., supra. The peracetic acidconcentrations produced in 1 min, 5 min, 20 min, 40 min and 60 min arelisted in Table 21.

TABLE 21 Dependence of peracetic acid (PAA) concentration onperhydrolase concentration in reactions containing triacetin (2 mM) andhydrogen peroxide (10 mM) in sodium bicarbonate buffer (10 mM, initialpH 8.1) at 20° C., using heat-treated extract protein from E. coliKLP18/pSW228 (Thermotoga maritima wild-type perhydrolase) or E. coliKLP18/pSW228/C277S (Thermotoga maritima C277S variant perhydrolase)(duplicate reactions). Thermotoga enzyme PAA, PAA, PAA, PAA, PAA,maritima concen. 1 min 5 min 20 min 40 min 60 min perhydrolase triacetin(mM) (μg/mL) (ppm) (ppm) (ppm) (ppm) (ppm) no enzyme 2 0 0 0 1 1 3 wildtype 2 0.2 0 2 7 13 19 wild type 2 0.2 0 1 5 11 15 wild type 2 0.5 0 212 19 25 wild type 2 0.5 0 2 12 21 26 wild type 2 1.0 0 5 20 29 31 wildtype 2 1.0 0 5 19 30 31 wild type 2 2.0 1 11 24 24 20 wild type 2 2.0 111 29 29 21 C277S 2 0.2 0 4 18 18 18 C277S 2 0.2 0 4 18 17 18 C277S 20.5 1 12 39 54 64 C277S 2 0.5 1 10 34 52 64 C277S 2 1.0 18 26 59 69 63C277S 2 1.0 18 25 60 70 64 C277S 2 2.0 9 38 66 60 48 C277S 2 2.0 9 34 6961 49

Example 30 Peracetic Add Production Using Perhydrolases

Reactions (100 mL total volume) containing triacetin (20 mM), hydrogenperoxide (10 mM) and from 0.1 μg/mL to 2.0 μg/mL heat-treated cellextract protein (prepared as described above, where the heat-treatmentwas performed at 85° C. for 20 min) were run in 10 mM sodium bicarbonatebuffer (initial pH 8.1) at 20° C. Determination of the concentration ofperacetic acid in the reaction mixtures was performed according to themethod described by Karst et al., supra. The peracetic acidconcentrations produced in 1 min, 5 min, 20 min, 40 min and 60 min arelisted in Table 22.

TABLE 22 Dependence of peracetic acid (PAA) concentration onperhydrolase concentration in reactions containing triacetin (20 mM) andhydrogen peroxide (10 mM) in sodium bicarbonate buffer (10 mM, initialpH 8.1) at 20° C., using heat-treated extract protein from E. coliKLP18/pSW228 (Thermotoga maritima wild-type perhydrolase) or E. coliKLP18/pSW228/C277S (Thermotoga maritima C277S variant perhydrolase)(duplicate reactions). Thermotoga enzyme PAA, PAA, PAA, PAA, PAA,maritima concen. 1 min 5 min 20 min 40 min 60 min perhydrolase triacetin(mM) (μg/mL) (ppm) (ppm) (ppm) (ppm) (ppm) no enzyme 20 0 2 3 3 7 9wild-type 20 0.2 3 10 15 27 35 wild-type 20 0.2 4 9 19 32 41 wild-type20 0.5 3 9 21 39 52 wild-type 20 0.5 3 8 22 39 54 wild-type 20 1.0 4 1335 62 82 wild-type 20 1.0 4 12 37 67 wild-type 20 2.0 9 20 52 91 122wild-type 20 2.0 10 20 52 87 114 C277S 20 0.2 7 16 67 109 148 C277S 200.2 9 24 67 112 144 C277S 20 0.5 16 43 140 202 260 C277S 20 0.5 17 48148 228 272 C277S 20 1.0 24 75 230 289 353 C277S 20 1.0 26 97 232 297372 C277S 20 2.0 32 130 318 402 443 C277S 20 2.0 37 135 323 401 430

Example 31 Peracetic Acid Production Using Perhydrolases

Reactions (40 mL total volume) were run at 25° C. in phosphate buffer(50 mM, pH 7.2) containing triacetin (100 mM), hydrogen peroxide (100mM) and from 10 μg/mL to 50 μg/mL of heat-treated T. neapolitana or T.maritima wild-type or C277 variant perhydrolases (as heat-treated cellextract protein prepared as described above, where the heat-treatmentwas performed at 75° C. for 20 min). Reactions were stirred for only thefirst 30 seconds of reaction to initially mix the reactants and enzyme.Determination of the concentration of peracetic acid in the reactionmixtures was performed according to the method described by Karst etal., supra. The peracetic acid concentrations produced in 1 min, 5 min,and 30 min are listed in Table 23.

TABLE 23 Peracetic acid (PAA) production in reactions containingtriacetin (100 mM) and hydrogen peroxide (100 mM) in phosphate buffer(50 mM, pH 7.2) at 25° C., using heat-treated T. neapolitana or T.maritima wild-type or C277 mutant perhydrolases. enzyme PAA, PAA, PAA,triacetin H₂O₂ concen. 1 min 5 min 30 min perhydrolase (mM) (mM) (μg/mL)(ppm) (ppm) (ppm) no enzyme 100 100 0 63 54 80 T. maritima 100 100 50529 1790 3785 wild-type T. maritima 100 100 10 979 3241 4635 C277S T.maritima 100 100 10 933 2882 3527 C277T T. maritima 100 100 10 442 20182485 C277A T. maritima 100 100 10 577 1931 2278 C277V T. neapolitana 100100 50 514 1837 3850 wild-type T. neapolitana 100 100 10 606 2237 4609C277S T. neapolitana 100 100 10 634 2198 3918 C277T T. neapolitana 100100 12.5 516 2041 3735 C277A T. neapolitana 100 100 12.5 451 1813 2758C277V

Example 32 Peracetic Acid Production Using Perhydrolases

Reactions (10 mL total volume) were run at 25° C. in sodium bicarbonatebuffer (1 mM, initial pH 6.0) containing triacetin (100 mM or 150 mM),hydrogen peroxide (100 mM, 250 mM or 420 mM) and heat-treated T.neapolitana or T. maritima wild-type, C277S or C277T varantperhydrolases (as heat-treated cell extract protein prepared asdescribed above, where the heat-treatment was performed at 75° C. for 20min; concentrations as listed in Table 24). Reactions run using 420 mMhydrogen peroxide additionally contained 500 ppm TURPINAL® SL. Reactionswere stirred for only the first 30 seconds of reaction to initially mixthe reactants and enzyme. Determination of the concentration ofperacetic acid in the reaction mixtures was performed according to themethod described by Karst et al., supra. The peracetic acidconcentrations produced in 1 min, 5 min, and 30 min are listed in Table24.

TABLE 24 Peracetic acid (PAA) production in reactions containingtriacetin and hydrogen peroxide in bicarbonate buffer (1 mM at pH 6.0 or100 mM at pH 8.1) or in deionized water (pH 5.0) at 25° C. usingheat-treated T. maritima wild- type, C277S or C277T variantperhydrolases. Thermotoga NaHCO₃ enzyme PAA, PAA, PAA, maritima H₂O₂buffer concen. 1 min 5 min 30 min perhydrolase triacetin (mM) (mM) (mM)(μg/mL) (ppm) (ppm) (ppm) no enzyme 100 100 1.0 0 28 78 141 wild-type100 100 1.0 75 434 494 608 wild-type 100 100 1.0 100 449 667 643 C277S100 100 1.0 15 989 1554 1476 C277S 100 100 1.0 20 1301 2139 2131 C277T100 100 1.0 15 1062 1513 1393 C277T 100 100 1.0 20 996 1430 1516 noenzyme 100 250 0 0 13 71 71 wild-type 100 250 0 75 512 535 533 wild-type100 250 0 100 576 668 654 C277S 100 250 0 15 653 671 675 C277S 100 250 020 943 927 903 C277T 100 250 0 15 717 711 765 C277T 100 250 0 20 730 755743 no enzyme 150 420 100 0 417 810 848 wild-type 150 420 100 500 63038627 9237 C277S 150 420 100 100 7822 10349 10197

1. A multi-component formulation for producing peroxycarboxylic acidcomprising: (a) a first component comprising: an enzyme powdercomprising: (1) at least one enzyme catalyst having perhydrolysisactivity, wherein said enzyme catalyst comprises an enzyme having acarbohydrate esterase family 7 (CE-7) signature motif that aligns withSEQ ID NO: 1 using CLUSTALW, said signature motif comprising: (A) an RGQmotif at amino acid positions aligning with 118-120 of SEQ ID NO:1; (B)a GXSQG motif at amino acid positions aligning with 179-183 of SEQ IDNO:1; and (C) an HE motif at amino acid positions aligning with 298-299of SEQ ID NO:1; said enzyme comprising at least 30% amino acid identityto SEQ ID NO: 1; and (2) at least one excipient; (ii) a carboxylic acidester substrate selected from the group consisting of (1) one or moreesters having the structure[X]_(m)R₅ wherein X is an ester group of the formula R₆C(O)O; R₆ is a C1to C7 linear, branched or cyclic hydrocarbyl moiety, optionallysubstituted with a hydroxyl group or C1 to C4 alkoxy group, wherein R₆optionally comprises one or more ether linkages where R₆ is C2 to C7; R₅is a C1 to C6 linear, branched, or cyclic hydrocarbyl moiety optionallysubstituted with a hydroxyl group, wherein each carbon atom in R₅individually comprises no more than one hydroxyl group or no more thanone ester group, and wherein R₅ optionally comprises one or more etherlinkages; m is 1 to the number of carbon atoms in R₅, said one or moreesters having solubility in water of at least 5 ppm at 25° C.; (2) oneor more glycerides having the structure

wherein R₁ is a C1 to C7 straight chain or branched chain alkyloptionally substituted with an hydroxyl or a C1 to C4 alkoxy group andR₃ and R₄ are individually H or R₁C(O); (3) one or more esters of theformula

wherein R₁ is a C1 to C7 straight chain or branched chain alkyloptionally substituted with an hydroxyl or a C1 to C4 alkoxy group andR₂ is a C1 to C10 straight chain or branched chain alkyl, alkenyl,alkynyl, aryl, alkylaryl, alkylheteroaryl, heteroaryi, (CH₂CH₂O)_(n), or(CH₂CH(CH₃)—O)_(n)H and n is 1 to 10; (4) one or more acetylatedmonosaccharides, acetylated disaccharides, or acetylatedpolysaccharides; and (5) any combination of (1) through (4); wherein theamount of the carboxylic acid ester substrate in the first component isdesigned to provide a final concentration of 0.5 wt % to 10 wt% in areaction formulation formed by combining the first and secondcomponents; (iii) a buffer selected from the group consisting ofbicarbonate, citrate, acetate, phosphate, pyrophosphate,methylphosphonate, succinate, malate, fumarate, tartrate, and maleate;(iv) a cosolvent selected from the group consisting of tripropyleneglycol methyl ether, dipropylene glycol methyl ether, propylene glycolmethyl ether, diethylene glycol butyl ether, dipropylene glycol,triethylene glycol, 1,2-propanediol, N-ethyl-2-pyrroldinone,isopropanol, ethanol, ethyl lactate, 1,3-propanediol, and anycombination thereof; and (v) optionally at least one surfactant; and (b)a second component comprising water, hydrogen peroxide, and a hydrogenperoxide stabilizer.
 2. The multi-component peroxycarboxylic acidformulation of claim 1 wherein the at least one excipient ranges fromabout 95 wt% to about 25 wt% of the enzyme powder.
 3. Themulti-component peroxycarboxylic acid formulation of claim 1 or claim 2wherein (a) the carboxylic acid ester substrate is triacetin; whereinthe amount of triacetin in the first component provides a finalconcentration of 0.5 wt % to 10 wt% triacetin in a reaction formulationformed by combining the first and second components; (b) the buffer isabout 0.1 wt% to about 10% wt of a the first component, wherein saidbuffer is selected from the group consisting of sodium bicarbonate,potassium bicarbonate, a mixture of sodium bicarbonate and potassiumbicarbonate, sodium phosphate, potassium phosphate, and a mixture ofsodium phosphate and potassium phosphate; (d) the cosolvent istripropylene glycol methyl ether and is in a concentration of up to 80wt% of the first component; (e) the surfactant is present and ispolysorbate 80; and (f) the hydrogen peroxide in the second component ispresent in an amount that provides a final concentration in a reactionformulation formed by combining the first and second components of from0.33 wt% to about 30 wt%.
 4. The multi-component formulation of claim 1or claim 2 wherein the first component is combined with said secondcomponent at a ratio of about 1:1 to about 1:10 by weight.
 5. Atwo-component formulation for producing peroxycarboxylic acid comprising(a) a first component comprising: an enzyme powder; said enzyme powdercomprising: (1) at least one CE-7 enzyme having perhydrolysis activity,wherein said at least one CE-7 enzyme comprises an amino acid sequenceselected from the group consisting of SEQ ID NO: 6, SEQ ID NO: 7, SEQ IDNO: 19 and SEQ ID NO: 20 or an amino acid sequence substantially similarto SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 19 or SEQ ID NO: 20; and (2)at least one excipient; (ii) a carboxylic acid ester substrate selectedfrom the group consisting of monoacetin, diacetin, triacetin, and amixtures thereof; wherein the amount of the carboxylic acid estersubstrate in the first component is designed to provide a finalconcentration of 0.5 wt % to 10 wt% in a reaction formulation formed bycombining the first and second components; (iii) a buffer selected fromthe group consisting of bicarbonate, citrate, acetate, phosphate,pyrophosphate, methylphosphonate, succinate, malate, fumarate, tartrate,and maleate; (iv) a cosolvent selected from the group consisting oftripropylene glycol methyl ether, dipropylene glycol methyl ether,propylene glycol methyl ether, diethylene glycol butyl ether,dipropylene glycol, triethylene glycol, 1,2-propanediol,N-ethyl-2-pyrroldinone, isopropanol, ethanol, ethyl lactate,1,3-propanediol, and any combination thereof; and (v) optionally atleast one surfactant; and (b) a second component comprising water,hydrogen peroxide, and a hydrogen peroxide stabilizer.
 6. The twocomponent formulation of claim 5 wherein: (a) the at least one CE-7enzyme comprises an amino acid sequence selected from the groupconsisting of SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 19 and SEQ ID NO:20, wherein amino acid residue 277 of SEQ ID NO: 19 or SEQ ID NO: 20 isselected from the group consisting of alanine, valine, serine, andthreonine; (b) the carboxylic acid ester substrate is triacetin; whereinthe amount of triacetin in the first component is designed to provide afinal concentration of 0.5 wt % to 10 wt% in a reaction formulationformed by combining the first and second components; (c) the buffer isin a concentration of about 0.1 wt% to about 10% wt of a the firstcomponent, wherein the buffer is selected from the group consisting ofsodium bicarbonate, potassium bicarbonate, a mixture of sodiumbicarbonate and potassium bicarbonate, sodium phosphate, potassiumphosphate, and a mixture of sodium phosphate and potassium phosphate;(d) the cosolvent is tripropylene glycol methyl ether and is in aconcentration of up to 80 wt% of the first component; (e) the surfactantis present and is polysorbate 80; and (f) the hydrogen peroxide in thesecond component is present in an amount that provides a finalconcentration in a reaction formulation formed by combining the firstand second components of from 0.33 wt% to about 30 wt%.
 7. The twocomponent formulation of claim 5 or claim 6 wherein the first componentis combined with said second component at a ratio of about 1:1 to about1:10 by weight to produce peroxycarboxylic acid.
 8. A two-componentformulation for producing peroxycarboxylic acid comprising: (a) a firstcomponent comprising a formulation of (i) about 0.1 wt % to about 5 wt%of the first component being an enzyme powder comprising: (1) about 20wt% to about 33 wt% of the enzyme powder comprising at least one CE-7enzyme and having perhydrolysis activity, wherein said at least one CE-7enzyme comprising an amino acid sequence selected from the groupconsisting of SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 19 and SEQ ID NO:20; (2) about 67 wt% to about 80 wt% of the enzyme powder comprising atleast one oligosaccharide excipient having a number average molecularweight of at least about 1250 and a weight average molecular weight ofat least about 9000; wherein the at least one oligosaccharide excipientis selected from the group consisting of maltodextrin, xylan, mannan,fucoidan, galactomannan, chitosan, raffinose, stachyose, pectin,insulin, levan, graminan, amylopectin, and mixtures thereof; (ii) acarboxylic acid ester substrate selected from the group consisting ofmonoacetin, diacetin, triacetin, and a mixtures thereof; wherein theamount of the carboxylic acid ester substrate in the first component isdesigned to provide a final concentration of 0.5 wt % to 10 wt% in areaction formulation formed by combining the two reaction components;(iii) about 0.1 wt% to about 10% wt of he first component comprising abuffer selected from the group consisting of sodium bicarbonate,potassium bicarbonate, a mixture of sodium bicarbonate and potassiumbicarbonate, sodium phosphate, potassium phosphate, and a mixture ofsodium phosphate and potassium phosphate; (iv) up to 80 wt% of the firstcomponent comprising a cosolvent having a log P value of less than 2,said cosolvent selected from the group consisting of tripropylene glycolmethyl ether, dipropylene glycol methyl ether, propylene glycol methylether, diethylene glycol butyl ether, dipropylene glycol, triethyleneglycol, 1,2-propanediol, N-ethyl-2-pyrroldinone, isopropanol, ethanol,ethyl lactate, 1,3-propanediol, and any combination thereof; and (v) atleast one surfactant in a range from about 0.1 wt% to about 5 wt % basedon the weight of total protein present in the enzyme powder; and (b) asecond component comprising (i) at least 70 wt% water; (ii) hydrogenperoxide in an amount that provides a final concentration of thehydrogen peroxide in the reaction formulation in range from 0.33 wt% toabout 30 wt%; and (iii) about 0.01 wt% to about 1% of a hydrogenperoxide stabilizer; wherein combining said first and said secondreaction components produces an aqueous formulation of peracetic acid.